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ABSTRACT 
Colorectal cancer (CRC) is a leading cause of cancer related death. Colon cancer stem 
cells (CCSCs) play important roles in CRC tumorigenesis and metastasis. The role of 
non-coding RNAs such as microRNAs and long non-coding RNAs (lncRNAs) in regulating 
cancer progression and stem cell renewal and differentiation are being increasingly 
appreciated. The aim of my study is to understand how non-coding RNAs regulate CRC 
initiation and metastasis.  
In Chapter 1, we identified that Lnc34a, a previously unidentified LncRNA, is enriched in 
CCSCs to create a spatial imbalance in microRNA miR-34a expression, leading to the 
initiation of asymmetric cell division. Lnc34a recruits Dnmt3a via PHB2 and HDAC1 to 
methylate and deacetylate the miR-34a promoter simultaneously, hence epigenetically 
silencing miR-34a expression independent of its upstream regulator p53. Lnc34a levels 
affect CCSC self-renewal and colorectal cancer (CRC) growth in xenograft models. 
Lnc34a is upregulated in late-stage CRCs, contributing to epigenetic miR-34a silencing 
and CRC proliferation. 
In Chapter 2, we describe that miR-34a regulates asymmetric division of normal intestinal 
stem cells (ISCs). Proinflammatory stress triggers asymmetric division of ISCs that 
normally undergo symmetric division. Silencing of miR-34a in ISCs inhibits asymmetric 
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division and increases inflammation-induced ISC proliferation. These findings suggest 
that miR-34a provides a safeguard mechanism against excessive stem cell proliferation 
under inflammation, which is common during tumorigenesis. 
In Chapter 3, we demonstrate that miR-34a deficiency leads to colon tumorigenesis after 
Citrobacter rodentium infection. miR-34a targets both immune and epithelial cells to 
restrain inflammation-induced reparative regeneration. miR-34a targets the Interleukin 6 
receptor (IL-6R) to suppress T helper 17 (Th17) cell differentiation, targets the Interleukin 
23 receptor (IL-23R) to block Th17 cell expansion, targets chemokine CCL22 production 
to hinder Th17 cell recruitment to the colon epithelium, and targets the Interleukin 17 
receptor D (IL17RD) in colon stem cells to inhibit IL17-induced stem cell proliferation. This 
study highlights the importance of microRNAs in protecting tissue integrity during pro-
inflammatory response despite their lack of function in regular tissue homeostasis. 
In Chapter 4, we show that the microRNA miR-1269a promotes CRC metastasis and 
forms a positive feedback loop with TGF-β signaling. miR-1269a is upregulated in late-
stage CRCs and strongly associated with risk of CRC relapse and metastasis. Consistent 
with clinical observations, miR-1269a significantly increases the ability of CRC cells to 
invade and metastasize in vivo. TGF-β activates miR-1269 via Sox4, while miR-1269a 
enhances TGF-β signaling by targeting Smad7 and HOXD10, hence forming a positive 
feedback loop to promote metastasis. Stage II CRC patients with high miR-1269a 
expression in resected tumors have significantly higher rate of relapse and worse 
prognosis. Our findings suggest that miR-1269a is a potential marker to guide adjuvant 
chemotherapy decisions for CRC patients and a potential therapeutic target to deter 
metastasis. 
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BACKGROUND 
1 Colorectal cancer (CRC) 
Colorectal cancer (CRC) is the third most commonly diagnosed cancer and the fourth 
leading cause of cancer-related death worldwide. There are more than one million new 
cases diagnosed annually, and the 5-year survival rate for metastatic CRC is around 14% 
[1]. The rate of CRC incidence continues to rise. New cases of CRC are estimated to 
increase by more than 2.2 million by 2030 [2]. There are unmet needs to improve our 
understanding of the mechanism of CRC tumorigenesis and metastasis. 
CRC progress through sequential genetic mutations such as APC, KRAS and p53 [3]. As 
mutations accumulate, adenomas turn into invasive carcinomas, then metastasize to 
distal organs such as the liver and lung. The role of transformed stem cells in CRC 
tumorigenesis has been demonstrated [4]. A growing body of evidence also supports the 
theory that chronic inflammation plays an important role in CRC initiation [5].  
Non-coding RNAs (ncRNAs) occupy the bulk of the human genome. Increasingly, studies 
have shown that non-coding RNAs play important role in the regulation of many diseases 
including cancer initiation and metastasis. Many ncRNAs serve as prognostic markers for 
cancer, and some microRNA mimics or inhibitors are currently in clinical trials to test their 
efficacy as chemotherapeutic agents [6]. Understanding the roles of colon stem cells, 
inflammation, and ncRNAs in CRC may lead to future CRC prevention and therapies. 
2 Colon Stem cell and CRC 
Intestine crypt 
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The small intestine and colon are lined with a single layer of epithelial cells. The intestinal 
epithelium is one of the most dynamic and fastest regenerating tissues in the body, 
replacing itself every 3 – 5 days. The intestinal crypt has a tubular shape and harbors 
stem cells and their proliferating progeny, which are responsible for driving epithelial 
homeostasis and regeneration. Epithelial regeneration relies on a small population of 
adult stem cells at the crypt base intercalated with Paneth cells, which continuously 
generate highly proliferating transit-amplifying (TA) cells that occupy the remainder of the 
crypt [7, 8].  
 
 
 
 
 
 
 
 
The nascent TA cells differentiate into various absorptive or secretory cell lineages on the 
villi such as enterocytes, tuft cells, goblet cells and enteroendocrine cells. These 
differentiated cells migrate upwards towards the base of the villi. Paneth cells are the only 
differentiated intestinal cell type that does not move upward out of the crypt but instead 
migrates downward to reside at the bottom of the crypt for up to 6-8 week [7, 8].   
Figure 1.  the organization of epithelium in the intestine [8].  
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Intestine/colon stem cell niche 
The activity and function of intestinal stem cells (ISCs) are regulated by factors produced 
by neighboring Paneth cells. These Paneth cells, found in close association with the 
Leucine-rich repeat-containing G-protein coupled receptor 5 (Lgr5) + ISCs at the crypt 
base, provide an important source of various niche factors including epidermal growth 
factor (EGF), Wnt3A, and Notch ligand [9]. Recent studies suggest that Paneth cells are 
not the sole niche component of ISCs. Ablation of Paneth cells by Diphtheria toxin 
receptor (DTR) did not affect crypt architecture, maintenance, or proliferation of ISCs [10]. 
It was also reported that lack of Wnt3, which is normally secreted by Paneth cells to 
support intestinal stem cell self-renewal, could not block the maintenance of intestinal 
stem cells in mice. This observation indicated the existence of redundant, non-epithelial 
sources of Wnt and other key niche signals [10]. Recent studies indicate that the stroma 
cells located beneath the intestinal crypts may contribute to the maintenance of the 
intestinal/colon stem cell niche for its self-renewal. For example, IL-22, produced by 
RORϒt + innate lymphoid cells in the intestine’s lamina propria, was shown to maintain 
epithelial integrity and protect stem cells against damage which plays important role in 
graft-versus-host disease [11]. Additionally, IL-22 was confirmed to promote organoid 
growth by activating the Stat3 pathway in Lgr5+ ISCs and by signaling to stem cells that 
express the IL-22 receptor [11].  
Paneth cells are absent from the colon, and the colonic stem cell niche is poorly 
characterized. Using multicolor, fluorescence-activated cell sorting technology and gene 
expression analysis of selected populations of single cells, the Clark lab found that 
cKit/CD117+ goblet cells expressed Dll1, Dll4, and epidermal growth factor analogously 
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to Paneth Cells.  Additionally, goblet cells formed a regular pattern with Lgr5+ stem cells 
at the crypt base, like the organization of the intestinal crypt.  Based on these findings, 
cKit/CD117+ goblet cells probably provide niche components for Lgr5+ stem cells [12]. 
However, the major Wnt source in the colon has yet to be identified. 
Colon cancer stem cell 
Cancer stem cells are a small population of cancer cells that retain some of the phenotypic 
characteristics of normal stem cells, including the abilities to self-renew and to 
differentiate into new progenies. Cancer stem cells could originate from the accumulation 
of mutations during stem cell development [13] or from mutations in adult stem cells or 
projector cells [14]. Differentiated tumor cells might also become cancer stem cells by 
dedifferentiation [15].  
Although it is still largely unclear, it has been suggested that mutations, which occur in 
normal intestine/colon stem cells, cause the stem cells to become malignant. The mutant 
stem cells then divide symmetrically or asymmetrically to generate other cancer stem 
cells or differentiated progenies for tumor progression. For example, the deletion of APC 
in Lgr5+ intestine/colon stem cells caused stem cell transformation and the development 
of microadenoma. In contrast, the loss of APC in a transit-amplifying cell rarely causes 
adenoma formation [3]. Specific markers have been identified in colon cancer stem cells 
including CD133, CD44, and ALDH1 [16-19]. These markers are correlated with stem cell 
phenotypes such as self-renewal, differentiation and tumorigenesis. 
Cancer stem cells can initiate and sustain cancer progression. Many cancer stem cells 
are resistant to chemotherapy and persist in the tumor mass even after tumor regression, 
leading to tumor relapse and metastasis [20]. Therefore, understanding cancer stem cells 
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and developing new therapeutic approaches will benefit patient survival and improve 
quality of life. 
Symmetric division and asymmetric division  
Stem cells can divide symmetrically to generate two stem cell daughters or 
asymmetrically to generate one stem cell and one differentiated cell.  By using 
asymmetric division, stem cells can maintain a constant number of stem cells to prevent 
overgrowth of the stem cell population. Thus, making asymmetric division necessary to 
maintain tissue homeostasis. During embryogenesis and wound recovery, the stem cells 
utilize a symmetric division strategy to rapidly proliferate instead of their asymmetric 
strategy used to maintain healthy, developed tissue. By dynamically switching between 
asymmetric and symmetric division strategies, the stem cell population can respond to a 
wider variety of conditions [21]. Therefore, stem cells use a symmetric division strategy 
to generate two daughter cells which can generate more stem cells and differentiated 
cells.  
Asymmetric division as tumor suppressor  
Stem cells proliferate via symmetric division, which doubles their number after each 
division. However, it increases the risk of tumorigenesis. On the other hand, asymmetric 
division does not increase the number of stem cells, hence reducing the risk. Drosophila 
neuroblasts undergo asymmetric division to keep the self-renewal and tissue 
homeostasis under the regulation of PINS, aPKC and lethal giant larvae (lgl) [22]. Once 
this regulatory machine is disrupted, neuroblasts switch from asymmetric division to 
symmetric division and can form tumors [22, 23].  After receiving mutated copies of raps, 
Numb, Pros or Mira brought in Larval brains transplantation, neuroblast division changed 
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from asymmetrical to symmetrical. Neuroblast division alteration caused about 20% of 
the brains to develop tumors [23].  Asymmetric division also occurs in other human cancer 
types including breast, glioma, colorectal, and lung cancer [24-28]. Furthermore, 
asymmetric division frequency is negatively correlated with their proliferative capacity [29].  
miR-34a regulates the balance between asymmetry and symmetry in CCSCs 
Our group previously discovered that CCSCs undergo both symmetric and asymmetric 
division [30]. miR-34a expression levels balance cell division mode and tumorigenic 
capability. A low miR-34a level increases the frequency of symmetric division, promotes 
CCSC self-renewal, and leads to tumor formation and growth. Analysis of CCSCs from 
different stages of colon cancer showed that cancer stem cells from the early stages of 
colon cancers have higher miR-34a expression, which leads to a higher frequency of 
asymmetric cell division.  
 
 
 
 
 
 
In contract, cancer stem cells from late stages of colon cancers display the opposite trend. 
Mechanistically, miR-34a directly targets Notch1 to generate a bimodal Notch1 
distribution, which produces binary cell fate decisions [30]. However, it is still unknown 
Figure 2. miR-34a regulates CCSC fate [30]. 
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whether normal intestine/colon stem cells divide asymmetrically in certain conditions and 
whether miR-34a regulates normal stem cell division as it does in CCSCs. 
3 Inflammation and CRC  
Chronic inflammation has been regarded as one of the most significant risk factors in 
CRC development [5, 31]. Patients with inflammatory bowel diseases (IBD) appear to 
have a high risk for developing colitis-associated CRC (CAC) with high mortality rate [32]. 
Although the clinical presentations of IBD usually do not show a clear onset of cancer, 
the fundamental role of inflammation in CAC progress can be inferred from clinical 
samples that show the association of tumor-associated inflammation and early stage 
cancer development in the gut [33].  
Th17 cell in CRC 
Inflammation often activates T helper cells including Th1, Th2 and Th17 cells [34]. 
Different T helper cells have distinct roles in their contribution to colon cancer progression. 
Systemic analysis of T helper cell enrichment and CRC prognosis revealed that CRC 
patients with high Th17 cell enrichment in CRC had a poor prognosis. In contrast, 
enrichment of Th1 cells benefits the patient survival. However, Th2 levels had little 
prognostic value [35]. Th17 cells were first identified in 2005. Since then, Th17 cells have 
been revealed to have significant roles in the pathogenesis of inflammatory and 
autoimmune diseases [36]. Recent studies have shown that Th17 cells are also heavily 
involved in the regulation of tumorigenesis. Th17 cells have been found in many different 
types of human tumors such as breast cancer [37], colon cancer [38], and liver cancer 
[39]. The level of tumor infiltrating Th17 cells is closely correlated with tumor progression 
and prognosis.  
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In mice, IL-6 and TGF-ß initiate the differentiation of CD4+ T cells into Th17 cells.  IL-23 
finalizes the Th17 cell differentiation process and maintains the differentiated Th17 cells 
[40]. Th17 cells mediate inflammatory responses through selective migration and 
accumulation at specific sites. Th17 cells express chemokine receptors such as CCR4 
and CCR6. Many cells including tumor cells secrete the corresponding chemokines and 
attract Th17 cells to their sites [41, 42]. For example, cervical cancer secretes CCL20 (the 
ligand of CCR6) and CCL22 (the ligand of CCR4), which recruits TH17 cells in the cervical 
cancer sites and promote cancer growth [43].   
 
 
 
 
IL-17 in CRC 
Th17 cells secrete various cytokines including IL-17A, IL-17F, IL2 and TNF. Among 
those, IL-17 (IL-17A) is the predominant cytokine that Th17 cells produce, as Th17 cells 
were named after their production of IL-17. IL-17 belongs to the IL-17 family consisting of 
six members from ILA17A to IL-17F [44]. IL-17 is an important cytokine that facilitates the 
host response against bacterial infection due to its role in the induction of other important 
cytokines, chemokines, and antimicrobial peptides [45]. Increasing recent evidence 
supports the theory that IL-17 acts as promoter for CRC initiation and progression. For 
example, ablation of IL-17, either by knockout from the host or treatment with anti-IL-17 
antibody, significantly reduces intestinal tumor initiation and progression due to the 
Figure 3. Th17 cell differentiation and infiltration. 
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disruption of the immune responses [46, 47]. The IL-17 receptor (IL-17R) family includes 
IL-17RA, IL-17RB, IL-17RC, IL-17RD, and IL-17RE. IL-17 is primarily thought to bind a 
homodimer of IL-17RA or IL-17RC or a heterodimer of IL-17RA and IL-17RC. IL-17RD 
was previously thought as an orphan receptor that is not involve in IL-17 mediating 
signaling. A recent study showed that IL-17RD associates with IL-17RA to mediate IL-17 
signaling [48]. However, it is largely unclear whether the interaction of IL-17 and its 
receptors is altered by varying physiological and pathological conditions in different tissue 
or cell types.  
4 Non-coding RNA and colon cancer 
Human genome sequencing revealed that only 2% of the human genome codes for 
proteins. This leaves 98% of the human genome, which is often called “junk DNA” or “dark 
genes” [49].  Increasing evidence has shown that these “junk DNA” can be transcribed 
into microRNA (miRNA), small nucleolar RNA (snoRNA), and long non-coding RNA 
(lncRNA). Most of these non-coding RNAs play a vital function in regulation of 
carcinogenesis, stem cell reprogramming, aging, cancer metastasis, and metabolism [49]. 
Several non-coding RNAs have been identified as biomarkers for diagnosis of disease. 
Specifically, miR-34a mimics has entered phase 2 clinical trials after the first 
demonstration of its anticancer activity in 2002 [50]. The rapid progress from discovery to 
application reflects its importance in human cancer.  
miRNA  
miRNAs are short non-protein coding RNA containing19-25 nucleotides. miRNA genes 
are estimated to account for 2-5% of the human genome, but regulate up to 20% of all 
human genes [49]. The sequences are first transcribed by Pol II/III to form a pri-miRNA, 
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which contains hundreds of nucleotides forming a stem and a terminal loop structure with 
flanking segments. Next, pri-miRNA is cleaved into pre-miRNA by the Drosha protein 
complex. Pre-miRNA is a hairpin RNA around 60-70bp long with 2bp overhangs at its 3’ 
end. Pre-miRNA is then transported from the nucleus to the cytoplasm by exportin-5. A 
cytoplasmic endonuclease RNase III, Dicer, helps generate a miRNA duplex containing 
the mature miRNA guide and its complementary passenger strand (miRNA*). The left 
single strand is integrated into the RNA-induced silencing complex (RISC), a 
ribonucleoprotein effector containing a catalytic endonuclease core, an Argonaute protein, 
and binds to the cognate site within the 3`-untranslated regions (3UTR) of the targeted 
mRNA. The targeted mRNA will be degraded or silenced when the seed region (the 5`-
end region of mature miRNA, around 6-8bp) of mature miRNA is complementarily 
matched with the 3 UTR of mRNA [50]. Increasing evidence has shown that miRNAs 
exert an important influence on cell development, metabolism, and carcinogenesis [51].  
miRNAs in CRC 
miRNAs have shown great promise for clinical applications. Due to their stability and 
robust expression pattern, miRNA has been used as biomarkers and prognostic 
indicators [52]. Many miRNAs have been discovered to be associated with CRC 
development, metastasis, and invasion in the past decades. For example, the Let-7 family 
targets the oncogenes including KRAS, c-Myc, CDC34, CDC25A, CDK6, HMGA2, Lin28, 
and Lin28b to inhibit migration, invasion, and angiogenesis [52, 53]. miR-21 is one of the 
more famous oncogenes. High miR-21 expression is correlated with the clinical CRC 
stage and is markedly increased in chemotherapy-resistant colon cancer. miR-21 also 
modulates stemness in CRC by regulating TGF-ßR2 [54] and targets PTEN and PDCD4 
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to promote tumor progression, invasion, and metastasis [55]. miR-21 is a candidate 
biomarker for advanced CRC diseases [54, 55]. 
miR-34a 
miR-34a belongs to the miR-34 family that consists of three members: miR-34a, miR-34b 
and miR-34c. miR-34a is transcribed from the human chromosome 1. In contrast, miR-
34b and miR-34c are transcribed from the same primary transcript on the human 
chromosome 11 [50, 56]. miR-34a is widely expressed in the body, e.g., in the brain, while 
miR-34b and miR-34c are mainly expressed in the lungs [56]. The miR-34 family is highly 
conserved throughout evolution [56]. 
upregulated by p53, miR-34a is a key tumor suppressor.  By silencing targets such as c-
Met, Bcl-2, MDM4 and E2F3, miR-34a has been proved to play important roles in the 
regulation of the cell cycle and cell proliferation [57]. In addition, increasing evidence has 
indicates that miR-34a is also heavily involved in tumor initiation and progression, and 
stem cell self-renewal and differentiation [58]. We have previously shown that miR-34a is 
asymmetrically distributed in differentiated daughter cells during colon cancer stem cell 
(CCSC) division [30]. High levels of miR-34a promoted CCSC differentiation, while 
inhibition of miR-34a expression enhanced CCSC self-renewal.  However, it is completely 
unclear how miR-34a asymmetric distribution is regulated. Although perturbation of p53 
expression level could alter CCSC division, p53 is distributed symmetrically during CCSC 
division, suggesting other factors may play role in regulation of miR-34a distribution.  
miR-34a expression is also epigenetically regulated. It has been reported that miR-34a is 
silenced in human cancers including breast, lung, colon, kidney, bladder and pancreatic 
carcinoma because of the methylation of CpG islands in the miR-34a promoter region 
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[59]. The miR-34a promoter becomes more methylated in late-stage CRC, consistent with 
its lower expression. However, it is largely unknown how the miR-34a promoter is 
methylated. 
Long non-coding RNA 
Long non-coding RNAs (lncRNAs) are non-protein coding transcripts with lengths greater 
than 200bp. In recent years, lncRNAs have gained widespread attentions because they 
play important roles in various diseases including tumorigenesis and cancer biology [60]. 
Expression profiles of lncRNAs have been compared between tumors and their 
corresponding tissues of origin, which showed marked alteration in all types of cancer 
[61]. The Cancer Genome Atlas (TCGA) analyzed alterations at transcriptional, genomic, 
and epigenetic levels of lncRNAs and protein-coding genes in 5,037 human tumor 
specimens across 13 cancer types, and found that lncRNAs were highly cancer-type 
specific compared with protein-coding genes [61]. Therefore, lncRNAs may serve as 
potential diagnostic and prognostic biomarkers. Elucidation of lncRNA-related functions 
and mechanisms will increase our understanding of cancer. 
LncRNAs play important roles in the regulation of tumorigenesis and tumor progression. 
For example, HOTAIR lncRNA targets PRC2 to alter histone H3 lysine 27 methylation, 
leading to increased cancer invasiveness and metastasis [62]. Currently, high expression 
of HOTAIR has been associated with poor prognosis in breast cancer [62], liver [63], 
colorectal cancer [64], gastrointestinal cancer [65], and pancreatic cancer [66]. MALAT1 
(metastasis-associated lung adenocarcinoma transcript) is highly associated with lung 
cancer metastasis [67].  Mechanistically, MALAT1 alters the activity of the polycomb2 
protein to active the target genes from a repressive status. Activation of these target 
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genes drives tumor growth and metastasis. LincRNA-p21 can serve as a repressor in 
p53-dependent transcriptional responses through interaction with heterogeneous nuclear 
ribonucleoprotein K (hnRNP-K), which explains why p53 activation cannot induce tumor 
cell apoptosis [68].  
LncRNA and epigenetics  
Epigenetic regulation seems to be an important mechanism for lncRNA to regulate gene 
expression. DNA in the form of chromatin can be packaged around histone proteins in 
the nucleus, and these histones can be modified by acetylation, methylation, sumoylation, 
and ubiquitylation. Histone modifications induce structural variations in chromatin (i.e. 
conversion of loosely-packed euchromatin to tightly-collapsed heterochromatin) and 
affect gene expression through altered chromatin accessibility. Futhermore, the effects of 
this process can persist for several generations independent of DNA sequence.  
The major function of lncRNAs is to recruit protein factors for the regulation of chromatin 
by methods such as DNA methylation and histone modifications. LncRNAs may function 
in cis strategies, acting on linked genes near the RNA synthesis sites. Alternatively, 
lncRNAs can act in trans strategies, regulating genes located in distant domains or 
chromosome. It has been shown that lncRNAs interact with chromatin-modifying 
complexes [69, 70].  For example, HOTAIR and Xist/RepA regulate gene expression by 
recruiting PRC2 [71]. LncRNA Air interacts with H3K9 histone methyltransferase G9a to 
modulate gene activity [72]. LncRNAs can also act as a scaffold that can assemble 
multiple proteins onto the promoter of the gene, allowing the complex to modify the 
chromatin [73]. For example, LncRNA HOTAIR binds polycomb repressive complex 2 
(PRC2) on its 5’ domains and binds LSD1/CoREST/REST complex on its 3’ domains to 
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tether these two distinct complexes for a RNA-mediated assembly of PRC2 and LSD1 to 
guide histone H3 lysine 27 methylation and lysine 4 demethylation for HOX silence [73]. 
Beyond histone modifications, lncRNAs can also epigenetically regulate DNA methylation 
at CpG dinucleotides, which is crucial for the stable repression of genes. LncRNA Tsix 
represses Xist by recruiting Dnmt3a to methylate and silence the Xist promoter [74]. 
Kcnq1ot1 recruits Dnmt1 to affect the methylated regions [75]. Besides recruiting 
epigenetic complexes to regulate gene expression, lncRNAs can function as molecular 
decoys for transcription factors to affect the process of transcription by competing for 
transcription factor binding sites or by influencing the cellular localization of transcriptional 
factors (TFs) [76].  
Crosstalk between lncRNA and microRNA 
Simultaneous dysregulation of lncRNAs, miRNAs, and their downstream targets has been 
observed in multiple types of cancers [77]. For example, MALAT1 has two binding sites 
for miR-125b. MALAT1 is negatively correlated with miR-125b in bladder cancer. 
Overexpression of miR-125b can inhibit MALAT1 expression while simultaneously 
blocking cell proliferation, migration and inducing apoptosis. Also, MALAT1 can reverse 
the roles of miR-125b mimics in bladder cancer [77]. LncRNA-ROR (Regulator of 
Reprogramming, core regulator of hESC self-renewal and differentiation) can bind to miR-
145 to suppress the latter’s function. LncRNA-ROR can reverse microRNA-mediated 
reprogramming core TFs’ suppression including Nanog, Sox2 and Oct4 [78]. Another 
example is that lncRNA SIRT1-AS can bind to the SIRT1’s 3-UTR, which blocks miR-29c 
binding sites on the SIRT1 [79]. The interaction will increase the expression level of SIRT1 
and subsequently increase cell proliferation and survival. miR-34a has also been reported 
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to directly target HOTAIR to suppress prostate cancer progression [80].  LncRNA H19 
has been found to promote epithelial to mesenchymal transition (EMT) in multiple cancer 
types including colorectal, ovarian, and gastric cancers. It has been suggested that H19 
reduces the activity of miR-138 and miR-200a in colon cancer [81].   
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Chapter 1 
A Long Non-Coding RNA Targets MicroRNA miR-34a to 
Regulate Colon Cancer Stem Cell Asymmetric Division 
This section is adapted from the following publication: 
Lihua Wang, *, Pengcheng Bu*, Yiwei Ai, Tara Srinivasan, Huanhuan Joyce Chen, Kun 
Xiang, Steven M. Lipkin, Xiling Shen. A large non-coding RNA regulates colon cancer 
stem cell asymmetric division. eLife. 2016; 10.7554/eLife.14620. 
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Chen performed the rest of the animal-related experiments.  
 
 
 
 
 
 
31 
 
INTRODUCTION 
A downstream target of p53, the microRNA miR-34a is a well-known tumor suppressor in 
various types of cancer [1,2]. Among its many functions, miR-34a has been shown to limit 
self-renewal of cancer stem cells [3,4]. miR-34a mimics such as MRX34 are among the 
first microRNA mimics to reach clinical trial for cancer therapy [5,6]. Besides cancer, miR-
34a has been shown to regulate stem cell differentiation, somatic stem cell 
reprogramming, cardiac aging, neurodegeneration, ciliogenesis, bone resorption, and 
metabolism [7-13]. 
Loss of p53 function can lead to downregulation of miR-34a. However, miR-34a 
expression also tends to be silenced due to aberrant CpG methylation of its promoter in 
many types of cancer, including breast, prostate, lung, colon, kidney, bladder, pancreatic, 
and ovarian cancer [14-16]. Methylation of the miR-34a promoter is inversely correlated 
with miR-34a expression and is positively correlated with progression of colorectal cancer 
(CRC) [17]. However, it is completely unclear how miR-34a is silenced by epigenetic 
modification. 
Normal stem cells often divide asymmetrically to produce one daughter cell like itself for 
self-renewal and another daughter cell unlike itself to go down a path of differentiation 
[18]. Asymmetric division allows stem cells to maintain self-renewal while generating a 
heterogeneous population for cellular diversity [19]. Tumor cells are usually 
heterogeneous and have a wide range of potential for tumorigenesis, proliferation, and 
metastasis. Recent studies have reported that cancer cells, including colorectal, glioma, 
lung and breast cancer cells, can also divide asymmetrically, generating progenies with 
different proliferation capabilities [3, 20-25]. The frequencies of symmetric vs. asymmetric 
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divisions are associated with cancer proliferation and progression. Disruption of 
asymmetric division in favor of symmetric self-renewal alters the balance between self-
renewal and differentiation, which has been linked to neoplastic transformation and tumor 
growth [25, 26].  
Here, we discovered that a novel lncRNA, Lnc34a, directly targets the miR-34a promoter 
for epigenetic silencing by recruiting the DNA methyltransferase Dnmt3a via Prohibitin-2 
(PHB2) and Histone Deacetylase 1 (HDAC1). Asymmetric distribution of Lnc34a during 
colon cancer stem cell (CCSC) division leads to asymmetric daughter cell fate. Its 
suppression leads to differentiation while its abundance leads to CCSC proliferation via 
symmetric self-renewal. Lnc34a tends to be upregulated in late-stage CRC, associated 
with miR-34a silencing. The ability of lncRNA to target microRNA provides RNA circuitry 
more ways to increases the complexity of the regulatory network. 
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RESULTS 
A lncRNA overlapping with miR-34a promoter 
We performed RT-PCR with 10 pairs of primers to scan for potential transcripts 
overlapping the miR-34a promoter and its downstream sequence. A 293-base pair (bp) 
transcript fragment was amplified. Rapid amplification of cDNA ends (RACE) further 
identified a full-length, 693bp transcript (Figures 1A and 1B). Northern blot confirmed the 
existence and size of the transcript in seven CRC cell lines and two colon cancer stem 
cell (CCSC) lines (Figures 1D, 2A and 2B). The CCSCs were isolated from two early-
stage CRC specimen, and were functionally validated by serial sphere formation, tumor 
initiation, and marker staining [3]. The original frozen stocks from the first passage were 
used in the study. The transcript is composed of two exons, spanning nearly 15.3 
kilobases (kb), and does not contain a valid Kozak sequence. The full-length transcript 
has no protein coding potential according to the Coding Potential Calculator (CPC) and 
Coding Potential Assessment Tool (CPAT) [27, 28]. We named the transcript Lnc34a.  
To analyze Lnc34a expression in CRC cells, RT-qPCR was performed in 9 commonly 
used CRC cell and the two CCSC lines. Consistent with the Northern blot measurement, 
Lnc34a levels were significantly higher in the CCSC sphere cells (Figures 1C and 2C). 
Cellular fractionation assays show enrichment of Lnc34a in the nuclear fraction (Figures 
2D and 2E), and RNA fluorescence in situ hybridization (RNA FISH) indicates that Lnc34a 
is mainly in the nucleus (Figure 2F). RNA FISH specificity was validated when the same 
RNA-FISH probe did not detect Lnc34a after Lnc34a was knocked down by lentiviral 
short-hairpin RNA (shRNA) vectors in CCSC spheres (Figure 3A). 
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Lnc34a asymmetry 
Notably, RNA-FISH showed that a small population among the CCSC sphere cells did 
not express Lnc34a, although the majority did (Figure 2F). We then separated the sphere 
cells into two populations based on the expression levels of ALDH1, a CCSC marker [29]. 
Flow analysis confirmed that ALDH1+ cells also express high levels of CD133, another 
CCSC marker (Figure 4A). RT-qPCR showed that, in both sphere cultures (CCSC1 and 
CCSC2), ALDH1+ cells have much higher Lnc34a expression levels than the ALDH1- 
cells (Figures 5A and 5B). We then performed the pair-cell assay by plating single cells 
and allowing them to progress through one cell division [30]. α-tubulin staining was used 
to identify dividing cells (Figure 5C). Co-staining revealed that Lnc34a was asymmetrically 
distributed and enriched in the ALDH1+ (CCSC) daughter cells, which were also CD133+ 
(Figures 4B, 4C, 5C and 5D). 
Lnc34a asymmetry in dividing cell pairs was confirmed in vivo by RNA-FISH and tubulin 
staining of xenograft tumors derived from subcutaneously injected CCSCs (Figures 5E 
and 5F). We investigated Lnc34a asymmetry in 23 early-stage (stage I/II) and 22 late-
stage (stage III/IV) human CRC specimens (Table 1). Lnc34a asymmetry in dividing cell 
pairs is more strongly associated with early-stage CRC, while late-stage CRC mostly has 
symmetric Lnc34a levels in dividing pairs (Figures 5G and 5H).  
To investigate whether Lnc34a regulates CCSC division symmetry, we first knocked down 
Lnc34a using lentiviral shRNAs, which have been reported to knock down certain nuclear 
lncRNAs efficiently [31-34]. Among the five tested shRNAs against Lnc34a, two showed 
efficient suppression of Lnc34a (shLnc34a1 and shLnc34a2; Figure 3B).  Lnc34a 
knockdown decreased asymmetric division while increasing symmetric, ALDH1-/ALDH1- 
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division (Figure 5I). We then ectopically expressed Lnc34a using lentiviral vectors. Higher 
level of ectopic Lnc34a was detected in the nucleus than in the cytoplasm (Figure 3C). 
Ectopic Lnc34a expression also decreased asymmetric division, but increased symmetric, 
ALDH1+/ALDH1+ division instead (Figure 5J). The phenotype was rescued by ectopic 
miR-34a expression, suggesting that Lnc34a regulates symmetry through miR-34a 
(Figure 5J). The same trend was observed with CD133 staining (Figures 4C and 4D). 
Therefore, ectopic Lnc34a seems to promote symmetric CCSC self-renewal, while 
Lnc34a silencing promotes differentiation. 
Pair-cell BrdU incorporation assay showed that, when cultured in proliferative medium 
(DMEM with 10% FBS), the Lnc34a+ daughter cell starts incorporating BrdU and enters 
into the next division immediately, whereas the Lnc34a- daughter cells do not incorporate 
BrdU (Figure 5K). Therefore, the Lnc34a+ daughter cell has higher proliferative capacity.  
Lnc34a enhances CCSC self-renewal and tumorigenesis 
Serial sphere propagation assays were performed to evaluate the effect of Lnc34a on 
CCSC self-renewal. CCSCs containing a control vector exhibited stable sphere formation 
capability through 3 generations of sphere propagation. Lnc34a knockdown strongly 
suppressed sphere formation capability, which was completely lost after 3 generations of 
passage (Figures 6A and 6B). In contrast, ectopic Lnc34a expression increased sphere 
numbers and sizes significantly. Ectopic miR-34a abrogated the effect of Lnc34a on 
sphere formation regulation, suggesting that Lnc34a promotes CCSC self-renewal by 
targeting miR-34a (Figures 6A and 6C). 
Next, we used the mouse xenograft model to examine whether Lnc34a influences tumor 
growth. All five mice in the control group (injected with sphere cells containing the control 
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vector) developed tumors. However, only three mice injected with sphere cells expressing 
shLnc34a1 and two mice injected with sphere cells expressing shLnc34a2 formed tumors, 
which were smaller than those of the control group (Figures 6D and 6E). All 5 mice 
injected with sphere cells ectopically expressing Lnc34a developed tumors, which were 
notably bigger than those in the control group. Ectopic miR-34a expression abrogates the 
effect of ectopic Lnc34a on tumor growth, resulting in similar tumor sizes as the control 
group (Figures 6F and 6G). Furthermore, we performed FACS on disassociated xenograft 
tumor cells. Lnc34a knockdown decreased the ALDH1+ CCSC population in the 
xenograft tumors (Figure 6H), while ectopic Lnc34a enriched the ALDH1+ CCSC 
population in the tumors (Figure 6I). Taken together, Lnc34a contributes to CCSC self-
renewal and tumorigenesis. 
Lnc34a suppresses miR-34a expression. 
Opposite to Lnc34a, miR-34a is downregulated in ALDH1+ CCSCs and upregulated in 
ALDH1- non-CCSCs (Figures 7A and 7B). Knockdown of Lnc34a significantly increased 
miR-34a expression levels, while ectopic Lnc34a expression decreased miR-34a levels 
(Figures 7C and 7D). Therefore, Lnc34a suppresses miR-34a expression. RNA FISH 
showed that Lnc34a and miR-34a are mutually exclusive in the same daughter 
compartment and are present in opposite daughter compartments in more than 70% of 
CCSC1 and around 80% of CCSC2 dividing pairs (Figures 7E and 7F). On the other hand, 
we only observed symmetric distribution of p53, the other miR-34a upstream regulator 
(Figure 8). Therefore, Lnc34a provides a potential mechanism that accounts for 
asymmetric miR-34a levels in daughter pairs.  
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Bisulfite sequencing was then performed to evaluate miR-34a promoter methylation in 
ALDH1+ CCSCs and ALDH1- non-CCSCs isolated from spheres. 93.3% of tested CpG 
islands were methylated in CCSCs. In contrast, methylation rate was as low as 2.2% in 
non-CCSCs (Figure 7G). Knockdown of Lnc34a diminished overall miR-34a promoter 
methylation in sphere cells (Figure 7H), whereas ectopic Lnc34a expression significantly 
enhanced miR-34a promoter methylation, compared with the control vector (Figure 7I). 
Besides methylation (Figure 7J), ectopic Lnc34a expression decreased acetylated 
histones H3 and H4 (Figure 7K). Taken together, the data suggests that Lnc34a silences 
miR-34a expression in CCSCs by promoting methylation and histone deacetylation of the 
miR-34a promoter. The effect of ectopic Lnc34a suggests that Lnc34a might act both in 
cis and in trans, as have been observed for various lncRNAs such as Evf-2, and some 
cis-acting lncRNAs to act in trans [32, 35-40].  
Lnc34a also silences miR-34a in common CRC cell lines. Ectopic Lnc34a expression 
suppressed miR-34a expression and promoted methylation and deacetylation of the miR-
34a promoter in CRC cell lines Caco-2 and HT29 (Figure 9). 
Lnc34a, miR-34a, and promoter methylation are correlated with CRC progression. 
RT-qPCR performed in 23 early-stage (stage I/II) and 22 late-stage (stage III/IV) CRC 
specimens showed that Lnc34a expression is correlated with CRC progression. Overall, 
Lnc34a expression is lower in early-stage CRC and increases in late-stage CRC (Figures 
8L and 10A). miR-34a expression follows a reverse trend (Figures 8M and 10A). 
Consistent with Lnc34a methylation of the miR-34a promoter, bisulfite sequencing 
revealed that the miR-34a promoter is more methylated in late-stage CRC than in early-
stage CRC (Figures 8N and 10B). 
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Lnc34a interacts with epigenetic regulators 
To understand the mechanisms via which Lnc34a regulates miR-34a expression, we 
performed an RNA pull-down assay with biotin-labeled Lnc34a, followed by mass 
spectrometry (MS), to search for potential Lnc34a-associated proteins. The DNA 
methyltransferase Dnmt3a, Histone Deacetylase 1 (HDAC1), and Prohibitin 2 (PHB2) 
were identified to be associated with Lnc34a (Figure 11A and Table 2). RNA 
immunoprecipitation (RIP) using specific antibodies against Dnmt3a, HDAC1 and PHB2 
further confirmed the interactions (Figure 11B). In contrast, RNA pulldown and RIP did 
not detect any interaction between Lnc34a and Dnmt1, an enzyme that plays important 
roles in maintaining methylation during DNA replication (data not shown). 
To investigate how Lnc34a interacts with Dnmt3a, HDAC1 and PHB2, we performed RIP 
while knocking down each of the proteins. Knockdown of PHB2 abolished the interaction 
between Lnc34a and Dnmt3a but had no effect on the interaction between Lnc34a and 
HDAC1 (Figure 11C). Knockdown of Dnmt3a did not affect the interaction of Lnc34a with 
either PHB2 or HDAC1 (Figure 11D). Knockdown of HDAC1 did not interrupt Lnc34a and 
Dnmt3a interaction and only had limited effect on Lnc34a and PHB2 interaction (Figure 
11E). These data suggest that Lnc34a interacts with PHB2 and HDAC1 and recruits 
Dnmt3a through PHB2.  
We then serially truncated Lnc34a and performed RNA pull-down assays to map HDAC1 
and PHB2 binding to Lnc34a. The 1-267bp fragment is sufficient to bind HDAC1, and the 
560-693bp fragment is sufficient to bind PHB2 (Figure 11F). Interaction between the 
fragments and their cognate proteins were further validated by the electrophoretic mobility 
shift assay (EMSA). Incubation of labeled RNA probes Lnc34a:1-267bp with recombinant 
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HDAC1 and Lnc34a:560-690bp with recombinant PHB2 resulted in specific gel 
retardation, while unlabeled RNA probes of the same fragments competitively disrupted 
those binding (Figure 11G). All three fragments are needed for full suppression of miR-
34a expression (Figure 11H). Although the 267-560bp fragment does not interact with 
either HDAC1 or PHB2, the in vitro interaction assay shows that it directly binds to the 
miR-34a promoter (Figure 11I). Therefore, Lnc34a binds to the miR-34a promoter via the 
267-560bp sequence and recruits HDAC1 and Dnmt3a/PHB2 via the two flanking (1-
267bp and 560-690) sequences (Figure 11J).  
We then knocked down PHB2, Dnmt3a, and HDAC1 respectively, followed by RT-qPCR 
measurements of miR-34a expression. Knockdown of PHB2, Dnmt3a, or HDAC1 
upregulated miR-34a expression (Figures 11I-11K). Inhibition of HDAC activity by SAHA 
and TSA also increased miR-34a expression (Figures 11L and 11M). The data suggest 
that these epigenetic regulators influence miR-34a expression levels. 
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DISCUSSION 
The abundance of lncRNA in the human genome is being increasingly appreciated, but 
our understanding of their diverse functions is still lagging [39,41]. We demonstrate that 
a lncRNA, Lnc34a, can initiate CCSC asymmetric division by targeting miR-34a. 
Previously, lncRNAs like HOTAIR and Xist have been shown to cause histone H3 lysine 
27 methylation or lysine 4 demethylation [42-44]. Here, Lnc34a binds to the miR-34a 
promoter via its middle fragment, and recruits PHB2/Dnmt3a and HDAC1 via its flanking 
sequences to methylate and deacetylate the promoter, silencing miR-34a expression. 
This process reminds us of the ordered steps of protein-mediated DNA methylation—a 
DNA binding protein first interacts with the promoter, via which DNA methyltransferases 
are further recruited [45-47].  
Lnc34a promotes CCSC self-renewal, and Lnc34a asymmetry leads to cell fate 
asymmetry in CCSC division. This effect is mediated by miR-34a, which has been shown 
to target factors of Notch and Wnt signaling pathways, both of which are essential for 
CCSC self-renewal [3, 48, 49]. In late-stage CRC, Lnc34a expression and miR-34a 
promoter methylation is upregulated, while miR-34a expression is downregulated. 
Lnc34a demonstrates that lncRNA can target microRNA for cellular control. Given that 
lncRNAs occupy the majority of the genome [50], lncRNA/microRNA circuitry can 
potentially increase the complexity of regulatory networks. 
p53 is a well-known upstream regulator of miR-34a, and loss of p53 function certainly 
downregulates miR-34a. However, the discovery of Lnc34a demonstrates an alternative, 
epigenetic mechanism that cancer cells can utilize to silence miR-34a without having to 
mutate p53. Although p53 knockout has been reported to reduce asymmetric division in 
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mammary stem cells [26], p53 is not known to be a major regulator of differentiation and 
is symmetric during CCSC division. Lnc34a provides normal and cancer cells a way to 
decouple mir-34a mediated cell fate decisions from p53, which may be present in both 
undifferentiated and differentiated cells.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
42 
 
METERIALS AND METHODS 
CCSC culture and sphere formation analysis 
Human CRC cell lines Colo205, SW480, HT29, SW620, LS174T, DLD1, Caco-2 were 
purchased from ATCC and cultured in RPMI-1640 medium. No mycoplasma 
contamination was detected. Human CCSCs were isolated and cultured as described 
previously [3]. Briefly, CCSCs were isolated from patient tumors by FACS based on 
markers CD44, CD133 and ALDH1 and functionally validated by serial sphere formation, 
tumor initiation, and self-renewal assays. For this study, original frozen stocks for the first 
passage were used. The CCSCs have not been authenticated by STR profiling. No 
mycoplasma contamination was detected.  CCSCs were cultured as spheres in ultralow-
attachment flasks (Corning) in DMEM/F12 (Invitrogen), supplemented with nonessential 
amino acids (Fisher), sodium pyruvate (Fisher), Penicillin-streptomycin (Fisher), N2 
supplement (Invitrogen), B27 supplement (Invitrogen), 4 µg/mL heparin (Sigma), 40 
ng/mL epidermal growth factor (Invitrogen), and 20 ng/mL basic fibroblast growth factor 
(Invitrogen) at 37 °C and 5% CO2.  
To measure tumor sphere formation, single CCSCs were plated in 24-well ultra-low 
attachment plates (Corning) at 1,000 cells per well. Tumor spheres were counted after 2 
weeks in culture by an inverted microscope (Olympus). 
Clinical specimens 
45 frozen CRC specimens of different clinical stages were acquired from Weill Cornell 
Medical College (WCMC) Colon Cancer Biobank. The CRC stage was determined 
according to the TNM staging system. The clinical data for the patients are summarized 
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in Figure 1-source data 1. The studies followed informed consent and approval of the IRB 
committee at Weill Cornell Medical College.  
Immunofluorescence  
Pair-cell assay for CCSC division were performed as described previously [30]. Briefly, 
spheres were dissociated and the single cells were plated on an uncoated glass culture 
slide (Corning) and allowed to divide once. After being fixed and blocked, the cells were 
incubated with anti-ALDH1 (clone H-4, 1:100, Santa Cruz), anti-CD133 (1:200, Abcam) 
and anti-α-tubulin (1:500, Abcam) antibodies overnight at 4 °C. For the BrdU incorporation 
assay, sphere cells were cultured in proliferative medium (DMEM with 10% FBS) for 24 
hours. Single cells were then plated and allowed to divide once in proliferative medium 
(1st division). After treatment with BrdU (Sigma) for 3 hours, the cells were fixed in cold 
70% ethanol, incubated in 2 M HCl for 1 hour, washed, and switched to 100 mM Na2B4O7 
for 2 minutes. After being blocked in 10% normal goat serum for 1 hour, the cells were 
then incubated with anti-BrdU (1:200, Sigma) antibody at 4 °C overnight. The cells were 
then incubated with fluorescence-conjugated secondary antibody or streptavidin 
(Invitrogen) for 1 hour at room temperature. After counterstaining with DAPI (Invitrogen), 
the slides were observed under a fluorescent microscope (Olympus). 
RNA FISH 
RNA FISH was performed as described previously [51]. In this study, Digoxigenin (DIG)–
labeled locked nucleic acid (LNA) probe (Exiqon) against miR-34a or Biotin-labeled LNA 
probe against Lnc34a (Exiqon) were used for RNA FISH. RNA expression was detected 
by Rhodamine Red labeled secondary antibody or Alexa Fluor 488 conjugated 
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streptavidin (Invitrogen). Anti-tubulin was used to identify dividing cells and DAPI 
(Invitrogen) was used for nucleic counterstaining. 
Lnc34a cloning, shRNAs, Northern blot and Bisulfite sequencing 
A 293 bp fragment was amplified using primers: 5`-GGTGGAGGAGATGCCGC-3` and 
5`-ACCTGGGTGCATGCTGGGACG-3`. To identify the full length of Lnc34a, 3`RACE 
and 5`RACE was performed using kit with the primers: 5`- 
GCAGGACTCCCGCAAAATCTC-3` and 5`- CTCAGTCCGTGCGAAAGTTTG-5` 
respectively.  The full length of Lnc34a was then amplified using the primers: 5`-
TTAACCAGTCGGCCTTCCTCGCC-3` and 5`-TGAGATTAACCGACTTTCCCAAG-3`, 
then cloned into pGEM-T (Promega) for sequencing. The full length of Lnc34a was cloned 
into pMSCV PIG vector (Addgene) for ectopic Lnc34a expression study.  shRNAs against 
Lnc34a were designed using Invitrogen online tool and cloned in pMSCV PIG vector. 
shRNAs against PHB2, Dnmt2a, and HDAC1 were purchased from Sigma. The 
knockdown efficiency was validated by RT-qPCR. Northern blot was performed using 
NorthernMax® Kit (Invitrogen) according to the manufacturer’s instructions. The probes 
were generated using PCR DIG Probe Synthesis Kit (Roche) with the primers: 5`- 
TAGCCGAGCAAAACCCC-3` and 5`- ATGTGGGACACGGATGAGA-3`. Bisulfite 
sequencing was performed using EZ DNA methylation kit (Zymo). 9 sequencing runs 
were carried out for each condition. 
Flow cytometry 
Flow cytometry were performed as described previously [3].CD133 expression was 
detected using anti-CD133 (clone C24B9, 1:50, Cell Signaling) and ALDH1 levels were 
analyzed using the Aldeflour kit.  The samples were analyzed using a BD LSR II flow 
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cytometer. The raw FACS data were analyzed with the FlowJo software to gate cells 
according to their forward (FSC) and side (SSC) scatter profiles.  
Quantitative real-time RT-PCR analysis 
Total RNA was extracted from the cells using the TRIzol Reagent (Invitrogen). cDNA was 
synthesized using the High Capacity cDNA Archive Kit (Applied Biosystems). Quantitative 
PCR was carried out using the TaqMan MicroRNA Assay (Applied Biosystems) to detect 
miR-34a levels and the SYBR Green System (Applied Biosystems) to detect another 
gene expression. The miR-34a primer and U6 primer were purchased from Applied 
Biosystems. Other primer sequences include: Lnc34a, 5'-
GGAGGCTACACAATTGAACAGG-3' and 5`-AGTCCGTGCGAAAGTTTGC-3`; actin, 5`-
CGCGAGAAGATGACCCAGAT-3` and 5`-ACAGCCTGGATAGCAACGTACAT-3`; The 
expression of each gene was defined from the threshold cycle (Ct), and the relative 
expression levels were calculated using the 2-△△Ct method after normalization to the 
actin expression level. 
RNA pull-down assay, mass spectrometry, and electrophoretic mobility shift assay 
(EMSA) 
Full length of Lnc34a cDNA and its truncations were cloned into pGEM-3ZF (+). Biotin-
labeled RNAs were transcribed from the linearized pGEM-3ZF plasmid in vitro using a 
biotin labeling mix (Roche) and T7 polymerase (Promega). The biotinylated RNA was 
heated to 90°C for 2 minutes, incubated on ice for 2 minutes, and then shifted to RT for 
20 mins with RNA renature buffer (10mM tris-HCL pH7.0, 0.1M KCL, 10mM MgCl2 to 
allow proper secondary structure formation. The cell lysates were freshly prepared using 
RIPA buffer (Millipore) with proteinase inhibitor (Roche). After preclearing using 
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Dynabeads M-270 streptavidin (Invitrogen), the cell lysates were diluted in binding buffer 
and incubated with the folded RNA for 2 hours at 4°C. Dynabeads M-270 streptavidin 
were then added into the mixture and incubated for 1 hour at 4°C. After washing, the 
RNA-binding protein complexes were released from the Dynabeads. The retrieved 
proteins were collected for Mass Spec and Western blotting validation. RNA-EMSA was 
performed using a LightShift Chemiluminescent RNA EMSA Kit (Thermo Scientific) 
according to the manufacturer’s instructions. 
RNA immunoprecipitation (RIP) and chromatin immunoprecipitation (ChIP) assays 
RIP assays were performed using a RIP RNA-binding protein immunoprecipitation kit 
(Millipore) according to the manufacturer’s instructions. Antibodies against PHB2 (Bethl), 
HDAC1 (Bethl), and Dnmt3a (Abcam) were added into the cell lysates. Lnc34a was 
retrieved from the complexes and evaluated by RT-qPCR. ChIP was performed using a 
ChIP assay kit (Millipore) as described previously [3]. Antibodies against acetylated 
histones H3 and H4 (Millipore) were used to evaluate histone modifications associated 
with the miR-34a promoter. Enrichment of miR-34a promoter fragments was quantified 
by RT-qPCR with the primers: 5'-CACCTGGTCCTCTTTCCTTT-3' and 5'- 
TCCTCCTTCCTGCTCGT -3'.  
Western blot 
Cells were lysed in RIPA lysis buffer supplemented with cocktail protease inhibitor 
(Roche). Proteins were separated by SDS-PAGE and transferred onto a Hybond 
membrane (Amersham). The membranes were incubated with primary antibodies either 
anti-PHB2 (1:1000, Bethl), anti-Dnmt3a (1:500, Abcam), anti-HDAC1(1:1000, Bethl) or 
anti-Actin (1:1000, Abcam) in 5% milk/TBST buffer (25 mM Tris pH 7.4, 150 mM NaCl, 
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2.5 mM KCl, 0.1% Triton-X100) overnight, followed by incubation with horseradish 
peroxidase (HRP)-conjugated anti-mouse or anti-rabbit IgG (Santa Cruz) for 1 hour. The 
target proteins were detected on membrane by enhanced chemiluminescence (Pierce). 
Statistical analysis 
Data were expressed as mean ± standard deviation of three biological repeats. Student 
t-tests were used for comparisons, with p<0.05 considered significant. 
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Figure 1. Identification of Lnc34a.  
(A) Schematic illustration of Lnc34a and miR-34a gene structures. Primers for RT-PCR 
and rapid amplification of cDNA ends (RACE) were shown. (B) RT-qPCR and RACE that 
amplified Lnc34a. (C) RT-qPCR detection of Lnc34a expression in CRC cell lines. (D) 
Northern blot detection of Lnc34a in CRC cell lines and CCSCs. The quantification of 
each band was carried out using Image J. 
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Figure 2. Characterization of Lnc34a. 
(A) Schematic illustration of Lnc34a (shown in black) and miR-34a (shown in blue) gene 
structure. Lnc34a and miR-34a contain two exons and are transcribed in different 
directions. P, probe for Northern blot in (B). (B) Northern blot detection of Lnc34a with the 
probe shown in (A), quantified by Image J. (C) RT-qPCR detection of Lnc34a expression 
in colon cancer stem cells (CCSC1 and CCSC2) and well-established colon cancer cell 
lines (HT29 and Caco-2). (D, E) RT-qPCR detection of Lnc34A level in cellular fractions 
from CCSC1 (D) and CCSC2 (E) sphere cells. U6 and actin are the nuclear and cytoplasm 
controls, respectively. (F) Lnc34a expression in CCSC sphere cells detected by RNA-
FISH. Scale bar, 20µm. 
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Figure 3. RNA FISH specificity and Lnc34a knockdown efficiency.  
(A) Knockdown of Lnc34a abolished RNA FISH signals. (B) RT-qPCR showing Lnc34a 
knockdown efficiencies by shLnc34a1 and shLnc34a2. (C) RT-qPCR detection of Lnc34a 
level in cellular fractions from CCSC1with Lnc34a ectopic expression. 
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Figure 4. CCSCs co-express ALDH1 and CD133.  
(A) FACS showing ALDH1+ sphere cells are CD133+. (B) Co-immunofluorescence of 
ALDH1 and CD133 showing ALDH1 and CD133 are expressed in the same daughter 
cell during CCSC division. (C) Percentages of CCSC divisions wherein miR-34a and 
ALDH1 are coexpressed (C.E.) or mutually exclusive (M.E.). (D, E) Effect of Lnc34a 
knockdown (D) and ectopic Lnc34a and miR-34a expression (E) on mode of division 
based on CD133 staining of dividing cell pairs. 
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Figure 5. Lnc34a Asymmetry in CCSC division. 
(A, B) RT-qPCR detection of lnc34a in ALDH1+ and ALDH1- populations isolated from 
spheres of two independent patient-derived lines, CCSC1 (A) and CCSC2 (B). Lnc34a is 
high in ALDH1+ (CCSC) but low in ALDH1- (non-CCSC) cells. (C) Representative images 
of Lnc34a distribution in dividing pairs. α-tubulin staining is consistent with the telophase 
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(final phase of mitosis) configuration of microtubules – the midbody at the division plane 
during cytokinesis and asters at the poles. ALDH1 identifies the CCSC daughter. (D) 
Quantification of Lnc34a/ALDH1 co-expression (C.E.) in daughter compartments of 
dividing pairs as shown in (C). (E) Representative images of Lnc34a asymmetry in 
dividing pairs in xenograft tumors derived from CCSC1 and CCSC2. Dividing pairs are 
identified by tubulin staining. (F) Percentage of Lnc34a asymmetry in dividing pairs in 
CCSC xenografts as shown in (E). (G) Representative images of asymmetric and 
symmetric Lnc34a distribution in dividing pairs in early- and late-stage human CRC 
specimens.  (H) Percentage of Lnc34a asymmetry in dividing pairs in human CRC 
specimens. (I) Effect of Lnc34a knockdown on mode of division based on ALDH1 staining 
of dividing cell pairs. Lnc34a knockdown decreased asymmetric (ALDH1+/ALDH1-) 
division and symmetric self-renewal (ALDH1+/ALDH1+), and increased differentiation 
(ALDH1-/ALDH-). (J) Effect of ectopic Lnc34a expression on mode of division. Ectopic 
Lnc34a increased symmetric self-renewal (ALDH1+/ALDH+), and reduced asymmetric 
division (ALDH1+/ALDH1-) and differentiation (ALDH1-/ALDH1-). The effect of ectopic 
Lnc34a expression was abrogated by ectopic miR-34a expression. (K) Pair-cell BrdU 
incorporation assay showing asymmetric proliferative potential. Left, schematic 
representation of the experimental approach. Single sphere cells were allowed to divide 
once (1st division). Cells were then treated with BrdU for 3 hours to label cells that were 
re-entering the 2nd division. Right, representative images showing that the Lnc34a+ cells 
were more proliferative and incorporated BrdU.  Scale bar, 8m. Error bars denote s.d. 
of triplicates. *, p<0.05; **, p<0.01; ***, p<0.001. p-value was calculated based on 
Student’s t-test. 
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Figure 6. Lnc34a promotes CCSC self-renewal and tumor formation. 
(A) Representative images of CCSC spheres with Lnc34a knockdown (shLnc34a1 and 
shLnc34a2), ectopic Lnc34a expression (Lnc34a), and ectopic Lnc34a/miR-34a 
expression. (B, C) Sphere formation during serial passages after Lnc34a knockdown (B) 
and ectopic Lnc34a and miR-34a expression (C). Equal number of cells was passaged 
for 3 generations to form spheres.  (D, E) Knockdown of Lnc34a (shLnc34a1 and 
shLnc34a2) reduced tumorigenicity, shown by images (D) and weights of xenograft 
tumors (E). (F, G) Ectopic Lnc34a expression (Lnc34a) enhances tumorigenicity, which 
can be abrogated by ectopic miR-34a expression.  (H, I) FACS plots identifying ALDH1+ 
(CCSC) populations in xenograft tumors with Lnc34a knockdown (H) or ectopic Lnc34a 
expression (I).  Scale bar, 50 m. Error bars denote s.d. of triplicates. **, p<0.01; ***, 
p<0.001. p-value was calculated based on Student’s t-test. 
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Figure 7. Lnc34a epigenetically silences miR-34a promoter. 
(A, B) RT-qPCR of miR-34a levels in CCSC1 (A) and CCSC2 (B). (C, D) RT-qPCR of 
miR-34a levels in CCSC1 (C) and CCSC2 (D) spheres with Lnc34a knockdown 
(shLnc34a1 and shLnc34a2) or ectopic expression (Lnc34a). NC is the control vector. (E) 
Representative images of Lnc34a and miR-34a asymmetry in CCSC1 and CCSC2 sphere 
cells. (F) Quantification of (E). Lnc34a and miR-34a distributions are mutually exclusive 
(M.E.) during most CCSC divisions. (G) Bisulfite sequencing analysis showing miR-34a 
promoter methylation status in ALDH1+ (CCSC) and ALDH1- (non-CCSC) cells isolated 
from sphere cells. PCR products amplified from bisulfite-treated genomic DNA were 
cloned and sequenced to reveal the methylation status of individual CpG sites. 
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Percentages of the methylated CpG sites (filled circles) among all scored sites are 
indicated. (H) Lnc34a knockdown decreased miR-34a promoter methylation in sphere 
cells. (I) Ectopic Lnc34a expression increased miR-34a promoter methylation in sphere 
cells. (J, K) ChIP-qPCR with antibodies against acetylated histones H3 and H4. Lnc34a 
knockdown decreased miR-34a promoter acetylation (J), while ectopic Lnc34a 
expression increased acetylation (K). (L) RT-qPCR measurements of Lnc34a expression 
in early- and late-stage CRC specimens. (M) RT-qPCR measurements of miR-34a 
expression in early- and late-stage CRC specimens. (N) Bisulfite sequencing analysis of 
miR-34a promoter methylation status in early- and late-stage CRC specimens. Scale bar, 
8m. Error bars denote s.d. of triplicates. **, p<0.01; ***, p<0.001. p-value was calculated 
based on Student’s t-test. 
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Figure 8. p53 symmetry.  
(A) Representative immunofluorescence images showing symmetric distribution of p53 
during CCSC division. (B) Percentage of p53 division type. (C) Representative 
immunofluorescence images showing symmetric distribution of p21 during CCSC division. 
(D) Percentage of p21 division type. Sym, symmetric segregation; Asym, asymmetric 
segregation; Am, ambiguous. 
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Figure 9. Lnc34a epigenetically silences miR-34a promoters in Caco-2 and HT29 
cells.  
(A, B) RT-qPCR of miR-34a levels in CRC lines Caco-2 (A) and HT29 (B). Ectopic Lnc34a 
expression suppressed miR-34a expression. (C, D) Bisulfite sequencing analysis 
showing ectopic Lnc34a expression increased miR-34a promoter methylation in Caco-2 
(C) and HT29 (D). (E, F) ChIP-qPCR with antibodies against acetylated histones H3 and 
H4. Ectopic Lnc34a expression decreased miR-34a promoter acetylation in Caco-2 (E) 
and HT29 (F). 
 
 
 
 
 
 
 
 
 
59 
 
 
Figure 10. Lnc34a, miR-34a, and promoter methylation levels in CRC specimens. 
(A) RT-qPCR showing Lnc34a and miR-34a expression in individual CRC specimens. 
Levels are normalized to corresponding actin levels. (B) Bisulfite sequencing analysis of 
miR-34a promoter methylation in the same CRC specimens shown in (A). 
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Figure 11. Lnc34a recruits epigenetic regulators. 
Western blot following RNA-pull down showing Lnc34a interaction with PHB2, Dnmt3a 
and HDAC1 in CCSC1 (left) and CCSC2 (right) sphere cells.  RNA-pull down was 
performed using CCSC lysates with biotin-labeled Lnc34a, antisense and tRNA. Actin 
was used for input control. (B) RNA immunoprecipitation (RIP) showing Lnc34a 
interaction with PHB2, Dnmt3a and HDAC1 in CCSC1 (left) and CCSC2 (right) sphere 
cells. (C) RIP showing PHB2 knockdown disrupts Lnc34a interaction with Dnmt3a, but 
has no effect on Lnc34a interaction with HDAC1. (D) RIP showing Dnmt3a knockdown 
does not affect Lnc34a interaction with PHB2 or HDAC1. (E) RIP showing HDAC1 
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knockdown has limited effect on Lnc34a interaction with PHB2 or Dnmt3a. (F) Mapping 
PHB2 and HDAC1 interaction domains on Lnc34a. Upper panel, schematic illustration of 
full-length Lnc34a and the truncated fragments for RNA put-down. Lower panel, Western 
blot of PHB2 and HDAC1 from RNA put-down of the fragments. (G) EMSA showing 
Lnc34a/PHB2 (left) and Lnc34a/HDAC1 (right) interactions. (H) RT-qPCR of miR-34a 
levels after expressing full-length or truncated fragments of Lnc34a. (I) In vitro interaction 
assay binding of the truncated fragment (267-560bp) to the DNA containing the miR-34a 
promoter sequence. (J) Schematic illustration of Lnc34a interaction with PHB2, Dnmt3a 
and HDAC1. (K, L, M) RT-qPCR showing knockdown of Dnmt3a (K), HDAC1 (L), and 
PHB2 (M) increased miR-34a expression in sphere cells. (N, O) RT-qPCR showing 
treatments with HDAC inhibitor SAHA (N) or TSA (O) increased miR-34a expression in 
sphere cells. Error bars denote s.d. of triplicates. ***, p<0.001. p-value was calculated 
based on Student’s t-test. 
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Table 1. Information of CRC patients. 
 
Patient  Gender Age at visit Stage Differentiation Lymph nodes  
P1 M 44.56 I Moderate N0 
P2 M 61 I Moderate N0 
P3 M 85 I NA N0 
P4 F 84 I Moderate N0 
P5 F 65 I Moderate N0 
P6 M 79 I NA N0 
P7 F 88 I Moderate N0 
P8 F 63 I Moderate N0 
P9 M 61 I Moderate N0 
P10 M 54 I Moderate N0 
P11 M 85 I NA N0 
P12 M 70 I Poor N0 
P13 M 66 I NA N0 
P14 M 81 I NA N0 
P15 M 52 I Well N0 
P16 F 57 IIA Moderate N0 
P17 F 70 IIA NA N0 
P18 M 43 IIA NA N0 
P19 F 48 IIA Moderate N0 
P20 F 68 IIA Poor N0 
P21 M 81 IIA Poor N0 
P22 F 92 IIB Well N0 
P23 M 81 IIB Poor N0 
P24 F 50 IIIA Moderate N1 1-3 
P24 M 73 IIIA Well N1 1-3 
P25 F 54 IIIB Moderate N1 1-3 
P26 M 62 IIIB NA N1 1-3 
P27 F 77 IIIB Poor N1 1-3 
P28 F 71 IIIC NA N2 >3 
P29 F 50 IIIC Poor N2 >3 
P30 F 84 IIIC Moderate N2 >3 
P31 M 85 IIIC Poor N2 >3 
P32 F 61 IIIC Poor N2 >3 
P33 F 88 IIIC Poor N2 >3 
P34 F 70 IIIC Poor N2 >3 
P35 F 73 IV Poor N2 >3 
P36 F 73 IV Moderate N1 1-3 
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P37 M 66 IV Poor N1 1-3 
P38 M 56 IV Poor N2 >3 
P39 F 68 IV Poor N2 >3 
P40 F 46 IV NA N1 1-3 
P41 F 73 IV Poor N1 1-3 
P42 M 37 IV Poor N2 >3 
P43 F 21 IV Moderate N1 1-3 
P45 F 69 IV Moderate N1 1-3 
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Table 2. Potential Lnc34a-associated proteins identified by biotinylated Lnc34a 
pull-down and mass spectrometry. 
 
 
 
 
 
 
 
 
 
 
 
Protein 
accession # 
Protein description 
Mass of 
protein 
# of peptide 
matching 
Protein 
coverage (%) 
gi5031857 lactate dehydrogenase A 43596 74 19 
gi332864 pyruvate kinase 3 isoform 1 67178 61 18.4 
gi315429 Chaperonin 73562 35 11.2 
gi545355 ras-related nuclear protein 28933 14 9.7 
gi13128860 Histone Deacetylase 1 (HDAC1) 55130 9 9.7 
gi488543 heat shock 70 protein 1B 81954 34 8.6 
gi600585 prohibitin 2 (PHB2) 37859 4 8.51 
gi59270 
splicing factor, arginine/serine-rich 
1 isoform 1 
29904 2 8.5 
gi892741 
cytokine induced apoptosis inhibitor 
1 
40777 4 8.3 
gi45505 
tumor-associated calcium signal 
transducer 1 precursor 
41981 4 7.42 
gi12751473 
DNA (cytosine-5)-
methyltransferase 3A isoform a 
(Dnmt3a) 
101585 11 6.1 
gi517461 
nucleosome assembly protein 1-like 
4 
50530 12 5.6 
gi482558 
protein kinase C substrate 80K-H 
isoform 1 
68149 6 4.33 
gi213611 
Na+/K+ -ATPase alpha 1 subunit 
isoform a proprotein 
127198 14 3.9 
gi45505 
tumor-associated calcium signal 
transducer 1 precursor 
41981 4 7.42 
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INTRODUCTION 
Cells usually divide symmetrically, producing two identical daughter cells. However, there 
are prokaryotic and eukaryotic cells that can divide asymmetrically, giving rise to daughter 
cells with different characteristics [1]. In higher organisms, asymmetric division is a 
property associated with many types of stem and progenitor cells in embryo, nervous 
system, skin, mammary gland, blood, etc. To balance proliferation and differentiation as 
well as aging [2-9]. Asymmetric division manages differentiation and self-renewal 
simultaneously while keeping the number of stem cells constant, making it an attractive 
mechanism for tissue homeostasis. On the other hand, symmetric division expands the 
number of stem cells and often occurs during early embryonic development, tissue 
regeneration, and repair [10]. These are certainly not fixed rules because stem cells often 
rely on a spatial niche to regulate their number and behavior [11]. For example, Lgr5+ 
crypt base columnar (CBC) cells in the intestine predominantly undergo symmetric 
division and rely on a neutral drift process in the niche to stabilize their number [12,13].  
Cancer stem cells or tumor initiating cells of various cancer types undergo both symmetric 
and asymmetric division [14-21]. Loss of tumor suppressor genes often favors increased 
symmetric divisions of cancer stem cells, which promote proliferation and tumor growth. 
Asymmetric cell division usually relies on imbalance of cell fate determinant proteins in 
the two cellular compartments to break symmetry, resulting in daughter cells with distinct 
cell fates. A canonical cell fate determinant in Drosophila neuroblasts and various 
mammalian stem cells, Numb targets membrane-bound Notch receptors for degradation 
[22, 23].  Furthermore, Numb is a cell fate determinant for various cancer stem cells, and 
has been used as a marker for distinguishing symmetric vs. asymmetric division [18].  
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Recently, emerging evidence suggests that asymmetric distribution of microRNAs can 
also give rise to asymmetric cell fates [24, 25]. For example, we have shown that miR-
34a directly targets Notch to form a cell fate determination switch in colon cancer stem 
cells (CCSCs). A tumor suppressor in many cancer types, miR-34a regulates 
differentiation of embryonic and neural stem cells, somatic cell reprogramming, and 
cardiac aging [26-29]. miR-34a mimics such as MRX34 are among the first microRNA 
mimics to reach clinical trial for cancer therapy [30,31].  
However, this raises the question as to whether microRNA and protein cell fate 
determinants act independently or coordinate with each other to determine cell fate. The 
relationship between miR-34a and Numb is intriguing because both target Notch in 
CCSCs. Here we show that miR-34a directly binds to the 3`UTR of Numb mRNA to 
suppress Numb expression so that miR-34a, Numb, and Notch form an incoherent 
feedforward loop (IFFL). Combination of computational analysis and quantitative 
experiments revealed that the unique regulatory kinetics among miR-34a, Numb, and 
Notch enable a robust binary switch so that the Notch level is steady and insensitive to 
precise miR-34a level except for a sharp transition region. The switch enforces bimodality 
and cell fate bifurcation in the population. Subversion of this IFFL via Numb knockdown 
degrades Notch bimodality and gives rise to an intermediate subpopulation of cells with 
ambiguous and plastic cell fate. We further show that this cell fate determination switch 
plays a role in mouse intestinal stem cells (ISCs). Although Lgr5+ ISCs divide 
symmetrically in normal tissue homeostasis, we found that excessive proliferation caused 
by pro-inflammatory stress or APC deficiency triggers asymmetric division, which 
restrains the number of Lgr5+ ISCs. Silencing of the miR-34a-mediated switch inhibits 
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ISC asymmetric division and contributes to CCSC-like proliferation in stressed tissue. 
Hence, the cell fate determinants provide a safeguard mechanism against excessive stem 
cell proliferation when normal homeostasis is disrupted by inflammation or oncogenic 
mutation. 
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RESULTS 
miR-34a directly targets Numb. 
Using CCSCs derived from patient tumors as we have previously described and 
characterized [24], we first examined whether miR-34a and Numb spatial distributions are 
independent or correlated in divided pairs by performing pair-cell assay with 
immunofluorescence [3, 24] (Figure 1A). During asymmetric CCSC division, miR-34a and 
Numb are mostly present in the NotchlowALDH1low non-CCSC daughter cells (Figure 1B), 
consistent with their function as Notch suppressors (Figures 1C and 1D) [24]. According 
to co-immunofluorescence for mir-34a and Numb, miR-34a and Numb were present in 
the same daughter cells in 82% of the divided pairs, whereas they were present in 
different daughter cells in 18% of the divided pairs (Figures 2A and 2B). Expression of 
Numbl, a Numb homologue involved in neurogenesis, was not detectable in CCSC. 
We then examined potential interaction between these two cell fate determinants with the 
initial hypothesis that one might upregulate the other. We first expressed miR-34a in 
CCSCs using lentiviral infection and measured Numb expression levels by RT-qPCR and 
Western blot. Unexpectedly, ectopic miR-34a suppressed Numb expression (Figures 2C 
and 2D). To investigate whether miR-34a directly targets Numb, we used the microRNA 
target prediction tool RNA22 to analyze the 3`UTR sequence of Numb and found a 
putative miR-34a binding site (Figure 2E). The Numb 3`UTR was then cloned into a 
luciferase reporter, which showed that ectopic miR-34a expression suppressed firefly 
luciferase activity, whereas mutation in the putative miR-34a seed region in the Numb 
3`UTRs abrogated the suppression by miR-34a (Figure 2F). Therefore, miR-34a directly 
targets Numb mRNA to silence its expression. 
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miR-34a, Numb, and Notch form an incoherent feedforward loop (IFFL). 
It is counterintuitive that miR-34a targets Numb for suppression, considering that both cell 
fate determinants suppress Notch and promote differentiation. Why does miR-34a 
suppress Notch directly but upregulate Notch indirectly via Numb? Here, miR-34a, Numb, 
and Notch form a motif called incoherent feedforward loop (IFFL) (Figure 3A). miR-34a 
suppresses Notch1 and Numb translation by binding to the 3`UTRs of their mRNA, and 
Numb suppresses Notch1 by promoting its endocytosis and degradation. 
Previous studies have found that IFFL can generate non-monotonic, adaptive, or pulse-
like responses in different contexts [32-34], but none of these properties seemed to be 
particularly relevant to cell fate determination. There have also been computational 
analyses suggesting that microRNA may reduce noise in IFFL, but those referred to a 
different topology where the microRNA is suppressed by the protein [35].  
To understand how miR-34a and Numb may synergize through this arrangement, we 
explored the quantitative aspects of this particular IFFL. We previously showed that miR-
34a generates a threshold response from Notch due to mutual sequestration while Numb 
regulates Notch in a graded, continuous way [24, 36, 37], raising the prospect that this 
IFFL may possess unique properties. A similar setup was used to characterize the newly 
discovered miR-34a suppression of Numb. We incrementally increased ectopic miR-34a 
expression level using a Doxycycline-inducible promoter and performed Fluorescence 
Activated Cell Sorting (FACS) with antibody against Numb. FACS analysis revealed that 
incremental miR-34a induction gradually suppressed Numb levels in Numbhigh cells 
(Figures 3B and 3C). 
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A computational IFFL model was then constructed by expanding our previously published 
miR-34a/Notch model to include miR-34a suppression of Numb and Numb suppression 
of Notch. The model assumes that miR-34a suppression of Notch1 is stronger than its 
suppression of Numb (which is more gradual), based on the experimental data. 
Simulation of the model over certain parameter ranges presented an interesting possibility 
that the IFFL could generate a more robust Notch switch than miR-34a alone (Figure 3D). 
With IFFL, ‘high’ and ‘low’ Notch levels are steady and insensitive to precise miR-34a 
level except for a narrow transition (threshold) region, which resembles a typical switch 
used in electronics. In contrast, Notch levels vary more with a wider transition region if 
there is only miR-34a but no Numb. Intuitively, when miR-34a level increases, Numb level 
is suppressed accordingly to offset, hence their combined suppression effect on Notch 
remains roughly constant until the mutual sequestration threshold is reached. Therefore, 
the IFFL buffers Notch level from miR-34a copy number variation and enforces a sharp 
transition only around the mutual sequestration threshold. Further simulations of the 
model suggested that the steepness of the transition is influenced by the relative strength 
between the direct and indirect paths (Figures 4A and 4B). 
The model made a further prediction that IFFL produces better bimodality of Notch levels 
(and hence cell fate determination) in the population. Intuitively, the narrower transition 
region of the IFFL minimizes the number of cells with intermediate Notch levels (Figure 
3D). Based on previous FACS measurements of Doxycycline-induced miR-34a level 
distributions in CCSC sphere cells [24], we performed stochastic simulations of IFFL and 
miR-34a alone (Numb knockdown). The simulations suggested that, even though miR-
34a alone could generate Notch bimodality due to mutual sequestration as previously 
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demonstrated [24], IFFL generates better Notch bimodality with more clearly defined 
peaks and fewer cells in between, thanks to its more robust switching behavior (Figure 
3E). 
miR-34a and Numb synergize for a robust Notch bimodal switch. 
Experiments were then designed to test whether the presence of Numb enhances miR-
34a regulation of Notch as a cell fate switch. First, we measured the response of Notch1 
level to incremental miR-34a levels with and without Numb. As previously demonstrated, 
we used CCSCs stably integrated with a lentiviral vector that drives ectopic miR-34a 
expression with a Doxycycline-inducible promoter [24] (Figure 5A). CCSCs were then 
infected with a lentiviral vector expressing short hairpin RNAs (shRNAs) against Numb to 
knock down Numb. The efficiency of Numb knockdown in CCSCs was verified by western 
blot (Figure 4C). 
CCSCs in separate wells were then treated with incremental dosages (0, 100, 200, 300, 
400, and 500 ng/ml) of Doxycycline. RT-qPCR verified that induced miR-34a expression 
level increased linearly with Doxycycline dosage in CCSCs with or without Numb 
knockdown (Figures 4D and 4E). Time-series measurements indicated that it took 
approximately 42 hours for Notch levels to stabilize after doxycycline induction (Figures 
4F-4I), so steady-state measurements were performed 48 hours post induction. With 
Numb, Notch levels remained largely steady until being abruptly turned off by 400 ng/ml 
Doxycycline induction of miR-34a (Figures 4J, 5B and 5D). In contrast, Notch levels 
gradually decreased and slowly turned off in response to increasing miR-34a levels when 
Numb was knocked down (Figures 4K, 5C and 5D). These measurements support the 
computational hypothesis in Figure 2D that miR-34a and Numb work in synergy to 
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generate a more robust switch. Without Numb, Notch level is more sensitive to miR-34a 
variation. 
We then tested whether the presence of Numb enhances miR-34a regulation of Notch to 
be more bimodal as the computational analysis predicted. Again, we induced miR-34a at 
different levels and measured Notch protein levels in individual cells using flow cytometry 
with antibody against Notch. In CCSCs with Numb, Notch displayed clear bimodality and 
individual cells were clustered around the Notchhigh or Notchlow peaks. In contrast, in 
CCSCs with Numb knockdown, even though Notch level distribution was still overall 
bimodal due to mutual sequestration, bimodality was degraded by a subpopulation of cells 
with intermediate Notch levels between high and low (Figure 5E). This result is consistent 
with the computational prediction in Figure 3E that the IFFL improves Notch bimodality. 
Intermediate Notch level leads to ambiguous and plastic cell fate. 
The implication of Notch bimodality on cell fate determination was then investigated. We 
isolated the Notchhigh, Notchlow and Notchinter cells by FACS (Figures 6A and 7A) and 
immediately performed immunofluorescence for the CCSC marker ALDH1 and 
differentiation marker CK20 (Figure 6B). Consistent with previous reports, Notchhigh cells 
are ALDH1+CK20- stem cells and Notchlow cells are ALDH1-CK20+ differentiated cells. 
Interestingly, the cells with intermediate Notch levels (Notchinter) expressed both ALDH1 
and CK20, reflecting an intermediate state between stem cell and differentiation. RNA-
seq transcriptome profiling revealed that Notchinter cells have a distinct gene expression 
signature between those of Notchhigh and Notchlow cells (Figures 6C and 7B). Notchinter 
cells express intermediate levels of stem cell and differentiation makers, while Notchhigh 
cells express high levels of stem cell markers and Notchlow cells express high levels of 
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differentiation markers (Figures 7C). Gene Set Enrichment Analysis (GSEA) show that 
pathways commonly associated with CCSCs, such as Notch, Wnt, and MAPK signaling 
pathways, are upregulated in Notchhigh cells (Figure 7D). 
We then performed serial sphere propagation assay to test these cells’ self-renewal 
ability, which is a measure of their stemness (Figures 6D, 6E, 7E). Notchhigh cells 
efficiently formed spheres in 3D Matrigel culture and maintained their sphere formation 
capability, whereas Notchlow cells formed few spheres in the first generation and lost their 
sphere formation capability after serial propagation. Notchinter cells could also form 
spheres, but the spheres were far fewer and smaller than those formed by Notchhigh cells. 
We then compared tumorigenic capability by subcutaneously injecting 1x104 Notchhigh, 
Notchinter and Notchlow cells respectively into Nude mice. During the observed period (6 
weeks), all 6 mice injected with Notchhigh cells grew tumors, only 2 mice injected with 
Notchinter cells grew small tumors, and none of the mice injected with Notchlow cells grew 
tumors (Figure 6F). Similar results were observed in mice injected with Notchhigh, Notchinter 
and Notchlow cells sorted from a second CCSC (CCSC2) line (Figure 7F). Therefore, 
Notchinter cells have intermediate self-renewal and tumorigenic capability compared to 
Notchhigh and Notchlow cells, consistent with their intermediate gene expression signature. 
Since Notchinter cells seem to occupy a state between Notchhigh CCSC and Notchlow non-
CCSC, we next examined their plasticity, or ability to convert into CCSC or non-CCSC. 
When cultured in FBS-free stem cell medium and low-attachment flask, Notchinter cells 
upregulated the CCSC marker ALDH1, while Notchlow cells did not express ALDH1 after 
7 days (Figure 6G). This suggests that Notchinter cells may possess the plasticity to 
dedifferentiate back into stem cells in contrast to Notchlow cells. On the other hand, 
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Notchinter cells are readier to differentiate than Notchhigh cells. When cultured in 
differentiation medium, Notchinter cells lost ALDH1 expression within 24 hours, whereas 
Notchhigh cells still retained ALDH1 expression (Figure 6H). It took 10 days for most 
Notchhigh cells to lose ALDH1 and express CK20. Collectively, these data suggest that 
Notchinter cells are in an intermediate state that can dedifferentiate into CCSCs or readily 
commit to differentiation. 
We then examined how the presence of the Notchinter cells affects cell division. Pair-cell 
assay followed by immunofluorescence for ALDH1 and CK20 revealed that Numb 
knockdown reduced asymmetric division and gave rise to significantly more ambiguous 
cell division outcomes, wherein one or both daughter cells co-expressed ALDH1 and 
CK20 (Figures 6I and 6J). 
Altogether, the computational analysis and experimental data combined suggest that 
miR-34a suppresses Numb to form an IFFL, which acts as a robust switch to generate 
Notch bimodality. Undermining this switch by Numb knockdown results in a subpopulation 
of cells with intermediate Notch levels. These cells express both stem cell and 
differentiation markers and show greater plasticity than Notchhigh and Notchlow cells.  
miR-34a and Numb are associated with differentiation of mouse intestinal stem 
cells. 
We have previously shown that miR-34a mediated asymmetric cell fate determination is 
mostly active in CCSCs isolated from early-stage CRC patient specimens and tends to 
be silenced in CCSCs isolated from late-stage CRC specimens. CCSCs from early-stage 
specimens form xenograft tumors in mice that maintain histopathology of their primary 
human CRCs, which still retain reminiscent features of original colon tissue [24]. This 
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raised the possibility that miR-34a and Numb perform cell fate-related functions in normal 
tissues, which was initially inherited by early-stage CCSCs but eventually subverted in 
late-stage CCSCs. 
To test this possibility, we first performed immunofluorescence for miR-34a and Numb in 
cryosectioned mouse intestinal crypts harvested from Lgr5-EGFP-IRES-CreERT2 
transgenic mice [38]. miR-34a and Numb expression are low in GFP-labeled Lgr5+ 
intestinal stem cells (ISCs) but become higher in more differentiated cells above the stem 
cell niche (Figures 8A and 8B). On the other hand, Notch1, the target of miR-34a and 
Numb suppression, was more expressed in Lgr5+ ISCs (Figure 5C), consistent with 
previous reports that Notch is expressed in ISC and essential for ISC self-renewal [39, 
40].  
To compare Numb and miR-34a expression levels between ISCs and more differentiated 
cells, we cultured mouse intestinal cells from Lgr5-EGFP-IRES-CreERT2 mice in 3D 
Matrigel, where they grew into crypt-villus like organoids [38] (Figure 8D). The Lgr5+ ISCs 
(also called CBCs) are capable of both self-renewal and generating other intestinal cell 
lineages in these organoids. RT-qPCR showed that both Numb and miR-34a expression 
levels are lower in Lgr5-GFP+ cells than in Lgr5-GFP- cells (Figures 8E and 8F). The 
difference in expression levels between Lgr5-GFP+ and Lgr5-GFP- cells is greater for 
miR-34a than for Numb. Flow analysis with RNA FISH probes confirmed low miR-34a 
expression in Lgr5-GFP+ cells (Figure 9A). Together, the immunofluorescence and RT-
qPCR data suggest that miR-34a and Numb expression are associated with more 
differentiated cells, whereas Notch1 is associated with Lgr5+ ISC. 
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To validate whether miR-34a and Numb suppress Notch1 in intestinal cells, we infected 
organoids with lentiviral vectors that express miR-34a or Numb. Transduction and 
knockdown efficiency was validated by RT-qPCR and Western blot (Figures 9B-9C). 
Western blot confirmed that ectopic miR-34a and Numb suppressed Notch1 expression 
in organoid cells (Figures 8G and 8H). Moreover, ectopic miR-34a expression also 
downregulated Numb expression, consistent with the IFFL (Figure 8I). 
We then investigated how miR-34a, Numb and Notch impact ISC cell fate decision. 
Inhibition of Notch by treating the organoids with the γ-secretase inhibitor DAPT- 
significantly reduced the Lgr5-GFP+ ISC population in the organoids (Figures 8J, 8N and 
9D). Ectopic expression of miR-34a or Numb via lentiviral infection of organoid cells had 
a similar effect of reducing Lgr5-GFP+ ISCs, consistent with their role of Notch 
suppression (Figures 8K-8L and 8O-8P). Next, we used a lentiviral vector to express 
shRNA against Numb in organoids to examine whether knockdown of Numb would impact 
intestinal cell fate bimodality as it does to early-stage CCSCs. The efficiency of Numb 
knockdown was validated by Western blot (Figure 9E). Indeed, a subpopulation of cells 
with intermediate Lgr5 expression levels between Lgr5high ISCs and Lgr5low non-ISCs 
emerged, and the Lgr5-GFP distribution was no longer bimodal (Figures 8M and 8Q). The 
effects on ISCs were further validated by measuring the levels of Ascl2, an alternative 
marker for Lgr5+ ISC [39, 41]. Consistently, inhibition of Notch signaling by DAPT, ectopic 
miR-34a, or Numb expression reduced Ascl2 levels, whereas Numb knockdown 
increased Ascl2 levels in organoids (Figures 8R-8Y). Notch inhibition by DAPT, ectopic 
miR-34a, or Numb expression also increased apoptotic cells shed into the lumen, a 
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process reminiscent of the shedding of terminally differentiated cells in vivo (Figures 9F-
9I) [38]. 
Inflammatory stress induced miR-34a-dependent asymmetric division. 
To investigate how loss of the miR-34a-mediated switch may specifically impact ISC cell 
fate decision, we crossed miR-34aflox/flox mice [42] with Lgr5-EGFP-IRES-CreERT2 mice 
and then intraperitoneally administered Tamoxifen, which activated Cre to knock out miR-
34a in Lgr5+ ISC specifically. miR-34a knockout in Lgr5+ ISCs did not cause noticeable 
changes to the crypt morphology or the number of Lgr5-GFP ISCs in vivo or in derived 
organoids (Figures 10A-10B). To confirm that miR-34a is not essential for crypt 
homeostasis, we examined the intestinal crypts from a constitutive miR-34a knockout 
(miR-34a-/-) model [29]. The crypt morphology again seems normal (Figures 10C). This 
suggests that the miR-34a-mediated switch is not essential for Lgr5+ ISC mediated 
intestinal homeostasis under normal physiological conditions. 
TNFα, a pro-inflammatory cytokine associated with chronic colitis, has been linked to risk 
of colorectal carcinogenesis [43, 44]. A low dosage (10ng/ml) treatment of TNFα for 3 
days caused modest proliferation of Lgr5-GFP+ ISCs, increasing their number from 12% 
to 19% of the total organoid cell population. The effect of TNFα treatment was amplified 
by miR-34a knockout. TNFα-induced ISC proliferation became more excessive in 
organoids derived from miR-34aflox/flox mice/Lgr5-GFP-IRES-CreERT2 mice after miR-34a 
knockout was induced, causing proliferating Lgr5-GFP+ ISCs to comprise 38% of the 
organoid cell population (Figure 11A). Consistent with the flow analyses, TNFα and loss 
of miR-34a greatly increased the expression of Lgr5 and Ascl2, the marker for Lgr5+ ISCs 
(Figures 11B-11D). Moreover, miR-34a knockout caused TNFα treated organoids to grow 
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into undifferentiated spheres that resemble CCSC spheres with enrichment of Lgr5-GFP+ 
ISCs (Figure 11E). BrdU incorporation assay showed that loss of miR-34a led to 
excessive proliferation in TNFα treated organoids (Figure 11F). Therefore, despite being 
non-essential for normal tissue homeostasis, the miR-34a-mediated cell fate switch 
provides a safeguard against excessive ISC proliferation when stem cells regenerate 
under pro-inflammatory stress. 
Lgr5+ ISCs are thought to divide symmetrically in normal conditions [12, 13]. We explored 
whether the presence of miR-34a has the capability to promote asymmetric division and 
differentiation to counter excessively proliferating ISCs. We first examined the division of 
intestinal organoid cells using both the pair-cell assay and direct immunofluorescence on 
Lgr5-GFP+ doublets freshly isolated by FACS, with antibodies against α or β tubulin to 
mark mitotic cells. Under normal organoid culture condition, only 4.6% of the Lgr5-GFP+ 
cells or 3.6% of Ascl2+ cells from Lgr5-EGFP-CreERT2 organoids divided asymmetrically, 
while asymmetric division was barely observed in miR-34a deficient Lgr5-GFP+ or Ascl2+ 
cells from Lgr5-EGFP-CreERT2/miR-34aflox/flox organoids. Remarkably, 3-day treatment of 
10ng/ml TNFα caused 19% of Lgr5-GFP+ cells or 17.3% Ascl2+ cells from Lgr5-EGFP-
CreERT2 organoids to divide asymmetrically. In contrast, miR-34a deficiency reduced 
such asymmetric division to less than 2% in Lgr5-EGFP-CreERT2/miR-34aflox/flox 
organoids (Figures 9J-9K and 11G-11H). 
miR-34a dependent asymmetric division in vivo 
To examine whether inflammation also activates ISC asymmetric division in a miR-34a 
dependent manner in vivo, Lgr5-EGFP-CreERT2 and Lgr5-EGFP-CreERT2/miR-34aflox/flox 
mice were treated with 3% dextran sodium sulfate (DSS) in daily drinking water for 5 days, 
83 
 
followed by 5 days of plain water supply for recovery. Tissues were then harvested and 
stained. Consistent with previous reports [45-47], DSS upregulated inflammatory factors 
TNF, IL-1 and IL-6 in mouse intestine and colon inflammation (Figures 10D and 10E). 
Regeneration after DSS-induced tissue damage increased the number of Lgr5-GFP+ 
ISCs and Lgr5 and Ascl2 expression in the intestine and colon, which was further 
amplified by loss of miR-34a (Figures 12A-12F and 10F-10G, 12A-12F). DSS treatment 
caused more proliferation in miR-34a deficient crypts as shown by the number of cells 
incorporating BrdU (Figures 10H-10I). Crypts were then stained for tubulin to identify 
dividing cell pairs with microtubule configuration consistent with telophase (the final phase 
of mitosis) – the midbody at the division plane during cytokinesis and asters at the poles. 
The cell polarity protein PARD3 was concurrently stained to validate division symmetry. 
Under stress, more ISCs switch to asymmetric division, from 2% to 13% of all Lgr5-GFP+ 
divisions and from 1.6% to 9% of all Ascl2+ divisions. Asymmetric division was 
remarkably decreased to 4% in miR-34a deficient mice (Figures 12G-12H and 13A-13B). 
Notably, colon stem cells follow the same trend. During recovery from DSS treatment, 
Lgr5-GFP and Ascl2+ colon stem cells underwent more asymmetric division in a miR-34a 
dependent manner (Figures 12I-12J and 13C-13D).  
We then tested whether asymmetric division can also be triggered by ISC proliferation 
due to genetic mutation. APC deficiency causes ISC proliferation and is an initiation step 
for adenomas and 90% of CRC [48]. We crossed transgenic mice carrying Lgr5-EGFP-
CreERT2 and APCflox/flox alleles, and co-immunofluorescence for Lgr5-GFP and Tubulin 
confirmed that APC-/- intestinal tissues derived from Lgr5-EGFP-CreERT2/APCflox/flox mice 
induced with Tamoxifen in vivo contain asymmetric LGR5+/LGR5- or Ascl2+/Ascl2- 
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division pairs (Figures 13E-13H). Hence ISC proliferations in APC-deficient mouse 
adenomas can trigger asymmetric division. 
To further validate the presence of asymmetric division in clinical samples, we examined 
12 pairs of human normal colon and CRC samples. 10.6% of the Lgr5+ and 8.4% of the 
Ascl2+ dividing pairs were undergoing asymmetric division in CRC samples, in contrast 
to less than 1% in normal colon samples (Figures 12K-12L and 13I-13J). 
Taken together, the in vitro and in vivo data indicate that, despite being rare in normal 
tissue, the frequency of asymmetric division can be increased to rein in excessive stem 
cell proliferation during inflammation-induced regeneration/repair. Loss of miR-34a 
inhibits asymmetric division and promotes symmetric division that exacerbates stem cell 
proliferation (Figure 14). 
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DISCUSSION 
Spatial imbalance of cell fate determinants can break symmetry and force bifurcation of 
cell fate. Here we show that the microRNA cell fate determinant miR-34a and canonical 
protein cell fate determinant Numb synergize to regulate self-renewal vs. differentiation 
of early-stage CCSC. miR-34a directly suppresses Numb to form an IFFL, which 
generates a robust binary switch response from Notch. This switch enhances bimodality 
of the population and separates CCSCs from non-CCSCs. Undermining this switch via 
Numb knockdown degrades bimodality and gives rise to an intermediate population of 
cells that have more ambiguous and plastic cell fate. We further showed that this cell fate 
determination switch likely provides a safeguard against excessive ISC self-renewal and 
proliferation in normal tissues. This safeguard mechanism can be triggered during tissue 
regeneration and repair after inflammation-induced damage, and its inactivation by miR-
34a deletion exacerbates Lgr5+ ISC proliferation. The miR-34a-mediated asymmetric 
division is active in early-stage CCSCs, likely triggered by their excessive proliferationand 
is eventually subverted by miR-34a silencing in late-stage CCSCs. 
Like most microRNAs, miR-34a targets multiple genes. The level of free miR-34a 
available to bind Notch1 mRNA is subject to variation due to the expression of other miR-
34a target genes. The IFFL may provide an additional benefit of buffering Notch and cell 
fate decision from such miR-34a copy number variation because the binary Notch level 
and its resulting bimodality are largely insensitive to precise miR-34a concentration as 
long as it does not cross the transition threshold. 
miR-34a and Numb are lower in mouse Lgr5+ ISCs and higher in more differentiated non-
ISCs, consistent with their roles of suppressing Notch. However, the fact that miR-34a 
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deletion generates no obvious intestinal phenotype was puzzling initially. However, the 
observation that miR-34a curbs excessive ISC proliferation under pro-inflammatory stress 
provides a potential answer: normal tissues possess seemingly non-essential or 
redundant mechanisms for robustness [49, 50], and the importance of such mechanisms 
can become more prominent under stress or disease conditions. CCSCs in late-stage 
tumors eventually remove this barrier by silencing miR-34a and asymmetric division, 
contributing to more undifferentiated tumors [24, 51]. The concept of robustness may also 
provide insights into other microRNAs that are important tumor suppressors but not 
essential for normal tissue homeostasis. 
The subject of ISC division symmetry has been intensely studied, which transformed our 
view of adult stem cell in mammalian tissue [52]. Previously, ISCs were thought to 
undergo asymmetric division exclusively to protect their number and genomic integrity 
[53-55]. However, Lgr5+ CBC cells were identified as actively cycling ISCs, and they 
perform symmetric division while competing in a neutral drift process [12, 13].  
Intriguingly, asymmetric division has been consistently observed in CCSCs, and its 
abrogation in favor of symmetric division increases their tumor initiating and proliferative 
capacity [18, 24, 25]. Similar observations have been made in other types of cancer stem 
cells as well [14-17, 19-21]. Why do CCSCs activate asymmetric division, seemingly de 
novo, which curbs proliferation and promotes differentiation? Our data provide a potential 
explanation to this paradox: the mechanism of asymmetric division exists in ISC, but is 
largely silent during normal tissue homeostasis. The rate of asymmetric division is 
increased to rein in the number of proliferating Lgr5+ stem cells during tissue regeneration 
after inflammatory damages. It is plausible that asymmetric division may be activated to 
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counter stem cell proliferation at the onset of oncogenesis and remains active in early-
stage CCSCs, until being eventually silenced (e.g., through silencing miR-34a) by tumor 
progression.  
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METERIALS AND METHODS 
CCSCs Isolation, Culture and Differentiation 
CCSCs isolation, culture and differentiation were performed as described as previously 
[24]. Briefly, CCSCs were isolated from patient tumors by FACS based on markers CD44, 
CD133 and ALDH1 and functionally validated by serial sphere formation, tumor initiation, 
and self-renewal assays [24]. CCSCs were cultured as spheres in ultralow-attachment 
flasks (Corning) in DMEM/F12 (Invitrogen), supplemented with nonessential amino acids 
(Fisher), sodium pyruvate (Fisher), Penicillin-streptomycin (Fisher), N2 supplement 
(Invitrogen), B27 supplement (Invitrogen), 4µg/mL heparin (Sigma), 40 ng/mL epidermal 
growth factor (Invitrogen), and 20 ng/mL basic fibroblast growth factor (Invitrogen) at 37 
°C and 5% CO2. To propagate in vitro, spheres were collected by gentle centrifugation, 
dissociated into single cells, and then cultured to form next generation spheres. 
Transgenic Mice and DSS treatment 
Lgr5-EGFP-creERT2/miR-34aflox/flox mice were generated by interbreeding Lgr5-EGFP-
creERT2 mice [38] and miR-34aflox/flox mice [42]. Lgr5-EGFP-creERT2/APCflox/flox mice were 
generated by interbreeding Lgr5-EGFP-creERT2 mice with APCflox/flox mice [56]. Cre 
recombinase was induced by intraperitoneal injection of Tamoxifen (Sigma) dissolved in 
sterile corn oil for 5 consecutive days at a dose of 75mg/kg. For DSS treatment, 6-8-
week-old mice were treated with DSS (36,000–50,000 kDa; MP Biomedicals) in daily 
drinking water for 5 days, followed by plain water for 5 days. All animal experiments were 
approved by The Cornell Center for Animal Resources and Education (CARE) and 
followed the protocol (2009-0071 and 2010-0100).  
Mouse intestinal organoid culture 
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Crypt isolation, cell dissociation, and organoid culturing were performed using previously 
described protocol [38]. For TNFα treatment, organoid cells were cultured in medium 
containing 10ng/ml TNFα (R&D) for 72 hours. 
Immunofluorescence  
Pair-cell assay was used to investigate CCSC division. Disassociated single CCSC 
sphere cells were plated on an uncoated glass culture slide (Corning) and allowed to 
divide once. After fixed in cold methanol, the cells were blocked in 10% normal goat serum 
for 1 hour and then incubated with anti-ALDH1 (clone H-4, 1:100, Santa Cruz), anti-CK20 
(clone H-70, 1:100, Santa Cruz), anti-Numb (1:100, Abcam) and anti-Notch1 (1:400, 
Abcam) antibody overnight at 4 °C. For the BrdU incorporation assay, the tissue sections 
were incubated in 1M HCl for 1 hour at 37 °C after fixation. The sections were then 
washed, and switched to 100 mM Na2B4O7 for 2 minutes.  After blocked in 10% normal 
goat serum for 1 hour, the cells were then incubated with anti-BrdU (1:200, Sigma). The 
cells were then incubated with Rhodamine Red labeled secondary antibody (Invitrogen) 
for 1 hour at room temperature. After counterstained with DAPI (Invitrogen), the slides 
were observed under a fluorescent microscope (Olympus). 
Divisions of Lgr5-EGFP ISCs were examined by three methods. First, Lgr5-GFP doublets 
were directly collected from intestinal organoids by FACS sorting based on GPF signal 
and cell size. The cells were then immediately fixed in 4% paraformaldehyde, 
permeabilized in 0.5% Triton-X and stained with anti-GFP-Alexa Fluor 488 (1:500, 
Abcam), anti-Ascl2 (1:100, Bioss) and anti--Tubulin-Cy3 antibodies (1:100, Sigma). In 
the second method, single Lgr5-GFP cells were plated in Matrigel and allowed to divide 
once. The cells were then fixed, permeabilized and stained with anti-GFP, anti-Ascl2 and 
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anti--tubulin (1:500, Abcam) antibodies. In the third method, intestines from LGR5-
EGFP-creERT2 and LGR5-EGFP-creERT2/APCflox/flox mice and human colon and CRC 
samples were fixed in 4% paraformaldehyde. Frozen sections were then prepared and 
stained with anti-GFP, anti-Ascl2, anti-PARD3 (1:200, Abcam) and anti--tubulin (1:500, 
Abcam) antibodies. After counterstaining with DAPI (Invitrogen), the slides were observed 
under a fluorescent microscope (Olympus). 
RNA FISH 
RNA FISH was performed as described as previously [24]. In brief, CCSCs were fixed 
with 4% formaldehyde for 30 minutes at room temperature, followed by permeabilization 
in 70% ethanol at 4 °C overnight. 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) 
fixation was applied to prevent the loss of miRNA. After a 2-hour incubation in 
prehybridization buffer (25% formamide, 0.05 M EDTA, 4×SSC, 10% dextran sulfate, 
1×Denhardt’s solution, 0.5 mg/ml Escherichia coli tRNA and 0.5 mg/ml RVC), digoxigenin 
(DIG)–labeled locked nucleic acid (LNA) probe (Exiqon) was added for hybridization. The 
slides were then incubated with anti-DIG antibody (1:400, Roche), and the miRNA 
expression was detected by Rhodamine Red labeled secondary antibody (Invitrogen). 
DAPI (Invitrogen) was used for nucleic counterstaining. The slide was then observed 
under a fluorescent microscope (Olympus). 
Flow Cytometry 
Single CCSC sphere cells were incubated with anti-Notch1 antibody (1:100, Abcam) after 
fixed with formaldehyde and further permeabilized by methanol. The cells were then 
incubated with PE labeled secondary antibody (Invitrogen). Notchhigh, Notchlow and 
Notchinter populations were isolated by FACS using a Notch signaling reporter with tandem 
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repeats of the RBP-Jk transcriptional response element (TRE) [24]. Lgr5-GFP population 
was evaluated by directly measuring GFP signal from intestinal organoids. ALDH1 levels 
were analyzed using the Alde flour kit.  The samples were analyzed using a BD LSR II 
flow cytometer. The raw FACS data were analyzed with the FlowJo software to gate cells 
according to their forward (FSC) and side (SSC) scatter profiles. 
Quantitative Real-time RT-PCR Analysis 
Total RNA was extracted from the cells using the TRIzol Reagent (Invitrogen). cDNA was 
synthesized from 500 ng of total RNA in 20µl of reaction volume using the High Capacity 
cDNA Archive Kit (Applied Biosystems). Quantitative PCR was carried out using the 
SYBR Green System (Applied Biosystems) to detect gene expression. All samples were 
run in triplicate three times. The primer sequences include: Notch1, 5`-
GTGACTGCTCCCTCAACTTCAAT-3` and 5`-CTGTCACAGTGGCCGTCACT-3`; 
Notch2, 5'-AACTGTCAGACCCTGGTGAAC-3' and 5`-CGACAAGTGTAGCCTCCAATC-
3`; Numb, 5`-GCTGCCTCTCCAGGTCTCTTC-3` and 5`- 
CGCTCTTAGACACCTCTTCTAACCA-3`; CK20, 5`- AGGAGACCAAGGCCCGTTA-3` 
and 5`- ATCAGTTGGGCCTCCAGAGA-3`; actin, 5`-CGCGAGAAGATGACCCAGAT-3` 
and 5`-ACAGCCTGGATAGCAACGTACAT-3`; The expression of each gene was defined 
from the threshold cycle (Ct), and the relative expression levels were calculated using the 
2-△△Ct method after normalization to the actin expression level. 
Western Blot 
Whole cell lysate was prepared in a lysis buffer (20 mM Tris pH 7.5, 150 mM NaCl, 1% 
Nonidet P-40, 0.5% Sodium Deoxycholate, 1 mM EDTA, 0.1% SDS, protease inhibitors). 
Proteins were first separated by 10% SDS-PAGE and then transferred to a Hybond 
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membrane (Amersham). The membranes were incubated with primary antibodies either 
anti-Notch1 (1:1000, Abcam), anti-Numb (1:1000, Abcam), anti-NICD (1:1000, R&D 
Systems), anti-Hes1 (1:500, Millipore), or anti-Action (1:1000, Abcam) in 5% milk/TBST 
buffer (25 mM Tris pH 7.4, 150 mM NaCl, 2.5 mM KCl, 0.1% Triton-X100) overnight, and 
then probed for 1 hour with secondary horseradish peroxidase (HRP)-conjugated anti-
mouse or anti-rabbit IgG (Santa Cruz). After extensive wash with PBST, the target 
proteins were detected on membrane by enhanced chemiluminescence (Pierce). 
Lentiviral Vector Constructs and Infection 
Lentiviral constructs expressing miR-34a or Numb shRNA have been described 
previously [24]. The Numb luciferase reporter was generated by cloning the Numb 3`UTR 
into the pGL3 construct. The QuickChange Site-directed Mutagenesis Kit (Stratagene) 
was used to mutate the miR-34a binding sequence in Numb 3`UTR. CCSCs and intestinal 
organoids were infected with the vectors as described previously [24]. 
Statistical Analysis 
Data were expressed as mean ± standard deviation of three biological repeats. Student 
t-tests were used for comparisons, with p<0.05 considered significant. 
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Figure 1. Asymmetric distribution of Notch-targeting miR-34a and Numb during 
CCSC division. 
(A) Schematic illustration of the pair-cell assay. (B) Representative images of pair-cell 
assay with staining for miR-34a (green) and Notch1 (red), Numb (green) and Notch1 (red), 
and ALDH1 (green) and Notch1 (red). Tubulin staining indicates dividing pairs in 
telophase. (C and D) Western blot of Notch1 levels with ectopic miR-34a (B) or Numb (C) 
expression. Scale bar, 8µm. 
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Figure 2. miR-34a directly targets Numb. 
(A)  Representative images of miR-34a (RNA FISH, red) and Numb (green) distribution 
during CCSC division. miR-34a and Numb can co-exist (C.E., top row) or be mutually 
exclusive (M.E., bottom row) in daughter cells. (B) Percentages of CCSC divisions 
wherein miR-34a and Numb are M.E. or C.E. (C and D) Western blot (C) and RT-qPCR 
(D) of Numb levels showing ectopic miR-34a expression (miR-34a OE) suppresses Numb 
expression compared to the control vector.  (E) Schematic illustration of predicted binding 
between miR-34a and Numb 3` UTR, and mutation introduced to the seed region. (F) 
Luciferase reporter assay confirming the miR-34a binding site in Numb 3`UTR. Numb 
3`UTR sequences containing the wild-type (Wt) or mutated (Mut) putative miR-34a 
binding sites were cloned into the 3`UTR of firefly luciferase (Fluc). Fluc signals were 
normalized by Renillar luciferase (Rluc) signals. Mutation of the binding site attenuated 
suppression of Numb by ectopic miR-34a expression (miR-34a OE). Scale bar, 8m. 
Error bars denote s.d. of triplicates. **, p<0.01; ***, p<0.001. p-value was calculated based 
on Student’s t-test. 
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Figure 3. Computational analysis of the incoherent feedforward loop (IFFL). 
(A) Schematic of the IFFL formed by miR-34a, Numb, and Notch1. (B) Schematic 
illustration of the inducible miR-34a construct used in the experiment shown in (C). (C) 
FACS analysis of Numb expression in CCSC sphere cells when miR-34a expression was 
incrementally induced by Doxycycline. (D) Simulated Notch1 vs. miR-34a levels from the 
ODE-based IFFL and Numb knockdown models. Shaded areas are transition regions (80% 
to 20% of peak Notch level). (E) Simulated Notch1 distributions with IFFL and Numb 
knockdown models. 
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Figure 4. IFFL generates a robust Notch switch.  
(A) Schematic of the IFFL. (B) Computational simulation shows the transition (threshold 
and slope) of the IFFL switch is influenced by the strength of miR-34a suppression of 
Notch (1) and Numb (2).  (C) Western blot showing shRNA knockdown of Numb in 
CCSCs.   (D) Time-series RT-qPCR measurements of induced miR-34a levels after 
addition of Doxycycline. (E) RT-qPCR measurements of miR-34a levels induced by 
different Doxycycline concentrations. (F and G) Time-series Western blot measurements 
of Notch1 levels without (F) or with (G) Numb knockdown after miR-34a expression in 
CCSC1 was induced by 400ng/ml Doxycycline. (H and I) Time-series Western blot 
measurements of Notch1 levels without (H) or with (I) Numb knockdown after miR-34a 
expression in CCSC2 was induced by 400ng/ml Doxycycline. (J and K) Western blots of 
Notch levels in scramble shRNA (J) and Numb shRNA (K) infected CCSC2 spheres with 
incremental miR-34a induction by Doxycycline. 
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Figure 5. IFFL generates a robust Notch switch. 
(A) Schematic illustration of the inducible miR-34a construct used in the experiments 
shown in (B to E). (B and C) Western blots of Notch levels in scramble shRNA (B) and 
Numb shRNA (C) infected CCSC spheres with incremental mir-34a induction by 
Doxycycline. (D) Quantification of Western blots in three independent repeats. (E) FACS 
analysis of Notch1 bimodality with incremental miR-34a induction by Doxycycline. Top 
row, intact IFFL; bottom row, Numb knockdown. miR-34a levels were measured by RT-
qPCR and shown on top of the FACs plots. 
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Figure 6. Numb knockdown gives rise to an intermediate population. 
(A) FACS plot showing Notchhigh, Notchinter, and Notchlow subpopulations of Numb 
knockdown sphere cells, treated with 200ng/ml Doxycycline. (B) Immunofluorescence of 
Notchhigh, Notchinter, and Notchlow cells for CK20 (green) and ALDH1 (red). Scale bar, 
20µm. (C) Heat-map of transcriptomes of Notchhigh, Notchinter, and Notchlow cells 
measured by RNA-seq.  (D) Representative images of spheres grown from Notchhigh, 
Notchinter, and Notchlow cells. Scale bar, 50µm.  (E) Serial Sphere propagation of Notchhigh, 
Notchinter, and Notchlow cells isolated from Numb knockdown sphere cells. Gen, 
generation. (F) Tumor images showing tumorigenic capability of transplanted Notchhigh, 
Notchinter, and Notchlow cells. (G) FACS analysis of Notchinter and Notchlow cells before (left) 
and after (right) being under stem cell culture condition for 7 days. Notchinter cells turned 
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on ALDH1 expression under stem cell culture condition, whereas Notchlow cells did not. 
(H) FACS analysis of Notchinter and Notchhigh cells before (left) and after (right) being in 
FBS-containing medium for 24 hours. Notchinter cells lost ALDH1 expression, whereas 
Notchhigh cells did not. (I) Representative immunofluorescence images for ALDH1 (red) 
and CK20 (green) illustrating four types of division: CCSC/CCSC (C/C), CCSC/non-
CCSC (C/D), non-CCSC/non-CCSC (D/D) and ambiguous (Am). Scale bar, 8µm. (J) 
Numb knockdown significantly increased Am divisions besides reducing C/D and D/D. 
Error bars denote s.d. of triplicates. **, p<0.01; ***, p<0.001. p-value was calculated based 
on Student’s t-test. 
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Figure 7. Characterizations of Notch intermediate population in CCSCs generated 
by Numb knockdown.  
(A) FACS plot showing Notchhigh, Notchinter, and Notchlow subpopulations of Numb 
knockdown CCSC2 sphere cells, treated with 200ng/ml Doxycycline. (B) Principle 
component analysis (PCA) of transcriptomic profiles of Notchhigh, Notchinter, and Notchlow 
cells. (C) Marker expression in Notchhigh, Notchinter, and Notchlow cells. (D) Pathways 
identified by Gene Set Enrichment Analysis (GSEA). (E) Serial Sphere propagation of 
Notchhigh, Notchinter, and Notchlow cells isolated from Numb Knockdown CCSC2 sphere 
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cells. Gen, generation. (F) Tumor images showing tumorigenic capability of transplanted 
Notchhigh, Notchinter, and Notchlow cells. Error bars denote s.d. of triplicates. ***, 
p<0.001. p-value was calculated based on Student’s t-test. 
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Figure 8. miR-34a and Numb expression in mouse intestinal cells. 
(A to C) Immunofluorescence images of intestinal crypts from an Lgr5-EGFP-CreERT2 
transgenic mouse. Scale bar, 20µm. (D) A representative image of an intestinal organoid 
with Lgr5-GFP labeled ISCs. Scale bar, 50µm. (E and F) miR-34a (E) and Numb (F) 
expression levels in Lgr5-GFP+ and Lgr5-GFP- cells isolated from Lgr5-EGFP-CreERT2 
intestinal organoids, measured by RT-qPCR. (G and H) Western blot showing that ectopic 
miR-34a (G) or Numb (H) expression decreased Notch1 level in organoid cells. (I) 
Western blot showing that ectopic miR-34a expression decreased Numb level in organoid 
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cells. (J) DAPT treatment decreased the Lgr5-GFP cell population in Lgr5-EGFP-
CreERT2 organoids. (K and L) Ectopic miR-34a (K) or Numb (L) expression decreased 
the Lgr5-GFP cell population in Lgr5-EGFP-CreERT2 organoids. (M) Numb knockdown 
gave rise to a subpopulation with intermediate Lgr5-GFP expression. (N to Q) RT-qPCR 
showing Lgr5 levels in conditions corresponding to J to M. (R to U) Western blot showing 
Ascl2 levels in conditions corresponding to J to M. (V to Y) RT-qPCR showing Ascl2 levels 
in conditions corresponding to J to M. Error bars denote s.d. of triplicates. **, p<0.01; ***, 
p<0.001. p-value was calculated based on Student’s t-test. 
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Figure 9. Perturbation of Notch signaling and asymmetric division in mouse 
intestinal organoids. 
(A) miR-34a expression in Lgr5-GFP+ cells by FACS with miR-34a FISH probes. (B) RT-
qPCR showing ectopic miR-34 expression. (C) Western blot showing ectopic Numb 
expression. (D) Western blot showing inhibition of Notch by DAPT. (E) Western blot 
showing Numb knockdown efficiency. (F-I) Representative images of organoids with 
DAPT treatment (F), ectopic miR-34a (G) or Numb (H) expression, and with Numb 
knockdown (I). (J) Representative images of symmetric and asymmetric division of Lgr5-
GFP ISCs in intestinal organoids. Tubulin staining indicates stages of mitosis. The 
anaphase/telophase images were taken from FACS-sorted Lgr5-GFP+ doublets that 
were fixed and stained immediately without recovery. The cytokinesis images were taken 
from the pair-cell assay. Scale bar, 8µm. (K) Frequency of asymmetric division of Lgr5-
GFP stem cells from Lgr5-EGFP-CreERT2 and Lgr5-EGFP-CreERT2/miR-34aflox/flox 
intestinal organoids with or without TNFα treatment. Error bars denote s.d. of triplicates. 
***, p<0.001. p-value was calculated based on Student’s t-test. 
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Figure 10. Loss of miR-34a increases DSS-induced proliferation in mouse intestinal 
crypts. 
(A and B) H&E staining (A) and immunofluorescence (B) of intestinal crypts from Lgr5-
EGFP-CreERT2 and Lgr5-EGFP-CreERT2/miR-34aflox/flox transgenic mice after 
Tamoxifen induction. No obvious phenotypes in terms of morphology or Lgr5-GFP (green) 
ISCs were observed. (C) H&E staining of intestinal crypts from wild type and miR-34a 
whole-body knockout mice.  (D) RT-qPCR showing TNF, IL-1 and IL-6 expression in 
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mouse intestine. (E) RT-qPCR showing TNF, IL-1 and IL-6 expression in mouse colon. 
(F and G) Representative images (F) and quantification (G) of intestinal crypts from Lgr5-
EGFP-CreERT2 and Lgr5-EGFP-CreERT2/miR-34aflox/flox mice administrated with 
DSS or plain water. DSS treatment followed by recovery increased Lgr5-GFP ISCs in the 
intestine. (H and I) Representative images (H) and quantification (I) of cell proliferation 
identified by the BrdU incorporation assay in mouse intestine. DSS and loss-of miR-34a 
increases proliferation. Scale bar, 50µm. *, p<0.05; **, p<0.001; ***, p<0.001. p-value was 
calculated based on Student’s t-test. 
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Figure 11. Loss of miR-34a inhibits asymmetric division and promotes ISC 
proliferation in organoids treated with TNFα. 
(A) FACS analysis of Lgr5-EGFP-CreERT2 and Lgr5-EGFP-CreERT2/miR-34aflox/flox 
organoids with or without TNFα treatment. Percentage of Lgr5-GFP ISCs increased more 
dramatically in organoids from Lgr5-EGFP-CreERT2/miR-34aflox/flox mice. (B) RT-
qPCR showing Lgr5 levels. (C and D) RT-qPCR (C) and Western blot (D) showing Ascl2 
levels. (E) Representative images of organoids. Intestinal organoids from Lgr5-EGFP-
CreERT2/miR-34aflox/flox mice grew into CCSC-like, undifferentiated spheres with high 
level of Lgr5-GPF upon TNF treatment. (F) Cell proliferation measured by BrdU 
incorporation. (G and H) Representative images (G) and quantification (H) of symmetric 
and asymmetric division of Ascl2+ ISCs in Lgr5-EGFP-CreERT2 and Lgr5-EGFP-
CreERT2/miR-34aflox/flox intestinal organoids with or without TNF treatment. Tubulin 
staining indicates stages of mitosis. The anaphase/telophase images were taken from 
FACS-sorted doublets that were fixed and stained immediately without recovery. The 
cytokinesis images were taken from the pair-cell assay. Scale bar, 8m. Error bars denote 
s.d. of triplicates. ***, p<0.001. p-value was calculated based on Student’s t-test.  
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Figure 12. Loss of miR-34a inhibits asymmetric division and promotes ISC 
proliferation in crypts recovering from DSS treatment. 
(A) RT-qPCR showing Lgr5 levels in mouse intestine. (B and C) RT-qPCR (B) and 
Western blot (C) showing Ascl2 levels in mouse intestine. (D) RT-qPCR showing Lgr5 
levels in mouse colon. (E and F) RT-qPCR (E) and Western blot (F) showing Ascl2 levels 
in mouse colon. (G and H) Representative images (G) and quantification (H) of symmetric 
and asymmetric division of Ascl2+ intestinal stem cells in Lgr5-EGFP-CreERT2 and Lgr5-
EGFP-CreERT2/miR-34aflox/flox mice with (+DSS) or without (-DSS) treatment. Cell 
polarity protein PARD3 was also stained.  (I and J) Representative images (I) and 
quantification (J) of symmetric and asymmetric division of Ascl2+ colon stem cells in Lgr5-
EGFP-CreERT2 and Lgr5-EGFP-CreERT2/miR-34aflox/flox mice with (+DSS) or without 
(-DSS) treatment.  PARD3 established cell polarity. (K and L) Representative images (I) 
and quantification (J) of symmetric and asymmetric division of Ascl2+ cells in human 
normal colon and CRC tissue. Scale bar, 20m. Error bars denote s.d. of triplicates. ***, 
p<0.001. p-value was calculated based on Student’s t-test.  
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Figure 13. DSS treatment increases asymmetric division and loss-of-miR-34a 
abrogates asymmetric division in mouse intestine and colon.  
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(A and B) Representative images (A) and quantification (B) of symmetric and asymmetric 
division of Lgr5-GFP intestinal stem cells in Lgr5-EGFP-CreERT2 and Lgr5-EGFP-
CreERT2/miR-34aflox/flox mice with (+DSS) or without (-DSS) treatment. (C and D) 
Representative images (C) and quantification (D) of symmetric and asymmetric division 
of Lgr5-GFP colon stem cells in Lgr5-EGFP-CreERT2 and Lgr5-EGFP-CreERT2/miR-
34aflox/flox mice with (+DSS) or without (-DSS) treatment.  (E and F) Representative 
images (E) and quantification (F) of Lgr5-GFP ISC division in Lgr5-EGFP-CreERT2 mice 
and Lgr5-EGFP-CreERT2/APCflox/flox mice. (G and H) Representative images (G) and 
quantification (H) of Ascl2+ ISC division in Lgr5-EGFP-CreERT2 mice and Lgr5-EGFP-
CreERT2/APCflox/flox mice. (I and J) Representative images (I) and quantification (J) of 
symmetric and asymmetric division of Lgr5+ cells in human normal colon and CRC tissue.  
Tubulin staining indicates dividing cell pair. Scale bar, 20m. Error bars denote s.d. of 
triplicates. ***, p<0.001. p-value was calculated based on Student’s t-test. 
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Figure 14. Schematic illustrating the effect of TNF-a/DSS treatment and miR-34a 
loss. 
TNF or DSS treatment causes cell proliferation. Asymmetric division is increased to curb 
the number of Lgr5+ ISCs. Loss of miR-34a suppresses asymmetric division, contributing 
to Lgr5+ ISC proliferation. 
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Chapter 3  
MicroRNA miR-34a provides a barrier against inflammation-
induced colon stem cell proliferation and oncogenesis 
This section is adapted from the following publication: 
Lihua Wang, Kun Xiang, Gary Zhou, Nikolai Rakhilin, Pengcheng Bu, Xiling Shen. 
MicroRNA miR-34a provides a barrier against inflammation-induced colon stem cell 
proliferation and oncogenesis.  Under review. 
Author contribution: Lihua Wang and Xiling Shen conceived the concept, designed the 
experiments, and co-wrote the manuscript. Lihua Wang performed the experiments with 
the assistance from Pengcheng Bu, Kun Xiang, and Gary Zhou for immunofluorescence 
and Nikolai Rakhilin for animal experiments. 
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INTRODUCTION 
The colon epithelium is one of the fastest generative tissues in the body. Since most of 
the gut microbiota resides in the colon, pathogenic bacteria often invade the epithelium 
causing inflammation. Persistent infections can lead to chronic inflammation, which has 
been linked to diseases such as inflammatory bowel disease (IBD) and recognized as a 
significant risk factor for colorectal cancer (CRC) development [1-3]. It has been 
estimated that chronic inflammation and persistent infections contribute to a significant 
portion of human cancers, especially CRC [2, 4]. 
Inflammation plays a dual role in tissue homeostasis. On one hand, inflammation is 
associated with damage to the tissue. On the other hand, it triggers reparative 
regeneration [5]. Events of damage and inflammation have been associated with 
regenerative signaling pathways such as Wnt to increase the numbers of intestinal stem 
cells and Paneth cells, causing intestinal crypts to become hyperplastic [6]. Regeneration 
of colon epithelium and crypts also involve non-canonical Wnt signaling [7]. 
Inflammation triggers intestinal and colon epithelial reparative regenerations via 
inflammatory cytokines including TNF-a, IL-6, IL-17, and IL-22, which stimulate 
downstream pathways such as MAPK, JAK-STAT3, and NF-κB [5, 8-11]. Deficiency in 
IL-22 or IL-17 Receptor E (IL-17RE) led to enhanced mucosal damage after infection by 
pathogenic bacteria such as Citrobacter rodentium [11, 12]. On the other hand, chronic 
inflammation causes excessive regeneration and the resulting hyperplasia could 
eventually lead to cancer. TNF-α is associated with CRC progression [13, 14], and 
blocking TNF-α reduces colorectal carcinogenesis associated with chronic colitis [15]. IL-
6 and IL-17 have also been shown to promote colitis-associated early colorectal 
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carcinogenesis [16, 17], and IL-22 stimulates stem cell growth after injury and promotes 
CRC stemness [18, 19]. Infiltration of T helper 1 (Th1) cells in CRC tumor specimens is 
associated with prolonged disease-free survival, whereas infiltration of T helper 17 (Th17) 
cells, which secrete IL-17 and IL-22, is predictive of poor prognosis for CRC patients [20].  
The microRNA miR-34a is an important tumor suppressor targeting pro-growth genes [21, 
22], and its mimics are among the first microRNA mimics to reach clinical trial for cancer 
therapy [23, 24]. miR-34a also limits self-renewal of cancer stem cells [25-27]. miR-34a 
expression is often silenced in various cancer types [28-30], and methylation of the miR-
34a promoter is correlated with CRC progression [31, 32]. Nevertheless, miR-34a 
deficiency does not increase susceptibility to spontaneous, irradiation-, or c-Myc–induced 
tumorigenesis [33], which raised a question about the role of miR-34a in tissue 
homeostasis.  
In this study, we demonstrate that miR-34a acts as a checkpoint to protect tissue integrity 
during inflammation-induced reparative regeneration. miR-34a deficiency led to colon 
tumorigenesis after C. rodentium infection, where Th17 cell infiltration and epithelial stem 
cell proliferation were observed. During the pro-inflammatory response, miR-34a 
suppresses Th17 cell differentiation by targeting IL-6R, Th17 cell expansion by targeting 
IL-23R, Th17 cell recruitment to the colon epithelium by targeting CCL22, and IL-17 
induced stem cell proliferation by targeting IL-17RD. Loss of miR-34a results in a 
reparative regeneration process that goes awry. 
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RESULTS 
C. rodentium infection promotes colon carcinogenesis in miR-34a-/- mice. 
Microbial dysbiosys causes chronic inflammation associated with CRC [34-37]. C. 
Rodentium is a mouse mucosal pathogen that shares pathogenic mechanisms and 67% 
of its genes with enteropathogenic Escherichia coli (EPEC) and enterohaemorrhagic E. 
coli (EHEC), which are two clinically important human gastrointestinal pathogens [38-43]. 
C. Rodentium has been used as a model to study mucosal immunology including 
intestinal inflammatory responses during bacteria-induced colitis and colon tumorigenesis 
[44-46]. C. rodentium infection increases the number of colonic adenomas in ApcMin mice 
but does not cause adenoma formation in wild-type mice [47]. 
When wild-type and miR-34a-/- mice were infected with C. rodentium (4x108 CFU) [48], 
both developed similar levels of diarrhea and weight loss within 2 weeks, and the 
symptoms subsided after 4 weeks. Nevertheless, 11 out of the 20 miR-34a-/- mice 
developed visible colon tumors after 6 months, whereas none of the wild-type mice 
developed any tumor (Figures 1A-1C).   
Marked by Lgr5 and Ascl2, both of which are enhanced by Wnt signaling [49], the colon 
stem cells that are usually confined at the base of the crypt in wild-type and miR-34a-/- 
mice became enriched throughout C. rodentium induced colon tumors in miR-34a-/- mice 
(Figure 1D). Enrichment of Lgr5 and Ascl2 expression in the colon tumors of infected 
miR-34a-/- mice was further confirmed by western blot (Figure 1E). 
Th17 cells are enriched in miR-34a-/- colon tumor. 
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CD4+ T helper (Th) cells are known to infiltrate and accumulate in the inflammatory 
environment, which can either promote or suppress tissue malignancy [50]. We isolated 
CD4+ Th cells from the colon epithelium of C. rodentium-infected wild-type and miR-34a-
/- mice and analyzed the relative abundance of Th1, Th2, Th17, and Treg subpopulations 
according to their associated expression of INF-γ, IL-4, IL-17 and FoxP3 respectively. 
INF-γ, IL-4 and FoxP3 levels were similar between wild-type and miR-34a-/-, but IL-17 
was significantly upregulated in miR-34a-/- tissue (Figure 2A).  Flow analysis confirmed 
that, although having little effect in uninfected mice, miR-34a deletion significantly 
enriched the IL17+ Th17 cell population among the CD4+ Th cells in the colon infected 
with C. rodentium (Figure 2B). Immunofluorescence suggested that many of the enriched 
CD4+IL-17+ Th17 cells were in proximity to Ascl2+ colon stem cells (Figures 2C and 2D). 
We then generated a miR-34a conditional knockout mice strain Lgr5-EGFP-
CreERT2/miR-34aflox/flox by crossing miR-34aflox/flox mice with Lgr5-EGFP-IRES-CreERT2 
mice [26]. In this strain, intraperitoneal injection of Tamoxifen deletes miR-34a in Lgr5-
EGFP+ stem cells and their progeny. As in the miR-34a-/- mice, Lgr5-EGFP-
CreERT2/miR-34aflox/flox mice did not develop colon tumors spontaneously. When infected 
with C. rodentium, 1 out of 7 mice developed colon tumor at the end of our observation 
(9 months) (Figure 3A). CD4+IL17+ Th17 cells increased in the infected colons of Lgr5-
EGFP-CreERT2/miR-34aflox/flox mice compared to wild-type mice (Figure 3B) but not to the 
degree of miR-34a-/- mice as shown in Figure 2B. 
miR-34a suppresses Th17 differentiation and expansion by targeting IL-6R and IL-
23R 
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We then aimed to understand how miR-34a deletion led to accumulation of Th17 cells in 
the C. rodentium-induced colon tumors. IL-6 is critical for initiating the differentiation of 
native CD4+ T cells into Th17 cells and IL-23 promotes the final step of Th17 cell 
differentiation, its proliferation and IL-17 expression [51, 52]. Protein levels of IL-6R and 
IL-23R, the receptors for IL-6 and IL-23, were upregulated in CD4+ T cells isolated from 
the C. rodentium-infected miR-34a-/- colon compared to the wild-type control (Figure 4A). 
The RNA22 algorithm identified putative miR-34a binding sites in the IL-6R and IL-23R 
3`UTR (Figures 4B and 4C), which were then confirmed by the luciferase reporter assay 
(Figures 4D and 4E).  
To evaluate the miR-34a/IL-6R and miR-34a/IL-23R axes for Th17 cell differentiation, we 
performed the in vitro Th17 differentiation assay [53] using CD4+ T cells isolated from the 
wild-type and miR-34a-/- mice. Loss of miR-34a significantly enhanced CD4+ T cell 
differentiation into Th17 cells, which was largely abrogated by knockdown of either IL-6R 
or IL-23R (Figure 4F and Figure 5). Therefore, miR-34a suppresses Th17 cell 
differentiation by targeting IL-6R and IL-23R. 
miR-34a suppresses Th17 recruitment by targeting CCL22. 
Th17 cells express chemokine receptors CCR6 and CCR4 [54], and the CCR6/CCL20 
and CCR4/CCL22 axes play important roles in Th17 cell migration [41]. Loss of miR-34a 
did not affect CCR6 or CCR4 expression in CD4+ T cells (Figure 6A). However, CCL22 
expression in the colon epithelium was significantly upregulated in the miR-34a-/- mice 
compared to the wild-type, while CCL20 expression remained unchanged (Figures 4G 
and 6B). A miR-34a binding site was identified in the 3`UTR of the CCL22 gene (Figure 
4H), which was validated by the luciferase reporter assay (Figure 4I).  
124 
 
Conditioned medium collected from miR-34a-/- colon tumor organoids enhanced the 
migration of in vitro-differentiated Th17 cells in comparison to medium from the wild-type 
colon organoids (Figure 4J). The addition of anti-CCL22 neutralizing antibody in the 
medium or knockdown of CCL22 in miR-34a-/- colon tumor organoids reduced Th17 
migration back to the wild-type level (Figure 4J and Figure 5). Therefore, miR-34a 
suppresses recruitment of Th17 cells by targeting CCL22 production in colon epithelial 
cells. 
Th17 cells promote colon organoid growth via IL-17. 
We then tested whether Th17 cells, which were enriched by loss of miR-34a and in 
proximity to Ascl2+ colon stem cells (Figures 2D and 2E), regulate colon epithelial cell 
proliferation. Mouse CD4+ T cells were induced to differentiate into Th17 cells and co-
cultured with colon organoids. The presence of Th17 cells significantly increased the 
organoids sizes, which were suppressed by the addition of anti-IL-17 neutralizing 
antibody, suggesting that the growth effect was via Th17-secreted IL-17 (Figure 7A). In 
the absence of Th17 cells, recombinant IL-17 in the medium increased organoid growth 
(Figures 7B-7C) and upregulated Lgr5 and Ascl2 (stem cell marker) expression (Figure 
7D). We then grew organoid culture from human colon tissue using an established 
protocol [55]. Consistent with mouse organoids, addition of human IL-17 into the medium 
increased the sizes of human colon organoids (Figures 7E-7F). We then examined 8 pairs 
of matched normal colon and colon tumor tissue samples from CRC patients (Table 1). 
The expression levels of the two Th17 cell markers, IL-17 and RORC, were consistently 
higher in tumor tissues than in matched normal colon tissues (Figures 7G-7H). 
IL-17 activates STAT3 signaling. 
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It has been reported that STAT3 activation is involved in Enterotoxigenic E. coli induced 
colon carcinogenesis in ApcMin mice [56].  We treated mouse colon organoids with 
recombinant IL-17 and measured STAT3 phosphorylation by western blot. IL-17 activated 
STAT3, which was abrogated by the STAT3 inhibitor, Stattic (Figure 8A).  Inhibition of 
STAT3 by Stattic impaired colon organoid growth (Figures 8B and 8C). 
miR-34a targets IL-17RD to suppress stem cell proliferation. 
The IL-17 receptor, IL-17RA, is essential for IL-17 mediated signaling [57]. 
Immunofluorescence showed that IL-17RA is evenly distributed along the mouse colon 
crypt axis (Figure 9A). IL-17RD, another IL-17 receptor, has been reported to interact with 
IL-17RA to mediate IL-17 signaling [58]. Unlike IL-17RA, IL-17RD is specifically 
expressed at the base of the crypt, largely overlapping with Ascl2+ stem cells (Figure 
10A). RT-qPCR showed that the IL-17RA transcript levels were similar between C. 
Rodentium-induced miR-34a-/- colon tumors and the wild-type colon, whereas the IL-
17RD transcript levels were significantly increased in miR-34a-/- colon tumors (Figure 9B). 
Western blot confirmed that the IL17RD protein level was upregulated in the miR-34a-/- 
colon tumor (Figure 10B).   
RNA22 predicted a miR-34a binding site in the IL-17RD 3`UTR (Figure 10C). The 
luciferase reporter assay confirmed that miR-34a directly targets IL-17RD and 
suppresses IL-17RD expression (Figure 10D). Co-immunoprecipitation confirmed 
interaction between IL-17RA and IL-17RD in mouse colon crypts (Figure 10E). 
Knockdown of either IL-17RA or IL-17RD inhibited IL-17-mediated STAT3 activation 
(phosphorylation) and colon organoid growth (Figures 10F-10H and Figure 5). 
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Furthermore, colon organoid growth spurred by loss of miR-34a was largely offset by IL-
17RD knockdown (Figure 10I). 
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DISCUSSION 
Our study indicates that miR-34a acts as a checkpoint against pathogen-induced colon 
malignancy by playing versatile roles (Figure 11). First, miR-34a suppresses Th17 cell 
differentiation and expansion by targeting IL-6R and IL-23R. Second, miR-34a limits Th17 
cell recruitment to the epithelium by targeting CCL22. Lastly, miR-34a hinders IL-17 
induced stem cell proliferation by targeting IL-17RD. 
Colon stem cells reside at the base of the crypt, relying on the niche to provide necessary 
signaling cues for self-renewal. cKit+/Reg4+ colonic crypt base secretory cells 
interdigitate with Lgr5+ stem cells, providing the latter with Notch ligands DLL1 and DLL4, 
and epidermal growth factor [59, 60]. Ablation of the crypt base secretory cells inhibits 
self-renewal of stem cells, disrupts the homeostasis of colonic crypts, and suppresses 
colon organoid growth. Normally, stem cells are constrained to this spatial niche and are 
forced to differentiate when they leave the niche. However, in human colon adenoma and 
carcinoma samples, Lgr5+ stem-like cells are highly upregulated and are not confined to 
the spatial niche as in normal crypts [61]. This is like what we observed in C. rodentium 
induced colon tumors in miR-34a-/- mice. Inflammatory cytokines such as IL-17 
potentially provide an enlarged “inflammatory niche” by stimulating receptors such as IL-
17RD on the stem cells, enabling them to ignore the constraint of the crypt base and do 
away with crypt base secretory cells. Interestingly, IL-17RD specifically amplifies IL-17RA 
signaling in stem cells, analogously to Lgr5 receptor amplification of Wnt signaling in stem 
cells for self-renewal. 
Non-coding RNAs occupy most of the mammalian genome [62, 63]. Evolutionarily, the 
percentage of genome devoted to the non-coding region is consistently associated with 
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the complexity of the organism, rising from less than 25% in prokaryotes, 25-50% in 
simple eukaryotes, more than 50% in fungi, plants and animals, to approximately 98.5% 
in humans—which have a genome size that is three orders of magnitude larger than 
prokaryotes [64]. Compared to microRNA, the role of long non-coding RNA (lncRNA) in 
regulating tumors has just started to be appreciated [65-67]. In fact, lncRNA has been 
shown to regulate miR-34a in human CRC, especially in cancer stem cells [32]. Like miR-
34a, many of the lncRNAs with strong functions in tumors are largely dispensable for 
normal development and tissue homeostasis [68, 69]. It is possible that the abundance 
of non-coding RNAs in mammals may provide extra surveillance to protect tissue integrity 
during stress conditions such as inflammation, which are often not captured by laboratory 
animal models raised in well-controlled circumstances. 
The miR-34a mimic was the first microRNA mimic to reach clinical trial for cancer therapy 
[23, 24]. Previous studies largely focused on the role of miR-34a to induce cell cycle arrest, 
senescence, and apoptosis. This study suggests that the miR-34a mimic may have 
additional benefits of suppressing Th17 cells in the tumor microenvironment. It might be 
worth paying extra attention to the delivery efficiency into CD4+ Th cells and evaluate 
therapeutics effects based on CRC classification, especially on the inflammatory subtype 
[70].     
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METERIALS AND METHODS 
Transgenic Mice and Bacterial Infection  
C57/B6 and B6(Cg)-Mir34atm1Lhe/J mice were ordered from the Jackson Laboratory. 
Lgr5-EGFP-creERT2/miR-34aflox/flox mice were generated as described as previously 
[26]. Cre recombinase was induced by intraperitoneal injection of tamoxifen (Sigma) 
dissolved in sterile corn oil at a dose of 75 mg/kg before infection with C. rodentium. 
Mouse maintenance and procedures were approved by Duke University DLAR and 
followed the protocol (A286-15-10). C. rodentium strain DBS100 was purchased from 
ATCC and cultured according to previously described methods [71].  4 × 108 C.F.U C. 
rodentium were infected into 6-8 weeks old mice by oral gavage. 
Clinical specimen and colon Organoid Culture  
Frozen CRC specimens and paired controls were acquired from Weill Cornell Medical 
College (WCMC) Colon Cancer Biobank for evaluation of Th17 cell related gene 
expression. Surgically resected fresh normal human colon tissues were obtained from 
Duke University hospital. The study was approved by the ethical committee of Duke 
University hospital, Duke University, and WCMC. All samples were obtained with 
informed consent. 
Mouse and human colon crypt isolation and organoid culturing were performed as 
described previously [55]. To investigate CCL22 regulation on Th17 cell migration, and 
IL-17RA and IL-17RD regulation on organoids growth, lentiviral vector carrying shRNA 
against CCL22, IL-17RA or IL-17RD were purchased from Sigma and infected into 
organoids according to the protocol described previously [72]. 
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CD4+ T cell isolation and Th17 cell differentiation 
To investigate Th17 cell enrichment in C. rodentium-infected colons, CD4+ T cells were 
first isolated from mouse colon as described previously [73]. Briefly, after washing with 
cold PBS, the mouse colon was cut into 0.5-1cm pieces and incubated in Ca2+ and Mg2+ 
free PBS containing 0.37mg/ml EDTA and 0.145mg/ml DTT in an orbital shaker at 37°C 
for 15 min. The supernatant was decanted and the remaining tissue was further incubated 
in RPMI-1640 containing 5% fetal calf serum, 20mM HEPES, 100U/ml each of penicillin 
and streptomycin and 0.1mg/ml collagenase dispose (Sigma) with shaking at 37°C for 90 
min. After filtering through a 70µm cell strainer, the cells were collected by centrifugation 
and the pellet was suspended in 35% percoll solution (Sigma). The cells were then 
collected by centrifugation at 2000rpm for 20mins and applied for CD4+ T cell isolation 
by a mouse CD4+ T cell isolation kit (StemCell Technology). After staining with CD4 and 
IL-17, Th17 cells were analyzed by Flow cytometry.  
To evaluate the effect of IL-6R and IL-23R on Th17 cell differentiation, CD4+ T cells were 
isolated from mouse spleen as described previously [73]. Briefly, the spleen was minced 
and squeezed through 70µm cell strainer to get the single cells. After collection by 
centrifugation, the cells were suspended into 35% percoll solution (Sigma) with heparin, 
followed by incubation in red cell lysis buffer (Abcam) to get rid of red cells. The cells were 
then washed and applied for CD4+ T cell isolation using a mouse CD4+ T cell isolation 
kit (StemCell Technology). Isolated CD4+ T cells were cultured in 24-well plate coated 
with anti-CD3e and anti-CD28 antibodies in 1640 RPMI medium with 10% FCS and 
recombinant mouse IL-2 (rmIL2, 20 ng/mL) at 1x106 /mL according to the previous 
protocol [74]. Lentiviral vector carrying shRNA against IL-6R or IL-23R were purchased 
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from Sigma and infected into CD4+ T cells followed the protocol [75]. After selection by 
antibiotics, the cells were induced to differentiate into Th17 cells using the FlowCellect 
Mouse Th17 Differentiation Kit according to the protocol (EMD Millipore).  Th17 cell 
differentiation efficiency was measured by Flow cytometry by CD4 and IL-17 staining. 
Co-culture Th17 cells with Organoids 
After differentiation from CD4+ T cells, Th17 cells were co-cultured with colon crypts at a 
10:1 ratio in Matrigel. To active and maintain Th17 cells, rmIL-2 (20ng/ml; Pepro-tech), 
mIL-6 (50ng/ml; Pepro-tech), TGF-β (10ng/ml; Pepro-tech), mIL-23 (30ng/ml; Pepro-tech) 
were added into the ENR organoids culture medium. A neutralizing monoclonal antibody 
against IL-17（Abcam）was used to abrogate IL-17 specific effects of Th17 cells.   
Chemotaxis assays 
The chemotaxis assay was performed as described previously [76]. Briefly, 1×105 Th17 
cells were applied to the upper well of the ChemoTex chambers (96-well, 5-μm pore size; 
NeuroProbe). Conditional medium from miR-34a-/- colon organoids or control organoids 
was added in the lower chamber. To evaluate CCL22 effect on Th17 migration, a 
neutralizing monoclonal antibody against CCL22 (R&D) was included in the conditional 
medium. After 2-hour incubation, the cells in the upper wells were removed and the 
migrated cells were collected by centrifugation. Migrated cells were counted by a 
haemocytometer. 
Immunofluorescence  
Immunofluorescence was performed on paraffin-embedded colon sections. After 
rehydration and antigen retrieve, the sections were blocked by 2% horse serum in PBS 
132 
 
for 2 hours at RT and incubated with anti-Ascl2 (1:200, Santa Cruz), anti-IL17 (1:200, 
Abcam), anti-CD4 (1:50, R&D Systems) or anti-GFP (1:500, Abcam) in antibody diluent 
buffer (DAKO) overnight at 4°C. After washing, the sections were then incubated with 
Rhodamine Red or Alexa fluor 488 labeled secondary antibodies (Invitrogen) for 1 hour 
at room temperature. After counterstained with DAPI (Invitrogen), the slides were 
observed under Axio Imager upright microscope (Zeiss). 
Flow Cytometry analysis 
Th17 cells were analyzed by CD4 and IL-17 staining. Briefly, single cells were fixed with 
4% formaldehyde and further permeabilized by methanol. The cells were then incubated 
with anti-IL-17 (1:200, Abcam) and anti-CD4 (1:100, R&D Systems) antibody, followed by 
incubation with APC or FITC labeled secondary antibody (Invitrogen).  The samples were 
analyzed using a Beckman Coulter flow cytometer. The raw FACS data were analyzed 
with the FlowJo software. 
Quantitative real-time PCR 
Total RNA was extracted from the tissue using the RNeasy mini kit (Qiagen). cDNA was 
synthesized from 500 ng of total RNA in 20µl of reaction volume using the High Capacity 
cDNA Archive Kit (Applied Biosystems). Quantitative PCR was carried out using the 
SYBR Green System (Applied Biosystems) to detect gene expression. The qPCR primers 
used are in Table 2. All samples were run in triplicate three times. The expression of each 
gene was defined from the threshold cycle (Ct), and the relative expression levels were 
calculated using the 2-△△Ct method after normalization to the actin expression level. 
Western Blot 
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Whole cell lysate was prepared in a RIPA lysis buffer (Millipore) with proteinase inhibitor 
(Roche). Proteins were first separated by 10% SDS-PAGE and then transferred to a 
Hybond membrane (Amersham). The membranes were incubated with primary 
antibodies either anti-lgr5 (1:500 ,Santa Cruz), anti-ASCL2 (1:1000, Bioss), anti-IL6R 
(1:1000, R&D Systems), anti-IL23R (1:500, R&D Systems), anti-CCL22(1:500, R&D 
Systems), anti-IL17RD (1:500, R&D Systems), anti-IL17RA (1:500, R&D Systems), anti-
pSTAT3 (1:1000, Cell Signaling) or anti-actin ( 1:2000, Cell Signaling) in 5% milk/TBST 
buffer (25 mM Tris pH 7.4, 150 mM NaCl, 2.5 mM KCl, 0.1% Triton-X100) overnight, and 
then probed for 2 hours with secondary horseradish peroxidase (HRP)-conjugated anti-
goat or anti-rabbit IgG (Santa Cruz). After extensive wash with PBST, the target proteins 
were detected on membrane by enhanced chemiluminescence (Pierce). 
Statistical Analysis 
Data were expressed as mean ± standard deviation of three biological repeats. Student 
t-tests were used for comparisons, with p<0.05 considered significant. 
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Figure 1 C. rodentium infection induces colonic tumor formation in miR-34a-/- mice. 
(A) Representative images of mouse colons uninfected or infected with C. rodentium. The 
arrows indicate the visible colon tumors. 4×108 CFU C. rodentium were used to infect the 
mice orally. Six months after the infection, the mice were euthanized and the colons were 
imaged. (B) Frequencies of colonic tumor formation in infected and uninfected mice. (C) 
Representative H&E colon staining of infected and uninfected mice. (D) 
Immunofluorescence of Ascl2 showing enriched colon stem cells in miR-34a-/- colon 
tumors. Scale bar, 40m. (E) Western blot of Ascl2 and Lgr5 showing enriched colon 
stem cells in miR-34a-/- colon tumors. 
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Figure 2. C. rodentium infection enhances colon stem cells self-renewal and Th17 
cell infiltration in miR-34a-/- colonic tumors. 
(A) RT-qPCR showing relative expression of the T lymphocyte genes associated with Th1 
(IFN- ), Th2 (IL-4), Th17 (IL-17) and Treg (FOXP3) cells in the colons from C. rodentium 
infected wild-type and miR-34a-/- mice. (B) FACS analyses of Th17 cells (CD4+, IL-17+) 
in the colons from infected and uninfected mice. (C and D) Immunofluorescence of CD4 
(C) and IL-17 (D) showing enhanced Th17 cells infiltrating in miR-34a-/- colonic tumors. 
Scale bar, 40m. Error bars denote s.d. of triplicates. ***, p<0.001. p-value was calculated 
based on Student’s t-test. 
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Figure 3. Colon tumorigenesis and Th17 cell accumulation in C. rodentium-
infected Lgr5-EGFP-CreERT2/miR-34aflox/flox mice. 
(A) Frequencies of colon tumor formation in C. rodentium infected and uninfected Lgr5-
EGFP-CreERT2/miR-34aflox/flox mice. (B) FACS analyses of Th17 cells (CD4+, IL-17+) in 
C. rodentium infected and uninfected Lgr5-EGFP-CreERT2/miR-34aflox/flox mice colon. 
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Figure 4. miR-34a targets IL-6R, IL-23R and CCL22. 
(A) Western blot showing IL-6R and IL-23R expression levels in CD4+ T cells isolated 
from C. rodentium infected wild-type and miR-34a-/- colon. (B and C) Schematic 
representation of mouse IL-6R (B) and IL-23R (C) 3`UTRs containing the putative miR-
34a binding sites. (D-E) Luciferase reporter assays confirming the miR-34a binding sites. 
3`UTRs of mouse IL-6R (D) and IL-23R (E) containing wild-type (Wt) or mutated (Mut) 
putative miR-34a binding sites were cloned into the 3`UTR of firefly luciferase (Fluc). 
Ectopic miR-34a expression in CT26 cells downregulated luciferase in Wt cells, but not 
in Mut cells. Fluc signals were normalized by a simultaneously delivered Renillar 
luciferase (Rluc) expression plasmid. (F) FACS showing knockdown of IL6R or IL-23R in 
CD4+ T cells largely offsets the effect of miR-34a loss on Th17 cell differentiation. (G) 
Western blot showing increase of CCL22 expression in miR-34a-/- colon crypts. (H) 
Schematic representation of miR-34a binding site on the mouse CCL22 3`UTR. (I) 
Luciferase reporter assays confirming the miR-34a binding sites in mouse CCL22 3`UTR. 
(J) Chemotaxis assay showing knockdown of CCL22 in colon tumor organoid cells or 
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neutralization of CCL22 with anti-CCL22 antibody suppresses Th17 cell migration to 
colon tumor organoid conditioned medium. Error bars denote s.d. of triplicates. **, p<0.01; 
***, p<0.001. p-value was calculated based on Student’s t-test. 
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Figure 5. Validation of gene knockdown efficiency. 
Western blots showing the knockdown efficiency of IL-6R, IL-23R, CCL22, IL-17RA, and 
IL-17RD. 
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Figure 6. Loss of miR-34a enhances CCL22 expression in colon epithelium. 
(A) RT-qPCR showing relative expression of CCR6 and CCR4 in CD4+ T cells derived 
from C. rodentium infected miR-34a-/- colon tumors and wild-type controls. (B) RT-qPCR 
showing relative expression of CCL20 and CCL22 in C. rodentium infected miR-34a-/- 
colon tumors and wild-type controls. Error bars denote s.d. of triplicates. ***, p<0.001. p-
value was calculated based on Student’s t-test. 
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Figure 7. Th17 cells enhance colon organoids growth through IL-17. 
(A) Th17 cells enhance colon organoid growth in co-culture. When co-cultured with Th17 
cells, colon organoids grow faster with bigger surface area. Anti-IL-17 antibody abrogates 
Th17 promotion of colon organoids growth. (B and C) Recombinant mouse IL-17 
enhances mouse organoids growth as shown by representative mouse colon organoids 
images (B) and quantitative organoid area (C). (D) Western blot showing that mouse IL-
17 increases the expression of colon stem cell markers, Ascl2 and Lgr5, in mouse colon 
organoids. (E and F) Human IL-17 enhances human colon organoids growth as shown 
by representative human colon organoids images (E) and quantitative organoids area (F). 
(G-H) RT-qPCR of 8 paired colon tumor and normal colon tissue samples from CRC 
patients (Table 1) showing higher expression levels of miR-34a and Th17 associated 
genes IL-17 and RORC in colon tumors. Error bars denote s.d. of triplicates. **, p<0.01; 
***, p<0.001. p-value was calculated based on Student’s t-test. 
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Figure 8. IL-17 mediated STAT3 activation enhances colon stem cell self-renewal. 
 
(A) Western blot showing IL-17 promotes STAT3 activation. (B and C) STAT3 activation 
is required for IL-17 mediated colon organoids growth showing by representative 
organoids images (B) and quantitative organoids area (C). Error bars denote s.d. of 
triplicates. **, p<0.01; ***, p<0.001. p-value was calculated based on Student’s t-test. 
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Figure 9. Expression of IL-17RA and IL-17RD. 
(A) Immunofluorescence showing IL-17RA expression along the colon crypt. (B) RT-
qPCR showing relative expression of IL-17RA and IL-17RD in C. rodentium infected 
miR-34a-/- colon tumors and wildtype controls. Scale bar, 40m. Error bars denote s.d. 
of triplicates. ***, p<0.001. p-value was calculated based on Student’s t-test. 
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Figure 10. The IL-17/IL-17RD axis promotes colon organoid growth. 
(A) Immunofluorescence showing IL-17RD expression in Ascl2+ stem cells at the base of 
the crypt. (B) Western blot showing increase of IL-17RD expression in miR-34a-/- colon 
tumors. (C) Schematic representation of mouse IL-17RD 3`UTR and the putative miR-
34a binding site. (D) Luciferase reporter assays confirming the miR-34a binding sites in 
mouse IL-17RD 3`UTR. (E) Immunoprecipitation showing the IL-17RA and IL-17RD 
complex in the colon crypt. (F) Western blot showing IL-17RA and IL-17RD are required 
for IL-17 mediated STAT3 activation. (G and H) IL-17RA and IL-17RD knockdown 
suppresses IL-17 mediated colon organoids growth as shown by representative 
organoids images (G) and quantitative organoids surface area (H). (I) IL-17RD 
knockdown reduces miR-34a deficiency induced colon organoids growth. Scale bar, 
50m. Error bars denote s.d. of triplicates. **, p<0.01; ***, p<0.001. p-value was 
calculated based on Student’s t-test. 
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Figure 11.  miR-34a regulates Th17 cell-mediated regeneration. 
A schematic illustration of the central role of miR-34a in Th17 cell-mediated colon stem 
cell proliferation. miR-34a suppresses Th17 cell differentiation and expansion by targeting 
IL-6R and IL-23R in immune cells. miR-34a further inhibits Th17 cells recruitment by 
targeting CCL22 in the colon epithelium. miR-34a also inhibits IL-17RD expression to 
suppress IL-17-IL-17RD/IL17-RA mediated colon stem cell proliferation. 
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Table 1. Information of CRC patients who provided matched tumor and normal 
colon samples for comparing IL-17 and RORC expression levels. 
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Table 2. RT-qPCR primers. 
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INTRODUCTION 
 
Many solid tumors progress through stages while accumulating genetic alterations and 
reprogramming microenvironments [1, 2]. Ranked among the most common cancers and 
a leading cause of cancer-related deaths [3, 4], CRC progresses through an adenoma to 
carcinoma sequence that eventually leads to metastasis [5, 6]. The stage of CRC is 
specified by the American Joint Committee on Cancer (AJCC) tumor-node-metastasis 
(TNM) staging system, which provides the guideline for treatment. Stages I and II are 
usually considered non-invasive, stage III has spread to lymph nodes, and stage IV 
involves metastasis. However, although there is consensus to treat stage I CRC with only 
surgery and stages III/IV CRC with chemotherapy in addition to surgery, the overall 
benefit of adjuvant chemotherapy after resection of stage II CRC remains unclear [7]. Still, 
chemotherapy likely improves survival for certain subsets of stage II patients. As patient 
survival drops from 80~90% for early-stage CRCs to below 10% for late-stage and 
metastatic CRCs, it is important to identify prognostic markers and therapeutic targets for 
chemoprevention [8]. 
microRNAs are small non-coding RNA molecules that suppress gene expression via the 
3` untranslated regions (UTRs) of target mRNAs. Individual microRNA can control many 
target genes and microRNA expression is often altered in cancer cells [9]. Among them, 
microRNAs that promote relapse and metastasis are of particular interest as potential 
prognostic biomarkers and therapeutic targets [10，11]. 
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RESULTS 
miR-1269 is upregulated in late-stage CRC tumors 
To investigate the roles of microRNAs in CRC progression, we systematically compared 
microRNA expression levels in early- versus late-stage CRC tumors using the latest colon 
adenocarcinoma (COAD) miRNASeq dataset in TCGA [12]. Differential expression 
analysis based on read counts identified miR-1269 as a top microRNA candidate that is 
upregulated in state IV CRCs vs. stage I & II CRCs, with a p-value of 0.01 (Figures 1A-
1C, 2 and Table 1). We did not include Stage III CRCs in our TCGA analysis because 
their metastatic potential was less clear and may vary widely between individuals. 
The miR-1269 family has two isoforms, miR-1269a and miR-1269b. To validate the TCGA 
analysis, we measured miR-1269a and miR-1269b expression levels in 12 early-stage 
and 17 late-stage CRC tumors acquired from the Weill Cornell Medical College (WCMC) 
Colon Cancer Biobank (Table 2). Late-stage CRCs have higher miR-1269a expression 
levels than early-stage CRCs in a statistically significant manner according to RT-qPCR 
measurements, consistent with the TCGA finding (Figure 1D). On the other hand, miR-
1269b level was not statistically different between early- and late-stage CRC samples. 
miR-1269 is a marker associated with CRC relapse and metastasis 
Generally, it is difficult to predict whether stage II CRC patients will relapse or develop 
metastasis after surgical removal of their primary tumors, although 10-20% of stage II 
patients will eventually relapse. To explore whether miR-1269a is a prognostic marker for 
relapse and metastasis, we performed a clinical study on 100 stage II CRC patients at 
the Catalan Institute of Oncology (Table 3) [13]. These disease-free patients were 
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considered “low-risk” for relapse and did not undergo chemotherapy after the surgery. 
The patients were divided into two cohorts, “miR-1269alow” and “miR-1269ahigh”, based 
on the miR-1269a expression levels measured in their surgically removed primary tumors. 
Based on risk of relapse for stage II CRC, we allocated the top 10% (10 patients) into the 
miR-1269ahigh cohort and the rest (90 patients) into the miR-1269alow cohort to see 
whether miR-1269a expression could distinguish the small subset of patients who actually 
had high risk of relapse. 
Follow-up revealed that high miR-1269a expression was associated with relapse and 
metastasis of these disease-free patients (log rank p=0.002). The miR-1269ahigh cohort 
had a significantly higher recurrence rate than the miR-1269alow cohort, based on 
disease-free survival curves from Kaplan-Meier analysis (Figure 1E). Distant metastasis 
developed in only 18% of the patients in the miR-1269alow cohort but in 60% of the 
patients in the miR-1269ahigh cohort (Table 3A). The prognostic value of miR-1269a was 
significant (p=0.015) in a multivariable Cox’ proportional hazards model adjusted for age, 
sex, sub-site (left/right) and sub-stage (IIa/IIb) (Table 3B). These results indicate that miR-
1269a could be a potential marker associated with a small subset of high-risk CRC Stage 
II patients who were previously deemed low-risk and may benefit from chemotherapy after 
surgery. We also explored cut points of miR-1269a expression that stratified patients at 
15 and 20 upper percentiles, and the miR-1269ahigh cohort still had higher recurrence rate 
than the miR-1269alow cohort in a statistically significant way (p=0.009 and 0.022). Similar 
analysis on miR-1269b showed that miR-1269b was not associated with risk of relapse 
(Figure 3A). 
miR-1269a expression is associated with metastatic potential in CRC cell lines. 
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We measured miR-1269a expression in 6 commonly used CRC cell lines (Figure 1F). In 
general, miR-1269a levels are low in cells with relatively low metastatic potential (HT29 
and SW480) and are high in cells with relatively high metastatic potential (DLD1, LoVo, 
LS174T, and SW620). One ambivalent case is the low miR-1269a expression in HCT116 
cells, which were derived from primary adenocarcinoma but seem to possess metastatic 
potential. It is likely that HCT116 cells have accumulated other metastasis-promoting 
mutations. Notably, the miR-1269a level is 6-fold higher in SW620 cells than in SW480 
cells. Originally from the same CRC patient, SW480 was derived from a primary colon 
adenocarcinoma prior to relapse while SW620 was derived from mesenteric lymph nodes 
metastases post-relapse [14]. Hence, this controlled comparison between the two patient-
matched cell lines supported that miR-1269a levels are associated with metastatic 
potential. Unlike miR-1269a, miR-1269b exhibited similar expression levels in SW480 and 
SW620 cells (Figure 3B). Therefore, we decided to focus on miR-1269a for the rest of the 
study. 
miR-1269a promotes CRC metastasis 
To evaluate the effect of miR-1269a on SW480 cells, which have low endogenous miR-
1269a expression, we ectopically expressed miR-1269a in SW480 cells. Ectopic miR-
1269a only slightly increased cell growth in vitro (Figure 4) and subcutaneous xenograft 
tumor growth in vivo (Figure 5A). However, transwell migration assay (Figure 5B) and 
Matrigel invasion assay (Figure 5C) showed that ectopic expression of miR-1269a 
increased migration and invasion of SW480 cells significantly. 
To investigate whether miR-1269a promotes metastasis in vivo, we used an established 
CRC orthotopic model by implanting human CRC cells into cecum terminus of NOD/SCID 
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mice [15, 16]. SW480 cells were infected with lentiviral vectors to establish two stable 
lines that either expressed miR-1269a (SW480-miR-1269a) or contained a control vector 
(SW480-NC). These cells also carry constitutive luciferase and mCherry reporter 
constructs. After cecal implantation of equal numbers of cells from both lines, metastasis 
was tracked using the whole-body IVIS bioluminescence imaging system. Once a mouse 
became moribund, all mice were sacrificed simultaneously and hepatic metastases 
expressing mCherry were analyzed by imaging the entire liver with a fluorescent 
microscope. SW480-NC cells failed to metastasize to liver in all 8 mice (0/8). In contrast, 
7 out 8 (7/8) mice injected with SW480-miR-1269a cells developed hepatic metastases 
(Figures 5D-5F, 5J, 6A and 6B). Hence ectopic miR-1269a expression promotes 
metastasis of SW480 cells in vivo. 
To investigate whether silencing of miR-1269a expression in metastatic cells impedes 
their ability to metastasize, we knocked down endogenous miR-1269a levels in SW620 
cells, the metastatic counterpart of SW480 from the same patient. SW620 cells were 
infected with lentiviral vectors to establish two stable lines that either expressed antisense 
RNA against miR-1269a (SW620-Anti-miR-1269a) or contained a control vector (SW620-
Anti-NC). The miR-1269a knockdown efficiency in SW620-Anti-miR-1269a cells was 
evaluated by a luciferase reporter (Figure 7). Equal numbers of SW620-Anti-NC and 
SW620-Anti-miR-1269a cells were implanted into the ceca of NOD/SCID mice. All mice 
were simultaneously sacrificed for metastasis examination when one became moribund. 
6 out of 8 (6/8) mice injected with SW620-Anti-NC cells developed hepatic metastases, 
whereas only 1 out of 8 (1/8) mice injected with SW620-Anti-miR-1269a cells developed 
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hepatic metastasis (Figures 5G-I, 5K, 6C and 6D). Thus, miR-1269a knockdown 
suppressed metastasis of SW620 cells in vivo. 
In addition to the cecum-injection model, we performed intravenous injection through tail 
vein with the same cells. In the group injected with SW480-miR-1269 cells, all 10 mice 
developed lung metastasis, with a large number of metastatic nodules covering the entire 
lung. In contrast, only 4 out of 10 mice injected with SW480-NC cells developed lung 
metastasis, with a small number of metastatic nodules (Figures 8A-8C). miR-1269a also 
promoted CRC colonization of liver.  Only 1 out of the 10 mice injected with SW480-NC 
cells developed liver metastasis while 5 out of the 10 mice injected SW480-miR-1269a 
cells developed liver metastasis (Figures 8D-8F). Consistent with SW480 cells, ectopic 
miR-1269a expression in HCT116 also enhanced lung and liver metastasis, compared 
with the control vector (Figures 8G and 8H). Therefore, miR-1269a expression promoted 
colonization of circulating SW480 and HCT116 cells in lung and liver. 
Similarly, equal numbers of SW620-Anti-NC and SW620-Anti-miR-1269a were 
intravenously injected through tail vein. In the control group (SW620-Anti-NC), all 10 mice 
(10/10) developed lung metastasis, and 4 out of 10 (4/10) developed liver metastasis, 
which is consistent with the high metastatic potential of SW620. miR-1269a knockdown 
significantly reduced lung and liver metastasis of SW620 cells. In the SW620-Anti-miR-
1269a group, only 3 out 10 (3/10) mice developed lung metastasis, and 1 out 10 (1/10) 
developed liver metastasis (Figures 8A-8F). The SW620 data were further corroborated 
by knocking down miR-1269a in LS174T cells, which also have high endogenous miR-
1269a expression. Injected LS174T control cells formed extensive metastasis in the lung, 
lymph nodes in the lateral thoracic region, and the bone. In contrast, miR-1269a 
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knockdown in LS174T cells significantly reduced metastasis in these regions (Figure 8I). 
Therefore, silencing of endogenous miR-1269a mitigated colonization of circulating 
SW620 and LS174T cells. 
Collectively, the in vitro migration and invasion assays and in vivo metastasis assays, 
with ectopic expression of miR-1269a in SW480 and HCT116 cells and knockdown of 
endogenous miR-1269a in SW620 and LS174T cells, indicate that miR-1269a promotes 
CRC metastasis. 
miR-1269a promotes an EMT-like process 
Since an EMT-like process has been associated with colon cancer metastasis [17], we 
examined whether miR-1269a promotes EMT. We measured the levels of the epithelial 
marker E-cadherin and the mesenchymal markers N-cadherin and Vimentin in SW480-
miR-1269a and SW480-NC cells using both Western blot and immunofluorescence. 
Compared with the control SW480-NC cells, which had high E-cadherin expression and 
low N-cadherin and Vimentin expression, SW480-miR-1269a cells had significantly 
downregulated E-cadherin expression and upregulated N-cadherin and Vimentin 
expression (Figures 9A and 9B). Consistent with the EMT markers, SW480-miR-1269a 
cells adopted a spindle-shaped, mesenchymal-like morphology in contrast to the 
epithelial-like morphology of SW480-NC cells (Figure 9C). Hence ectopic miR-1269a 
expression causes SW480 cells to undergo EMT. 
We then examined whether silencing of miR-1269a could impede the ability of cells to 
undergo EMT. As the metastatic counterpart of SW480, SW620 cells have higher 
endogenous miR-1269a expression levels than SW480 cells. miR-1269a knockdown 
reduced N-cadherin and Vimentin levels in SW620 cells, as shown by 
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immunofluorescence and Western blot (Figures 9D and 9E). TGF-β treatment turned on 
N-cadherin and Vimentin expression and turned down E-cadherin expression in the 
control (SW620-Anti-NC) cells, which started to display a mesenchymal-like morphology 
(Figure 9F). In contrast, the effect of TGF-β induction was much attenuated by miR-1269a 
knockdown, as SW620-Anti-miR-1269a cells largely maintained E-cadherin expression 
and the epithelial-like morphology in the presence of TGF-β (Figures 9D-9F). Therefore, 
miR-1269a knockdown impedes the ability of SW620 cells to undergo an EMT-like 
process upon TGF-β induction. Together, the data indicate that miR-1269a not only 
promotes an EMT-like process but is also involved with TGF-β induced transformation of 
CRC cells. 
TGF-β activates miR-1269a via Sox4. 
To explore the crosstalk between miR-1269a and TGF-β, we treated SW480 cells with 
TGF-β and measured the response of miR-1269a by RT-qPCR. TGF-β treatment 
upregulated miR-1269a expression, suggesting that TGF-β is an upstream regulator of 
miR-1269a (Figure 10A). Genomic analysis identified 2 Sox4 binding motifs at -173 to -
166 (site 1) and -947 to -940 (site 2) inside the putative miR-1269 promoter region (Figure 
10B). Notably, Sox4 is a downstream target gene of TGF-β [18] and has been reported 
to be a master regulator of EMT and cancer metastasis [19]. Therefore, Sox4 is a potential 
intermediate between TGF-β and miR-1269a. Notably, Sox4 expression level was higher 
in SW620 cells than in SW480 cells, similar to miR-1269 (Figure 11) 
We then tested whether Sox4 can activate the miR-1269a promoter as suggested by their 
binding motifs. In SW480 cells, ectopic expression of Sox4 caused a 4-fold increase of 
miR-1269a expression level, compared with cells transfected with a control vector (Figure 
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10C). We then tested whether Sox4 is the intermediate regulator that is required for TGF-
β induced miR-1269a upregulation. Compared to the control cells, Sox4 knockdown by 
shRNA (shSox4) completely abolished the effect of TGF-β on miR-1269a expression, 
consistent with Sox4 as an intermediate regulator between TGF-β and miR-1269a (Figure 
10D). 
To address whether Sox4 directly activates miR-1269a expression, we performed 
chromatin immunoprecipitation (ChIP) assays in SW480 and HT29 cells. ChIP confirmed 
that Sox4 proteins were recruited to both binding sites in the putative miR-1269a promoter, 
with the majority of Sox4 bound to site 1 (Figures 10E and 10F). To test whether the 
binding of Sox4 is sufficient to activate miR-1269a expression, we cloned the putative 
miR-1269a promoter sequence into a pGL4-basic vector, which were subsequently 
transfected into SW480 and HT29 cells. A dual-luciferase reporter assay revealed that 
ectopic expression of Sox4 activated the transcription of firefly luciferase that was driven 
by the wild type miR-1269a promoter. When the binding sequence of site 1 was mutated, 
firefly luciferase expression dropped 6.8-fold in SW480 cells and 5.4-fold in HT29. When 
the binding sequence of site 2 was mutated, firefly luciferase expression dropped 4.6-fold 
in SW480 and 5.7-fold in HT29 (Figures 10G and 10H). Therefore, Sox4 directly binds to 
these two sites to activate miR-1269a expression.  
We then examined whether endogenous Sox4 binding to the miR-1269 promoter 
increases upon TGF-β induction. We treated SW480 cells with TGF-β and then performed 
ChIP. As expected, more Sox4 proteins were recruited to both binding sites in the miR-
1269 promoter after TGF-β treatment (Figure 10I). Next, to investigate whether Sox4 
promotes in vivo metastasis as miR-1269 does, we ectopically expressed Sox4 in SW480 
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cells and implanted them into mouse cecum. Consistent with ectopic miR-1269 
expression, ectopic Sox4 expression significantly enhanced SW480 hepatic metastasis 
(Figures 10J and 10K). 
Taken together, our data indicate that TGF-β upregulates miR-1269a through Sox4, 
which binds to the two Sox4 binding sites in the miR-1269a promoter to activate miR-
1269a expression. Thus, TGF-β , Sox4, and miR-1269a act synergistically to promote 
EMT and metastasis. 
miR-1269a targets Smad7 and HOXD10. 
To determine miR-1269a target genes, we searched for computationally predicted 
candidates using miRecords, which compiles 11 microRNA targets prediction databases 
such as PicTar, miRanda, TargetScan, and RNA hybrid (Table 4). We then used RT-
qPCR to compare expression levels of the candidate genes between ectopic miR-1269a 
expression and control in SW480 and HT29 cells. Among the candidates, homeobox D10 
(HOXD10) has been reported to suppress tumor invasion and metastasis [20], while 
Smad7 is a well-known antagonist of TGF-β signaling [21]. Smad7 and HOXD10 were 
downregulated in both SW480 and HT29 cells by miR-1269a (Figures 12A and 12B). 
Western blot confirmed that miR-1269a suppresses Smad7 and HOXD10 protein levels 
(Figures 12C and 12D).  
To test whether they are direct targeted by miR-1269a, the 3`UTRs of the two genes were 
cloned downstream of firefly luciferase. The luciferase reporters were then co-transfected 
with a miR-1269a expressing construct or an empty control vector into SW480 cells. Cells 
with ectopic miR-1269a expression had suppressed Smad7 and HOXD10 levels, in 
contrast to the control cells, whereas mutation in the putative miR-1269a seed regions in 
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the 3`UTRs of either Smad7 or HOXD10 abrogated the suppression of miR-1269a 
(Figures 12E and 13). Therefore, miR-1269a directly targets Smad7 and HOXD10 
through the identified binding sites in their 3UTR. 
HOXD10 has been reported to suppress tumor invasion and metastasis [20]. To test 
whether miR-1269a suppression of HOXD10 promotes invasion and metastasis, we 
transfected SW480 cells with vector constructs expressing both miR-1269a and HOXD10 
mRNA without its 3`UTR (hence resistant to miR-1269a suppression). Transwell 
migration and Matrigel invasion assays revealed that ectopic expression of HOXD10 was 
able to abrogate miR-1269a-induced cell migration and invasion (Figure 12F). We then 
ectopically expressed HOXD10 in SW620 cells and implanted the cells orthotopically into 
mouse cecum termini. Consistent with the in vitro migration and invasion assays, ectopic 
HOXD10 expression dramatically reduced hepatic metastasis in vivo (Figures 12G and 
12H). 
miR-1269a and TGF-β forms a positive feedback loop. 
Smad7 is a well-known antagonist of TGF-β signaling [21], but the effect of HOXD10 on 
TGF-β signaling is unclear. This raised the question as to whether miR-1269a regulates 
TGF-β signaling in CRC cells through its direct targets. Western blot showed that ectopic 
expression of miR-1269 in SW480 cells enhanced Smad2 phosphorylation. Consistently, 
knockdown of miR-1269 target Smad7 or HOXD10 also promoted Smad2 
phosphorylation (Figure 14A). To evaluate the effect of HOXD10 and Smad7 on TGF-β 
targets gene expression, we established cells lines either expressing Smad7 or HOXD10, 
or containing a control vector. The cell lines were treated with TGF-β for 96 hours before 
RT-qPCR and Western blot were performed to measure TGF-β target genes, Slug, Snail 
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and Sox4. As expected, TGF-β upregulated Slug, Snail, and Sox4 expression in cell lines 
with the control vector.  However, the upregulation was significantly reduced by ectopic 
expression of Smad7 or HOXD10 (Figures 14B-14E, 15A-15D), suggesting that HOXD10 
is also an antagonist of TGF-β signaling in CRC cells. Ectopic expression of Smad7 or 
HOXD10 also reduced TGF-β induced miR-1269a upregulation, consistent with the fact 
that Sox4 levels are down (Figures 14F, and 15E). Taken together, these data indicate 
that Smad7 and HOXD10 are antagonists of TGF-β signaling. 
Since miR-1269a directly targets Smad7 and HOXD10, both of which are antagonists of 
TGF-β signaling, we examined whether miR-1269a upregulates TGF-β signaling. As 
showed in Figures 14G-14I and 15F-15H, ectopic expression of miR-1269a increased the 
expression levels of all three target genes of TGF-β signaling, Slug, Snail, and Sox4, in 
SW480 and HT29 cells. Slug, Snail, and Sox4 are master regulators of EMT, and their 
expression in SW480 cells downregulated E-cadherin and upregulated N-cadherin 
(Figure 14J). These data provide an explanation for the strong induction of EMT by miR-
1269a in CRC cells – miR-1269a upregulates TGF-β signaling and its target genes, Slug, 
Snail, and Sox4, via suppression of TGF-β antagonists Smad7 and HOXD10. To examine 
whether miR-1269a induces TGF-β expression, we performed RT-qPCR in SW480 cells 
that ectopically express miR-1269a. miR-1269a increased TGF-β1 expression but had 
little effect on TGF-β2 and TGF-β3 expression (Figure 16). ELISA confirmed that miR-
1269a also increased TGF-β1 protein level in SW480 medium (Figure 14K). miR-1269a 
seems to upregulate TGF-β1 via a regulatory route independent of Smad7 and HOXD10, 
since knockdown of Smad7 and HOXD10 did not affect TGF-β1 level (Figure 14I). Our 
studies suggest that TGF-β and miR-1269a form a positive feedback loop, wherein TGF-
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β upregulates miR-1269 via Sox4, while miR-1269 upregulates TGF-β and enhances 
TGF-β signaling by suppressing its antagonists Smad7 and HOXD10 (Figure 17). 
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DISCUSSION 
In this study, we performed differential analysis between early- and late-stage CRCs in 
TCGA to identify miR-1269 as a top candidate, which was confirmed by additional 29 
CRC samples. A study of 100 stage II CRC patients revealed that miR-1269a expression 
level was associated with risk of relapse and metastasis. Mechanistically, this is because 
miR-1269a and TGF-β form a positive feedback loop via Sox4, HOXD10, and Smad7 to 
promote EMT and metastasis. 
miR-1269a was a somewhat surprising candidate that emerged from our analysis 
because very little was known about this microRNA. A global study of 8 paired samples 
of normal mucosa and CRC tumor reported that miR-1269 was one of the 16 microRNAs 
that were deregulated in tumor tissues [22]. Nevertheless, a differential expression 
analysis between normal and tumor tissues in TCGA did not suggest a statistically 
significant change in miR-1269a expression. Regardless, our analysis suggests that miR-
1269a likely plays a more prominent role in CRC relapse and metastasis than in 
oncogenesis. Hence the practice of grouping CRC tumors of various stages into a single 
group may mask the complexity of microRNA regulation during tumor progression. 
miR-1269a does not promote metastasis alone. Instead, it forms a positive feedback loop 
with TGF-β. This finding is consistent with the increasing appreciation that microRNAs 
form regulatory motifs with protein regulators to confer robustness to biological processes, 
and their subversion can expose cells to elevated risk of malfunction [23]. Therefore, the 
context is important for understanding the role of microRNAs in regulatory networks. For 
example, positive feedback is known to amplify a response and commits into a self-
sustained mode that is autonomous to the original stimuli. It is tempting to speculate that, 
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once induced by TGF-β, the miR-1269a-mediated feedback loop allows CRC cells to 
become more autonomous. This would enhance the ability of CRC cells to invade and 
metastasize to new microenvironments, which would explain the strong pro-metastasis 
phenotype we have observed. 
Elevated TGF-β production is associated with high risk of CRC relapse and metastasis 
[24]. Stromal cells in the CRC microenvironment can also produce TGF-β, which 
increases the efficiency of organ colonization by CRC cells. In a likely scenario, TGF-β  
released from the microenvironment reaches a certain concentration to activate the 
positive feedback loop in CRC cells and promote their dissemination. Hence miR-1269a 
may play an integrated role in the TGF-β -mediated crosstalk between CRC and stromal 
cells to confer a survival advantage to metastatic cells. 
On the other hand, we certainly have to caution against over-simplification of CRC 
metastasis, which is a complicated process involving many players. Mutations could 
interfere with this feedback loop, while miR-1269a might also affect metastasis through 
other targets independent of TGF-β. Neither miR-1269 nor the positive feedback loop is 
likely to be sufficient or necessary for metastasis. 
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METERIALS AND METHODS 
Cell lines 
Human CRC cell lines SW480, SW620, HCT116, HT29, DLD1, LoVo and LS174T were 
acquired from ATCC and cultured under the conditions recommended by the provider. 
For TGF-β activation, the cells were treated with 10ng/ml TGF-β for 96 hours, and TGF- 
β was replaced after 48 hours. 
Kaplan-Meier relapse analysis and clinical specimens 
The studies followed informed consent and approval of the ethical committees at Catalan 
Institute of Oncology and Weill Cornell Medical College. Tumor relapse was analyzed by 
tracking 100 stage II CRC patients. The patients were divided into two groups, “miR-
1269low” and “miR-1269high”, based on the miR-1269 expression levels measured in their 
surgically removed primary tumors. microRNA expression was measured using Solid IV 
small-RNA sequencing and bowtie2 mapped to miRbase [20]. Sample counts were 
normalized according to the library size using the DESeq bioconductor package 
(http://genomebiology.com/2010/11/10/r106). The cutoff threshold was set to separate 
the top 10% miR-1269high patients from the 90% “miR-1269low patients. The disease-free 
survival curves were estimated using the Kaplan-Meier method and compared with the 
log-rank test.  
To evaluate miR-1269a expression in early- and late-stage CRC tumors, frozen CRC 
specimens were acquired from Weill Cornell Medical College (WCMC) Colon Cancer 
Biobank. Total RNA was then isolated from the frozen tissues using the Allprep DNA/RNA 
kit (Qiagen). 
Quantitative real-time RT-PCR analysis 
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Total RNA was extracted from the cells using the TRIzol Reagent (Invitrogen). cDNA was 
synthesized from 500 ng of total RNA in 20 µl of reaction volume using the High Capacity 
cDNA Archive Kit (Applied Biosystems). miR-1269a and miR-1269b levels were 
measured by quantitative PCR using the TaqMan MicroRNA Assay (Applied Biosystems). 
Gene expression levels were measured by quantitative PCR using the SYBR Green 
System (Applied Biosystems). All samples were run in triplicates and were repeated three 
times. The respective miR-1269a and miR-1269b primers and U6 primer were purchased 
from Applied Biosystems. Other primer sequences include: HOXD10, 5`-
GTGCAGGAGAAGGAAAGCAAAG-3` and 5`-TAACGCTCTTACTGATCTCTAGGC-3`; 
Smad7, 5'-TGCTCCCATCCTGTGTGTTAAG-3' and 5`-
TCAGCCTAGGATGGTACCTTGG-3`; Slug, 5`-CATGCCTGTCATACCACAAC-3` and 
5`- GGTGTCAGATGGAGGAGGG-3`; Snail, 5`- GAGGCGGTGGCAGACTAG-3` and 5`- 
GACACATCGGTCAGACCAG-3`; Sox4, 5`- CACATCAAGCGACCCATGAAC-3` and 5`- 
CCGGTACTTGTAGTCGGGGTAGT-3`; TGF-1, 5`-CTCTCCGACCTGCCACAGA-3` 
and 5`-AACCTAGATGGGCGCGATCT-3`; TGF-2, 5`-CCGCCCACTTTCTACAGACCC-
3` and 5`-GCGCTGGGTGGGAGATGTTAA-3`; TGF-3, 5`-
CTGGCCCTGCTGAACTTTG-3` and 5`-AAGGTGGTGCAAGTGGACAGA-3`; actin, 5`-
CGCGAGAAGATGACCCAGAT-3` and 5`-ACAGCCTGGATAGCAACGTACAT-3`. The 
expression of each gene was defined from the threshold cycle (Ct), and the relative 
expression levels were calculated using the 2-△△Ct method after normalization to the 
actin expression level. 
Lentiviral Vector Constructs and Infection  
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miR-1269a was ectopically expressed by the GFP hsa-miR-1269a Letivector and 
silenced by the inhibitor hsa-miR-1269a Letivector. These two vectors and the control 
vectors were ordered from Applied Biological Material. The Smad7 luciferase reporter, 
with the Smad7 3`UTR in the pMirtarget Vector, was ordered from OriGene. The HOXD10 
luciferase reporter, pMIR-D10 UTR, was order from Addgene. miR-1269a binding 
sequences in the Smad7 and HOXD10 luciferase reporters were mutated using the 
QuickChange Site-directed Mutagenesis Kit (Stratagene). In order to construct the 
reporter for miR-1269a promoter activity, the miR-1269a promoter sequence was 
amplified from human genomic DNA and cloned into the pGL4.10 vector (Promega). The 
putative Sox4 binding site in the miR-1269a promoter sequence was further mutated 
using the QuickChange Site-directed Mutagenesis Kit (Stratagene). Expression vectors 
for HOXD10, Smad7, Sox4, Slug, and Snail (HOXD10-pcDNA, pBabe-puro-Smad7-HA, 
pWPXL-Sox4, pBabe-puro-Slug and pBabe-puro-Snail) were ordered from Addgene. 
shRNA constructs against HOXD10 and Smad7 were ordered from Sigma. The reporter 
construct carrying luciferase and mCherry was order from Addgene. The lentiviral vectors 
were co-transfected with helper plasmids into 293T cells. The retroviral vectors were 
transfected into phoenix cells. The viral supernatant was collected 48 hours after 
transfection and was used to infect CRC cells. 
Luciferase reporter assay 
To validate the Sox4 binding sites in the miR-1269a promoter, miR-1269a promoter 
reporter construct with wide-type or mutated Sox4 binding sites was transfected with the 
pRL-SV40 Renilla luciferase vectors into SW480 and HT29 cells using the LT1 
Transfection Reagent (Mirus). To validate whether HOXD10 and Smad7 are direct targets 
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of miR-1269a, HOXD10 and Smad7 luciferase reporter constructs with wide-type or 
mutated miR-1269a binding sites were transfected with the pRL-SV40 Renilla luciferase 
vector into SW480 and HT29 cells. 48 hours after transfection, Luciferase assays were 
performed using the dual luciferase reporter assay system (Promega). Measurements 
from triplicate transfections were analyzed after normalization to the Firefly luciferase 
activity. 
Immunofluorescence 
Cells were grown on glass culture slides (BD Biosciences) and fixed with 4% cold 
methanol at -20 °C for 10 minutes. Subsequently, cells were blocked with 10 % goat 
serum for 1 hour and incubated with primary antibodies against E-cadherin (24E10, 1:200, 
Cell Signaling), N-cadherin (1:100, BD Biosciences) and Vimentin (D21H3, 1:100, Cell 
Signaling) at 4 °C for 1 hour and then incubated with Rhodamine Red or Alexa Fluor 488 
labeled secondary antibody (Invitrogen) for 1 hour at room temperature. After 
counterstained with DAPI (Invitrogen), the slide was observed under a confocal 
microscope (Zeiss). 
Chromatin immunoprecipitation (ChIp) assay 
ChIP was performed using a ChIP assay kit (Millipore) according to the manufacturer’s 
instructions. Briefly, SW480 and HT29 cells either infected with a vector expressing Sox4 
or treated with TGF-β1 were incubated in 1% formaldehyde for 10 minutes at room 
temperature to crosslink their DNA. The cells were lysed in lysis buffer, sonicated to 
generate DNA fragments less than 500 base pairs in length and then diluted by 10 folds 
in ChIP Dilution Buffer. Before immunoprecipitation, nuclear extracts were pre-cleared 
with 50% protein G–Sepharose slurry, goat normal serum and sheared salmon sperm 
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DNA for 2 hours at 4 ºC. Anti-Sox4 antibody (H-90, 1:50, Santa Cruz) was then added to 
form complexes with Sox4 protein and associated chromatin. These immunocomplexes 
were recovered by protein G–Sepharose beads, and the associated DNA was purified by 
extraction with phenol/chloroform.  PCR Primers 5`-
CAGTGGATTGAGTGAGGAAGATTCT-3` and 5`-TGAGCCCCAGAGTCCAAGAG-3` for 
site 1 and primers 5`-CCCTCACAGCAATTTTATAGCATCT-3` and 5`-
TCAAACAAATATGCCAGTCACTTCA-3` were used to measure the enrichment of the 
putative Sox4 binding site in the miR-1269a promoter. 
Western Blot 
Whole cell lysate was prepared in a lysis buffer (20 mM Tris pH 7.5, 150 mM NaCl, 1% 
Nonidet P-40, 0.5% Sodium Deoxycholate, 1 mM EDTA, 0.1% SDS, protease inhibitors). 
Proteins were first separated by 10% SDS-PAGE and then transferred to a Hybond 
membrane (Amersham). The membranes were incubated with primary antibodies either 
anti-E-cadherin (24E10, 1:1000, Cell Signailing), anti-N-cadherin (1:1000, BD 
Biosciences), anti-HOXD10 (H-80, 1:1000, Santa Cruz), anti-Smad7 (B-8, 1:500, Santa 
Cruz), anti-Snail (C15D3, 1:1000, Cell Signaling), anti-Slug (C19G7, 1:1000, Cell 
Signaling), anti-Sox4 (C20, 1:100, Santa Cruz) anti-Phospho-Smad2 (1:1000, Cell 
Signaling) or anti- -actin (13E5, 1:1000, Cell Signaling) in 5% milk/TBST buffer (25 mM 
Tris pH 7.4, 150 mM NaCl, 2.5 mM KCl, 0.1% Triton-X100) overnight, and then probed 
for 1 hour with secondary horseradish peroxidase (HRP)-conjugated anti-mouse or anti-
rabbit IgG (Santa Cruz). After extensive wash with PBST, the target proteins were 
detected on membrane by enhanced chemiluminescence (Pierce). 
Analysis of Proliferation, migration and invasion 
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SW480 cells were infected with either the control or miR-1269a expression lentiviral 
vectors. The infection efficiency was measured by GFP expression from the vectors. Cell 
proliferation under differentiating condition was analyzed using the WST-1 Cell 
Proliferation Reagent (Clontech). Migration assay and invasion assay were performed as 
previously described. Briefly, 1×105 cells were plated in the serum-free medium in the 
upper chamber with the non-coated membrane (24-well insert; pore size, 8 mm; BD 
Biosciences) for migration assay and with Matrigel-coated membrane (24-well insert; pore 
size, 8 mm; BD Biosciences) for invasion assay. The lower chamber was filled with 
medium containing 20% FBS. The cells were incubated for 24 hours at 37°C. The cells 
that did not traverse the membrane were removed by a cotton swab, and the cells on the 
lower surface of the membrane were stained with crystal violet and observed under a 
microscope. 
In Vivo experiments 
All animal experiments were approved by The Cornell Center for Animal Resources and 
Education (CARE) and followed the protocol (2009-0071 and 2010-0100). For 
subcutaneous injection, 8×106 cancer cells were injected into the lower back region of 5-
week-old female nude mice, with 5 mice per group. The mice were sacrificed and the 
tumors were collected and weighed when one of the mice had developed severe tumor 
burden. 
For intravenous injection, 2×106 cancer cells were injected into 5-week-old female 
NOD/SCID mice, with 10 mice per group. The mice were sacrificed and lung/liver 
metastasis was evaluated when one of them became moribund. 
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For cecum injection, cells were carrying a reporter construct expressing luciferase and 
mCherry. After FACS sorting, 4×106 cells were injected into 5-week-old female 
NOD/SCID mice, with 8 mice per group. After injection, luciferase signal was tracked in 
vivo using the IVIS luciferase imaging system 200 (Xenogen). When one of the mice 
became moribund, all mice were sacrificed and liver metastases were evaluated based 
on mCherry signals by an OV100 microscope (Olympus). 
Immunohistochemistry 
Lung and liver tissue from mice injected with CRC cells with miR-1269a expression or 
silencing vectors were removed and fixed in 4% paraformaldehyde overnight. Paraffin-
embedded sections were processed for H&E staining. 
Bioinformatics analysis 
microRNA expression profiles of CRC tumors at different stages were compared by 
analyzing miRNASeq data from the TCGA COlon ADenocarcinoma (COAD) dataset. A 
total of 409 samples were grouped according to AJCC TNM staging. Stage I (68 samples) 
and Stage II (162 samples) CRCs were combined to form the early-stage CRC cohort, 
which was compared with stage IV samples (59 samples) as the late-stage cohort. DESeq 
was used for differential analysis of the microRNA expression profiling between early- 
(stage I and II) and late-stage (stage IV) CRC cohorts. 
Statistical Analysis 
Data were expressed as mean ± standard deviation of no smaller than three biological 
repeats, unless otherwise noted. Student t tests were used for comparisons, with 
p<0.05 considered significant. Survival curves were estimated using the Kaplan-Meier 
method and compared using the logrank test. The multivariate analysis was performed 
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with a Cox’s proportional hazards model. Hazard ratios and 95% confidence intervals 
were derived from the model. 
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Figure 1. miR-1269 level is associated with CRC progression, relapse and 
metastasis. 
(a) Volcano plot comparing miRNASeq data between Stage I/II CRCs and Stage IV CRCs 
from the TCGA COAD dataset. Each dot represents a microRNA. Dots in the upper right 
quadrant represent microRNAs that are upregulated in Stage IV CRCs with enough 
statistical significance (p-value < 0.05). (b) MA plot comparing miRNASeq data between 
Stage I/II CRCs and Stage IV CRCs. Dots in the upper right quadrant represent 
microRNAs that are abundant and upregulated in Stage IV CRCs. (c) miR-1269 
expression in early- (Stage I/II, n=230) and late-stage (Stage IV, n=59) CRCs. Each dot 
represents a CRC sample from COAD. (d) RT-qPCR measurements of miR-1269a 
expression in early- (Stage I/II, n=12) and late-stage (Stage III/IV, n=17) CRC samples 
from WCMC Colon Cancer Biobank. (e) Kaplan-Meier analysis of relapses of Stage II 
CRC patients with high (red, n=10) and low (blue, n=90) miR-1269a levels in their 
surgically removed primary tumors. (f) RT-qPCR measurements of miR-1269a 
expression in various CRC lines. Error bars denote s.d. of triplicates. 
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Figure 2. microRNAs upregulated in late-stage CRCs according to TCGA.  
Expression levels of micoRNAs from Table 1 in individual early-(stageI/II, n=230) and 
late-stage (stage IV, n=59) CRCs according to miRNASeq data from COAD.  
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Figure 3. The effect of miR-1269 on cell growth in vitro. 
SWT-1 assay measuring the growth of SW-480 cells with a control (NC) or a miR-1269 
expression vector. Error bars denote the s. d. between triplicates. *. p<0.05. 
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Figure. 4. Efficiencies of ectopic expression and silencing of miR-1269.  
Luciferase reporter assay showing the efficiency of an anti-miR-1269 construct in SW480 
cells. Error bars denote the s. d. between triplicates. ***, p<0.001.   
 
 
181 
 
 
Figure 5. miR-1269a promotes CRC metastasis 
(a) Growth of subcutanous xenograft CRC tumor, as shown by tumor weight (upper panel) 
and representative tumor images (lower panel), with a control vector (NC) or with ectopic 
miR-1269a expression (miR-1269a). Error bars denote s.d. of 5 mice in each group. (b,c) 
Transwell assay measuring CRC cell migration (b) and invasion (c) with a control vector 
(NC) or with ectopic miR-1269a expression (miR-1269a). Error bars denote s.d. of 
triplicates. (d-f) Analysis of CRC liver metastasis in mice with orthotopic (cecal) injection 
of SW480-NC and SW480-miR-1269a cells carrying luciferase and mCherry reporter 
constructs. Representative IVIS luciferase in vivo images (d), bright field and fluorescent 
(mCherry) images of livers isolated from mice (e), and number of liver metastatic nodules 
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(f) show ectopic miR-1269a expression promoted liver metastasis of SW480 cells. (g-i) 
Analysis of CRC liver metastasis in mice with orthotopic (cecal) injection of SW620-Anti-
NC and SW620-Anti-miR-1269a cells carrying luciferase and mCherry reporter constructs. 
Representative IVIS luciferase in vivo images (g), bright field and fluorescent (mCherry) 
images of livers (h), and number of liver metastatic nodules (i) show knockdown of 
endogenous miR-1269a by antisense RNA suppressed liver metastasis of SW620 cells. 
Error bars denote s.d. of 8 mice in each group. (j-k) H&E staining of liver sections isolated 
from mice orthotopically injected with SW480-NC or SW480-miR-1269a cells (j) or 
SW6200-Anti-NC or SW620-Anti-miR-1269a cells (k). Error bars denote s.d. of 8 mice in 
each group. *, p<0.05; **, p<0.01; ***, p<0.001. Scale bar, 15 µm. 
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Figure 6. miR-1269 promotes CRC metastasis  
(a) Ectopic miR-1269 expression in HCT116 cells enhanced their liver and lung 
metastasis. (b) Representative H&E images of liver and lung metastasis from HCT116 
cells with a control (NC) or a miR-1269 expression (miR-1269) vector. (c) Representative 
images showing miR-1269 knockdown by antisense RNA in LS174T cells reduced lymph 
node metastasis.  
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Figure 7. shRNA silencing of miR-1269a. 
(a) Schematic illustration of the reporter vector used in (b). (b) Luciferase reporter assay 
showing the knockdown efficiency of an anti-miR-1269a construct in SW620 cells. Error 
bars denote s.d. of triplicates. ***, p<0.001. 
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Figure 8. miR-1269a promotes CRC cell colonization of liver and lung after 
intravenous injection. 
(a-c) Representative images (a), H&E staining (b), and number of metastatic nodules (c) 
of lung metastasis. Ectopic miR-1269 expression promoted lung metastasis of SW480 
cells (upper panel). Knockdown of endogenous miR-1269 by antisense RNA suppressed 
lung metastasis of SW620 cells (lower panel). (d-f) Representative images (d), H&E 
staining (e), and number of metastatic nodules (f) of liver metastasis. Ectopic miR-1269 
expression promoted liver metastasis of SW480 cells (upper panel). Knockdown of 
endogenous miR-1269 by antisense RNA suppressed liver metastasis of SW620 cells 
(lower panel). (g-h) Representative images (g), H&E staining of liver and lung metastasis. 
Ectopic miR-1269 expression in HCT116 cells enhanced their liver and lung metastasis. 
(i) Representative images showing miR-1269 knockdown in LS174T cells reduced lymph 
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node metastasis. In the H&E staining, inserts highlight big magnification of the indicated 
regions. Error bars denote s.d. of triplicates. *, p<0.05; ***, p<0.001. 
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Figure 9. miR-1269a regulates EMT. 
(a-c) Western blot (a), Immunofluorescence (b), and phase-contract images (c) of SW480 
cells with a control vector (NC) or with ectopic miR-1269a expression (miR-1269a). 
Ectopic miR-1269a downregulated the epithelial marker E-cadherin, upregulated the 
mesenchymal markers N-cadherin and Vimentin, and changed cell morphology. (d-f) 
Immunofluorescence (d), Western blot (e), and phase-contract images (f) of SW620 cells 
with a control vector (Anti-NC) or with antisense RNA against endogenous miR-1269a 
(Anti-miR-1269a). SW620 cells are either untreated (d, upper panel) or treated with TGF-
β (d, lower panel). miR-1269a knockdown suppressed TGF-β induction of EMT, as 
indicated by downregulation of N-cadherin and Vimentin, upregulation of E-cadeherin, 
and reversion from a mesenchymal-like morphology to an epithelial-like morphology. 
Scale bar, 15 µm. 
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Figure 10. Sox4 activates miR-1269a expression directly. 
(a) RT-qPCR showing TGF-β treatment induces miR-1269a expression in SW480 cells. 
(b) A schematic diagram illustrating the two putative Sox4 binding sites in the miR-1269a 
promoter. (c) RT-qPCR showing ectopic Sox4 expression upregulates miR-1269a 
expression in SW480 cells. (d) RT-qPCR showing Sox4 knockdown by a shRNA 
abolishes TGF-β induction of miR-1269a. (e, f) ChIP assay of SW480 (e) and HT29 (f) 
cells infected with a control (NC) or a Sox expression (Sox4) vector. Binding of Sox4 to 
the two sites was confirmed by PCR with primers specific for the two sites. (g, h) 
Luciferase reporter assays confirming Sox4 activation of the miR-1269a promoter through 
the two Sox4 binding sites in SW480 (g) and HT29 (h) cells. Expression of firefly luciferase 
(Fluc) was driven by miR-1269a promoter sequences containing either wild-type (Wt) or 
mutated (Mut1, Mut2) Sox4 binding sites. Ectopic expression of Sox4 upregulates 
luciferase in Wt cells, but not in Mut1 and Mut2 cells. Fluc signals were normalized by a 
simultaneously delivered Renillar luciferase (Rluc) expression plasmid. (i) ChIP assay of 
SW480 cells treated with TGF-β. Sox4 binding to the two sites was confirmed by PCR 
with primers specific for the two sites. (j, k) Bright field and fluorescent (mCherry) images 
of livers isolated from mice orthotopically injected with SW480-NC and SW480-Sox4 cells 
(j), and number of liver metastatic nodules. Ectopic Sox4 expression promoted liver 
metastasis of SW480 cells. Error bars in (k) denote s.d of each group (8 mice). In 
remaining cases, error bars denote s.d. of triplicates. ***, p<0.001. 
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Figure 11. Sox4 expression in SW480 and SW620 cells. 
Sox4 expression levels in SW620 and SW480 cells, measured by RT-qPCR. Error bars 
denote s.d. of triplicates. **, p<0.01. 
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Figure 12. HOXD10 and Smad7 are direct targets of miR-1269a. 
(a,b) RT-qPCR of Smad7 (a) and HOXD10 (b) mRNA levels in SW480 and HT29 cells 
with a control vector (NC) or with an ectopic miR-1269a expression vector (miR-1269a). 
(c,d) Western blot of Smad7 (c) and HOXD10 (d) protein levels in SW480 and HT29 cells 
with a control vector (NC) or with an ectopic miR-1269a expression vector (miR-1269a). 
(e) Luciferase reporter assays confirming the miR-1269a binding sites in Smad7 and 
HOXD10 3`UTRs. 3`UTRs of Smad7 (left) and HOXD10 (right) containing wild-type (Wt) 
or mutated (Mut) putative miR-1269a binding sites were cloned into the 3`UTR of firefly 
luciferase (Fluc). Ectopic miR-1269a expression in SW480 cells downregulated luciferase 
in Wt cells, but not in Mut cells. Fluc signals were normalized by a simultaneously 
delivered Renillar luciferase (Rluc) expression plasmid. (f) Transwell migration assay (left) 
and Matrigel invasion assay (right) of SW480 cells carrying control (NC) or miR-1269a 
expression (miR-1269a) vectors. Transient expression of HOXD10 abrogated miR-1269a 
induced migration and invasion. Error bars denote the s.d. between triplicates. (g,h) 
Bright field and fluorescent (mCherry) images of livers isolated from mice orthotopically 
injected with SW620-NC and SW620-HOXD10 cells (j), and number of liver metastatic 
nodules (h). Ectopic HOXD10 expression reduced liver metastasis of SW620 cells. Error 
bars in (h) denote s.d. of each group (8 mice). In remaining cases, error bars denote s.d. 
of triplicates. ***, p<0.001; **, p<0.01; ***, p<0.001. 
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Figure 13. Schematic representation of miR-1269a binding sites in the Smad7 and 
HOXD10 3`UTR. 
(a) The predicted duplex formations between Smad7 3` UTR and miR-1269a, and 
mutation introduced to the seed region. (b) The predicted duplex formations between 
HOXD10 3` UTR and miR-1269a, and mutation introduced to the seed region. 
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Figure 14. miR-1269a upregulates TGF-β signaling by targeting Smad7 and 
HOXD10. 
 (a) Western blot of phosphorylated Smad2, levels of which were increased by ectopic 
miR-1269a expression or knockdown of Smad7 or/and HOXD10. (b-e) RT-qPCR and 
Western blot showing ectopic expression of HOXD10 or Smad7 significantly reduced 
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TGF-β induction of Snail, Slug and Sox4 expression in SW480. (f) RT-qPCR showing 
ectopic expression of HOXD10 or Smad7 significantly reduced TGF-β induction of miR-
1269a in SW480 cells. (g-i) RT-qPCR showing ectopic expression of miR-1269a 
upregulated Snail, Slug, and Sox4 in SW480 cells. (j) Western blot showing ectopic Snail, 
Slug or Sox4 upregulated E-cadherin and downregulated N-cadherin in SW480 cells. (j) 
ELISA assay showing that ectoptic miR-1269a expression increased TGF-1 level in 
SW480 medium. (k) ELISA assay showing that knockdown of Smad7 and HOXD10 had 
little effect on TGF-1 level in SW480 medium. In all case, error bars denote s.d. of 
triplicates. **, p<0.01; ***, p<0.001. 
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Figure 15. miR-1269a upregulates TGF-1 signaling by targeting Smad7 and 
HOXD10. 
(a-d) RT-qPCR (a-c) and Western blot (d) showing ectopic expression of HOXD10 or 
Smad7 reduced TGF-1 induction of Snail (a), Slug (b) and Sox4 (c) expression HT29 
cells. (e) RT-qPCR showing ectopic expression of HOXD10 or Smad7 reduced TGF-1 
induction of miR-1269a in HT-29 cells. (f-h) RT-qPCR showing ectopic expression of miR-
1269a upregulated Snail (f), Slug (g), and Sox4 (h) in HT29 cells. Error bars denote the 
s.d. of triplicates. **, p<0.01; ***, p<0.001. 
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Figure 16. The effect of miR-1269a on TGF- expression. 
RT-qPCR showing that ectoptic expression of miR-1269a increased TGF-1 expression 
with little effect on TGF-2 and TGF-3 expression. Error bars denote the s.d. of triplicates. 
**, p<0.01. 
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Figure 17. A positive feedback loop between TGF-β and miR-1269a. 
A schematic illustration of the positive feedback loop. miR1269a upregulates TGF-β1 and 
TGF-β signaling by suppressing its antagonists Smad7 and HOXD10. TGF-β in turn 
upregulates miR-1269 through Sox4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
199 
 
Table 1. Top 16 microRNAs upregulated in stage IV CRCs vs. stage I/II CRCs.  
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Table 2. Information of patients who provided tissue samples for comparing miR-
1269 expression levels in early- vs. late – stage CRC tumors.  
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Table 3. Relationship between miR-1269 and clinic pathological features of 100 
stage II CRC patients.   
 
a, Mann-Whitney test  
b, Fisher exact test  
c, Metastasis occurred after surgery  
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Chapter 5 
CONCLUDING REMARKS AND FUTURE DIRECTIONS 
5.1 Conclusion  
We have previously reported that asymmetric distribution of miR-34a determines colon 
cancer stem cell (CCSC) asymmetry by creating bimodal Notch signaling in daughter cells. 
However, it remained unknown how miR-34a asymmetry in cancer stem cells is initiated 
and how miR-34a is eventually silenced in many types of cancer.  My thesis described a 
novel lncRNA, lnc34a, that is capable of initiating CCSC asymmetric division. Lnc34a 
directly targets the miR-34a promoter to epigenetically silence miR-34a expression 
through recruitment of epigenetic regulators HDAC1 and DNMT3a via PHB2. Clinical data 
has confirmed a strong correlation between the upregulation of the lncRNA and 
epigenetic miR-34a silencing along colorectal cancer (CRC) progression. This study 
elucidated that lncRNAs not only target protein-coding genes but also target microRNAs 
such as miR-34a via epigenetic silencing. Furthermore, the finding that spatial imbalance 
of a lncRNA can initiate cancer stem cell asymmetric division highlights the versatility of 
ncRNA regulation. Given that miR-34a regulates cell division in both colon cancer stem 
cells and normal intestine/colon stem cells.   
Further studies revealed that miR-34a-mediated asymmetric divisions also occur in 
normal intestine/colon stem cells. Normal intestine/colon stem cells normally divide 
symmetrically, but switch to asymmetric division when trigged by inflammation. Loss of 
miR-34a abolishes stem cell asymmetric division and further induces stem cell 
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proliferation. We showed that inflammation promotes intestine/colon stem cell 
proliferation for regeneration, but miR-34a-mediated asymmetric division limits excessive 
colon stem cell proliferation, serving as a safeguard against hyperplasia. 
Infection of gut pathogens and microbial dysbiosys causes chronic inflammation that has 
been associated with CRC. In the thesis, we described that miR-34a deficiency led to 
colon tumorigenesis after Citrobacter rodentium infection while wildtype mice treated by 
C. rodentim only resulted in inflammation.  Mechanistically, loss of miR-34a systematically 
increased IL-6R and IL-23R expression in immune cells to facilitate Th17 cell 
differentiation from CD4 T cells. By targeting chemokine CCL22 and IL-17RD in epithelial 
cells, miR-34a blocks Th17 cells recruitment to colon epithelium and inhibits colon stem 
cell proliferation. Thus, miR-34a targets both immune and epithelial cells to restrain 
inflammation-induced reparative regeneration. This study provided a novel insight into 
colon stem cell niche and inflammation-mediated colon tumorigenesis. 
Cancer metastasis continues to account for most of cancer-related deaths and remains 
a clinical challenge. Current chemotherapy for advanced CRC does not target metastases 
specifically. Discovery and targeting CRC metastasis biomarker could be a promising 
approach for CRC therapy. miRNAs may be utilized as prognostic indicators and 
therapeutic targets due to their stability and robust expression pattern. In this study, a 
novel miRNA, miR-1269, was discovered by analyzing the colon adenocarcinoma (COAD) 
miRNASeq dataset in TCGA.  miR-1269 promotes colorectal cancer (CRC) metastasis 
through a positive feedback loop with TGF-β signaling. miR-1269 is upregulated in late-
stage CRCs, and long-term monitoring of 100 stage II CRC patients revealed that miR-
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1269 expression in their surgically removed primary tumors correlates strongly with risk 
of CRC relapse and metastasis. 
5.2 Future directions  
1. A Long Non-Coding RNA Targets MicroRNA miR-34a to Regulate Colon Cancer 
Stem Cell Asymmetric Division 
In this study presented in my thesis, we discovered a novel lncRNA, Lnc34a. Lnc34a 
silences miR-34a by recruiting Dnmt3a via PHB2 and HDAC1 to methylate and 
deacetylate the miR-34a promoter. Spatial imbalance of Lnc34a regulates asymmetric 
division of colon cancer stem cells (CCSCs), and high lnc34a expression promotes CCSC 
self-renewal and colon cancer growth. It is also important to know whether Lnc34a also 
regulates normal intestine/colon stem cell fate like miR-34a does. If Lnc34a does function 
in normal stem cells, does it share the same mechanism as it does in CCSCs?  
Lnc34a is highly expressed in CCSCs and low in non-CCSCs. In addition, Lnc34a 
expression is closely correlated with CRC progression with higher level in late stage of 
CRC in contrast to early stage of CRC. However, it is still unknown how lnc34a expression 
is regulated. RNA FISH showed Lnc34a co-localized with ALDH1 while mutually exclusive 
with miR-34a during the CCSC division, which raised an important question: What is the 
mechanism causing Lnc34a asymmetric distribution? Also, do Lnc34a asymmetric 
distribution and upregulation share the same mechanism? 
2. MicroRNA miR-34a provides a barrier against inflammation-induced colon stem cell 
proliferation and oncogenesis 
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This study demonstrates that the miR-34a plays a central role in protecting tissue 
integrity during inflammation-induced reparative regeneration. miR-34a deficient mice 
develop colon tumors after infection of the pathogenic Citrobacter bacteria, whereas 
wild-type mice always recover without tumor formation. It turned out that miR-34a 
controls both pro-inflammatory immune cells and the colon epithelial cells. miR-34a 
suppresses the differentiation and expansion of Th17 cells by targeting IL-6R and IL-
22R, hinders recruitment of Th17 cells to the colon epithelium by targeting CCL22, and 
limits stem cell proliferation by targeting IL-17RD. However, this conclusion primarily 
arises from data collected from a colorectal cancer mouse model. The clinical relevance 
of these findings has not been compellingly demonstrated. The RNA22 algorithm 
identified putative miR-34a binding sites of human IL-6R, IL-23R, CCL22, and IL-17RD. 
Experiments need to be performed to validate the miR-34a potential targets and 
regulation mechanism in humans.  
3. miR-1269 Promotes Metastasis and Forms a Positive Feedback Loop with TGF-β 
The study presented in my thesis provides evidence that miR-1269 forms feedback loop 
with TGF- to induce CRC cell EMT and metastasis. In the feedback loop, activation of 
TGF- signaling upregulates miR-1269 expression. miR-1269 in turn amplifies TGF- 
signaling activity by directly targeting TGF- signaling inhibitor, Hoxd10 and Smad7. miR-
1269 is upregulated in late-stage CRCs and correlates strongly with relapse and 
metastasis of stage II CRC patients after surgical removal of their primary tumors. 
However, there are remaining issues that need to be further investigated. For instance, 
TGF- is required for initiation of the feedback loop. However, it is largely unknown where 
the TGF- are from. It has been reported that tumor cells could produce TGF- to sustain 
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TGF- signaling activity. Alternatively, TGF- could also be provided by tumor 
environment such as stroma cells. Investigation of the role of TGF-β in the tumor 
microenvironment will enhance our understanding of the TGF-β/miR-1269 axis in the 
context of CRC metastasis and prognosis.  
 
 
